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Abstract  
Repair of the adult mammalian spinal cord is prohibited by several extrinsic and 
intrinsic factors. As the CNS matures, growth-promoting proteins such as integrins are 
developmentally downregulated resulting in a reduced capacity for axonal outgrowth. 
Integrins are heterodimeric receptors involved in cell-cell and cell-matrix interactions. 
Specifically, within mature corticospinal tract (CST) axons, integrins are not 
transported into the axonal compartment. One integrin heterodimer, α9β1, is of 
particular interest for its ability to promote neurite outgrowth when bound to a 
component of the injury-induced milieu, tenascin-C. This project aimed to increase 
integrin expression within the CNS using induced pluripotent stem cell-derived human 
neural progenitor cells (iPSC-hNPCs).  
Using immunocytochemistry and western blotting, endogenous integrin expression 
within iPSC-hNPCs was determined. In addition, overexpression of α9 integrin was 
achieved using transfection and lentiviral transduction. The capacity of wild type (WT) 
and α9-hNPCs to extend neurites on tenascin-C was assessed using neurite outgrowth 
assays. Results revealed increasing α9 integrin expression in hNPCs significantly 
promoted neurite outgrowth when cultured on tenascin-C. Interestingly, increasing the 
concentration of human tenascin-C, resulted in increasingly longer neurites from WT 
hNPCs suggesting hNPCs could actively upregulate integrin expression. 
Subsequently, WT and α9-hNPCs were transplanted into layer V of the neonatal rat 
sensorimotor cortex, which projects to the CST. WT and α9-hNPCs survived up to 8 
weeks post-transplantation and produced projections along white matter tracts, 
including areas of the CST. Additionally, hNPCs retained α9-eYFP protein expression 
in vivo over time and was localised within axonal projections. 
These results highlight the capabilities of iPSC-hNPCs to promote integrin expression 
within the rodent CNS presenting one potential avenue to target neuronal replacement 
following spinal injury. Future research should focus on assessing the regenerative 
capacity of WT and α9-hNPCs within an injury model concentrating on the ability of 
these cells to adapt within an injured environment. 
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1.1 CNS injury  
1.1.1 General background and statistics on SCI 
Repair of the central nervous system (CNS) after injury is one of the biggest challenges 
facing neuroscientists today. Currently, 1,000 people each year suffer a spinal cord 
injury (SCI) in the UK and Ireland (Spinal Research UK, 2016) and this number 
increases to between 250,000 and 500,000 worldwide (Bickenbach, 2013). Traumatic 
SCI is estimated to have a global incidence rate of 23 cases per million (Lee et al., 
2014). The most common causes of traumatic SCI are preventable and include road 
traffic accidents, falls, violence and contact sports (National SCI Statistical Center, 
2017) which often leave individuals with various types of sensory, motor and/or 
autonomic deficits. Non-traumatic SCI often results from pathophysiological causes 
including cancer, infectious diseases or genetic conditions including spina bifida 
(Bickenbach, 2013). Traumatic SCI is more common in males than females and occurs 
most commonly in young adulthood (15-29 years) and older age (over 60) 
(Bickenbach, 2013). Treatment is limited for SCI, and mainly revolves around 
preventing further damage however rehabilitation interventions are currently the main 
line of treatment. 
The spine consists of 33 vertebrae within five distinct regions, cervical, thoracic, 
lumbar, sacral and coccygeal. Within the spinal column lies the spinal cord, a bundle 
of myelinated and unmyelinated axonal nerve fibres that transmit information between 
the brain and the rest of the body. There are 31 pairs of spinal nerves that branch out 
from the spinal cord, one on each side of the body, into the spaces between the 
vertebrae termed intervertebral foramina each making their way to the periphery 
thereby connecting the CNS and the peripheral nervous system (PNS). These branches 
consist of a number of ventral roots, comprising motor fibres, and dorsal roots, 
comprising sensory fibres. Each set of spinal nerves corresponds to a particular area 
of the body, termed dermatomes (Figure 1.1). The spinal cord, contained within the 
vertebrae of the spinal column, is encased in three meningeal layers known as the pia 
mater, the arachnoid mater and the dura mater.  




Figure 1.1 The human spinal cord and corresponding dermatomes. The spinal column consists of 
five different regions, cervical, thoracic, lumbar, sacral and coccygeal, and comprises the spinal cord, a 
long bundle of nerve fibres emanating from the brain stem. From the spinal cord 31 pairs of spinal 
nerves branch out between the vertebrae, one set at each level. Each set of spinal nerves control the 
sensory and motor function for one particular part of the body termed dermatomes. For example, C1, 
C2 and C3 spinal nerves control sensory and motor function of the head and neck. Injury to this region 
is considered the most severe as it can result in loss of motor and or/sensory function below this leaving 
an individual tetraplegic. Figure modified from Mayfield Brain and Spine, 2016.  
 
An injury to the spinal cord can leave individuals with various losses in sensory, motor 
and/or autonomic function depending on the level of the injury. SCI can be classified 
as complete or incomplete, and can affect either side of the body or both. In general, 
any damage to one particular level of the spine often affects the areas of the body at 
and/or below that level. The severity of symptoms is greater the more rostral the 
location of the injury. For example, a complete injury between C1-C4 will leave an 
individual paralysed from the neck down and hinder autonomic activity, including 
breathing ability and heart rate. In these situations, individuals require assistance with 
ventilation and often 24-hour care. An injury within the lower cervical region (C5 and 
below) would still likely leave an individual tetraplegic, without complete use of their 
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arms and legs, but is likely to leave breathing and heart rate intact. An injury occurring 
lower in the spine, such as the lower thoracic and lumbar regions, would likely leave 
an individual paraplegic without control of their bladder, bowel or sexual function, 
however they would still have use of their upper body including their arms.  
1.1.2 Pathophysiology after CNS injury 
One of the reasons the spinal cord is so difficult to repair after injury is due to the 
complex and distinctive pathophysiology that occurs following impact. The 
underlying biology of SCI consists of a primary and a secondary phase. The primary 
phase is the initial injury suffered upon impact. This can include pressure on the spine, 
severed axons and nerves as well as internal bleeding. Depending on the type of injury, 
the blood-brain barrier may become permeable resulting in leukocyte infiltration 
(Reviewed in Trivedi et al., 2006; Trahanas et al., 2015) as well as disruption of the 
ionic homeostasis creating changes in calcium and potassium concentrations at the 
injury site (Young and Koreh, 1986; Chesler et al., 1994). Furthermore, disruption of 
blood supply to the injury site can result in inadequate oxygen and nutrient supply. At 
this stage, emergency treatment is required to prevent further damage, which includes 
stabilisation of the spine often followed by surgical decompression in order to reduce 
the inflammatory response and stop any bleeding. Over the subsequent weeks and 
months, the injury enters the secondary phase resulting in progressive 
neurodegeneration. This phase is associated with a second set of symptoms including 
inflammation, axonal demyelination, apoptosis, glutamate excitotoxicity and reactive 
astrogliosis leading to formation of a glial scar. Much of spinal cord and axonal injury 
research focuses on treatment and prevention of these secondary mechanisms.  
1.1.3 Extrinsic mechanisms inhibiting CNS regeneration 
1.1.3.1 The glial scar and associated inhibitory proteins 
Unlike the PNS, the adult mammalian CNS has a reduced ability to regenerate. The 
differences in capacity for regeneration between the two nervous systems was 
demonstrated by Aguayo and colleagues who showed peripheral nerve grafts into the 
injured rat spinal cord create a permissive environment allowing axons of the CNS to 
regenerate (Richardson et al., 1980; David and Aguayo, 1981; Munz et al., 1985). 
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Following a SCI, the lack of regeneration from the CNS is, in part, a result of these 
secondary mechanisms and the formation of a characteristic glial scar at the injury site. 
This is a fluid-filled cavity surrounded by reactive astrocytes and fibroblasts which 
acts not only as a barrier to prevent further damage, but also inhibits axonal 
regeneration (Figure 1.2) (Reviewed in Silver and Miller, 2004). Alongside scar 
formation, there is axonal demyelination and Wallerian degeneration, and as a result, 
axonal retraction (George and Griffin, 1994), apoptosis, potential disruption of the 
blood-brain barrier as well as an upregulation of a number of inhibitory proteins 
including chondroitin sulphate proteoglycans (CSPGs), myelin-associated proteins 
and chemorepellent proteins (Reviewed in Silver and Miller, 2004). Furthermore, the 
immune system reacts after injury resulting in microglial, macrophage and astrocyte 
activation. Activation of microglia after SCI has been shown to contribute to sustained 
chronic pain often suffered by individuals following injury (Hains and Waxman, 2006; 
Reviewed in Milligan and Watkins, 2009). Together this biological cascade of events 
creates an inhibitory environment, reducing axonal plasticity and preventing repair.  
 
 
Figure 1.2 Glial scar formation after axonal injury. Following CNS injury, a fluid-filled cystic 
cavity, termed a glial scar, forms around the lesion site (A). This scar consists of reactive astrocytes and 
fibroblasts that act to protect the spread of further damage, but also impedes repair of injured axons. 
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Alongside the scar there can be severed axons, demyelination and Wallerian degeneration, apoptosis, 
glutamate excitotoxicity and activation of the immune response including activated microglia (B). 
Furthermore, a number of inhibitory proteins that prevent axonal repair are secreted, including CSPGs, 
such as aggrecan, and myelin-associated proteins, such as Nogo. Figure modified from Macaya and 
Spector, 2012.  
 
CSPGs are the main family of inhibitory proteins associated with axonal injury. This 
includes the subgroup lecticans (comprising aggrecan, brevican, versican and 
neurocan), small leucine-rich proteoglycans (including biglycan and decorin), 
phosphacan/receptor-type-protein-tyrosine phosphatase β and other proteoglycans, 
including neuron-glial antigen 2 (NG2) and neuroglycan-C (Reviewed in Galtrey and 
Fawcett, 2007). The CSPGs are secreted into the extracellular matrix (ECM), mainly 
by reactive astrocytes and neurons (Asher et al., 2000; Carulli et al., 2006), but 
research suggests they are also secreted by macrophages and oligodendrocytes (Uhlin-
Hansen et al., 1993; Asher et al., 2002; Jones et al., 2003) increasing their abundance 
at the injury site. The main feature contributing to the inhibitory nature of CSPGs are 
their structure as they have a number of glycosaminoglycan (GAG) side chains. Each 
CSPG varies in the number of side chains they have, for example research suggests 
aggrecan contains over 100 GAG side chains and others contain less than 10 
(Reviewed in Galtrey and Fawcett, 2007). The number of chains and the sulphation 
status of CSPGs can determine the functional effect of the CSPGs (Lin et al., 2008; 
Wang et al., 2008; Yi et al., 2012). At the site of injury astrocytes become reactive and 
secrete CSPGs into the ECM creating an increased presence of CSPGs at the injury 
site contributing to an inhibitory milieu.  
CSPGs bind to the transmembrane-associated protein tyrosine phosphate sigma 
(PTPσ) receptors located on neurons (Shen et al., 2009). When CSPGs bind to PTPσ 
they initiate activation of the guanosine triphosphatase (GTPase) Rho signalling 
pathway resulting in inhibition of axonal growth (Monnier et al., 2003; Shen et al., 
2009). Animal models of SCI lacking PTPσ show increased regeneration of the 
corticospinal tract (CST) (Fry et al., 2010). The enzyme chondroitinase ABC 
(ChABC) acts to digest the GAG sugar chains of CSPGs preventing CSPGs from 
interacting with their receptors and has been shown to be effective in promoting axonal 
plasticity and regeneration in many models of SCI (Bradbury et al., 2002; Carulli et 
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al., 2010). Interestingly after thoracic contusion injury in adult rats and treatment with 
ChABC, the microglial phenotype changed from M1 to the more regenerative M2 
phenotype and resulted in improved sensorimotor function (Bartus et al., 2014). 
Because ChABC is an enzyme it has its limitations, primarily degradation over time 
(Lin et al., 2008). As a result, repeated dosing is required to maintain adequate 
enzymatic activity in order to promote repair. Long-term expression of ChABC has 
been obtained in rat models of SCI using lentivirus (LV) or adeno-associated virus 
(Alves et al., 2014), promoting regeneration of CST axons (Zhao et al., 2011). 
However, constitutive expression of ChABC over a long period of time may result in 
unwanted plasticity within the CNS.  
1.1.3.2 Perineuronal nets 
Within the CNS, CSPGs can associate with structures termed perineuronal nets 
(PNNs) which surround the soma and dendrites of mature neurons. PNNs are 
comprised of ECM proteins including hyaluronan; linking proteins, including cartilage 
link protein 1 (Crtl1) and brain-specific link protein 2 (Bral2); CSPGs; and tenascin-
R (TN-R) (Galtrey et al., 2008). This structure forms a highly stable and robust net-
like structure (Deepa et al., 2006), stabilising mature neurons and reducing dendritic 
spine plasticity (de Vivo et al., 2013). Within the PNN structure, there are a number 
of CSPGs, including brevican, neurocan, aggrecan, phosphacan and versican, which 
bind to the hyaluronan back bone of the PNN (Deepa et al., 2006). When specific 
components of cortical neuron PNNs are missing, for example the link protein Crtl1, 
PNN formation is reduced and neuronal plasticity is enhanced following damage to 
the visual or somatosensory pathways (Carulli et al., 2010). CSPGs are located within 
the PNN structure and digestion of these structures using ChABC can promote 
neuronal plasticity, but it has also been suggested that PNNs contain only 2% of all 
CSPGs within the brain (Reviewed in Fawcett, 2015). Moreover, some CSPGs have 
been shown to have an important role during development of the CST, surrounding 
CST axons aiding axonal guidance and likely preventing unwanted migration and 
deviation of developing axons (Hsu et al., 2005).  
1.1.3.3 Demyelination and inhibitory myelin-associated proteins  
After axonal insult, significant demyelination occurs (Gledhill et al., 1973; Griffiths 
and McCulloch, 1983; Olby and Blakemore, 1996) resulting in increased myelin debris 
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at the injury site. After demyelination, a number of myelin-associated proteins, 
including Nogo-A (Chen et al., 2000; Reviewed in Schweigreiter and Bandtlow, 
2006), oligodendrocyte myelin glycoprotein (OMgp) (Mikol et al., 1990; Wang et al., 
2002) and myelin-associated glycoprotein (MAG) (McKerracher et al., 1994; 
Mukhopadhyay et al., 1994) remain at the injury site contributing to the inhibitory 
environment. Research shows the presence of this debris can persist for years after the 
event (Buss et al., 2005) further adding to the inhibition of axonal repair. All three 
proteins, Nogo-A, OMgp and MAG, bind to the same receptors, Nogo receptor 1 
(NgR1), a glycosylphosphatidylinositol-anchored receptor (Fournier et al., 2001; 
Domeniconi et al., 2002; Wang et al., 2002), and paired immunoglobulin-like receptor 
B (PirB) (Atwal et al., 2008), which suggests they share common signalling pathways 
presenting focal targets to aid repair.  
From mice knockout (KO) studies of all three proteins (OMgp, Nogo-A and MAG), 
research has shown that Nogo-A exerts the greatest inhibitory effect on axonal repair 
(Cafferty et al., 2010). The myelin-associated protein, Nogo-A, binds to NgR1 on 
neurons via a specific 66 amino acid sequence on the C-terminus of Nogo-A (Fournier 
et al., 2001), and acts to destabilise synapses (Aloy et al., 2007) and promote growth 
cone collapse via Rho A signalling (Joset et al., 2010). Nogo-A is a splice variant of 
which the others include Nogo-B and Nogo-C. Nogo activity can be inhibited by 
blocking its interaction with NgR1, using antibodies against Nogo-A (Caroni and 
Schwab, 1988; Brösamle et al., 2000; Liebscher et al., 2005), or by targeting 
downstream signalling proteins, such as cyclic adenosine monophosphate (cAMP). 
Literature suggests Nogo signalling reduces phosphorylated cAMP levels which has 
further been linked to reduced axonal trafficking (Qiu et al., 2002). Interestingly, 
increasing cAMP levels by exposing dorsal root ganglia (DRGs) to dibutryl-(db) 
cAMP allows cells to overcome the inhibitory effects of Nogo resulting in increased 
neurite outgrowth (Joset et al., 2010). Application of anti-Nogo-A monoclonal 
antibodies, bind to specific Nogo-A inhibitory domains blocking its function and 
resulting in axonal regeneration (Liebscher et al., 2005). However, the beneficial 
effects of Nogo-A antibodies are time dependent with research showing delayed 
treatment (2 weeks after injury) cannot promote robust regeneration of CST motor 
fibres after incomplete thoracic SCI in rats (Gonzenbach et al., 2012). However, 
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combining both anti-Nogo-A with ChABC treatment along with rehabilitation was 
able to promote significant regeneration after partial cervical SCI in adult rats, more 
so than either treatment alone (Zhao et al., 2013). Additionally, research into 
treatments for SCI has focused on the reduction of myelin debris at the lesion site by 
increasing phagocytic activity of macrophages. This has resulted in beneficial effects 
for axonal regrowth when myelin-derived proteins are cleared using 
lipopolysaccharide in the mouse spinal cord (Vallières et al., 2006). 
Not all myelin-derived proteins are inhibitory following axonal injury however as 
research suggests some oligodendrocyte populations may attempt to remyelinate 
injured and sprouting axons (McTigue et al., 2001). Furthermore, Schwann cells (SCs) 
infiltrating from the PNS have been shown to remyelinate injured CNS axons (Black 
et al., 1986; Guest et al., 2005). Similarly MAG, has previously been shown to 
promote neurite outgrowth in developing DRG neurons (Mukhopadhyay et al., 1994) 
suggesting myelin-derived proteins may also have an age-specific function in axonal 
elongation. 
1.1.3.4 TN-C and semaphorins 
Alongside the increased levels of CSPGs, there are a number of developmental 
proteins that are upregulated after axonal injury in the mature CNS, including tenascin-
C (TN-C), semaphorins, ephrins and netrins (Zhang et al., 1997; De Winter et al., 
2002; Willson et al., 2003; Petit et al., 2007). In the developing CNS, these proteins 
act to promote axonal extension, guidance and growth cone formation but in the 
injured mature CNS, they become inhibitory to regrowth. In addition to a glial scar 
formation at the lesion site, reactive astrocytes secrete further inhibitory proteins into 
the extracellular milieu including the glycoprotein TN-C (Zhang et al., 1997). TN-C, 
the most abundant ECM glycoprotein within the CNS, is highly expressed during 
development, aiding axonal growth. However, as the mammalian CNS matures, TN-
C is downregulated. Conversely, TN-R levels are increased as the mammalian CNS 
matures, due to the increased formation of PNNs, acting to stabilise mature neurons 
(Carulli et al., 2007). Generally, TN-C exerts an inhibitory effect on mature axons. 
However, when bound to a specific heterodimeric integrin receptor, α9β1, which is 
downregulated in the mature CNS, TN-C can promote neurite outgrowth (Andrews et 
al., 2009; Cheah et al., 2016) (see section 1.2.4.1 for further discussion on TN-C).  
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Semaphorins are a class of membrane-associated proteins involved in axonal growth, 
guidance and formation of new synaptic connections during embryonic development 
(Reviewed in Jongbloets and Pasterkamp, 2014), however they are also expressed 
within the adult CNS including within the glial scar post-injury (Pasterkamp et al., 
1999; Reviewed in Pasterkamp and Verhaagen, 2001; De Winter et al., 2002). 
Interestingly particular semaphorin subtypes, such as sema4D, are upregulated after 
CNS injury and can prevent axonal growth in vitro suggesting it may contribute to the 
myelin-associated inhibitory environment at the lesion site in vivo (Moreau-Fauvarque 
et al., 2003). A further subtype that is upregulated after injury is sema3A (DeWinter 
et al., 2002), which has been implicated in preventing regeneration after SCI (Kaneko 
et al., 2006; Wanigasekara and Keast, 2006), with expression remaining 4 weeks after 
the initial injury (Kaneko et al., 2006). Selective inhibition of sema3A using SM-
216289 can promote axonal regeneration, enhance SC migration to the lesion site, 
inhibit apoptosis and significantly improve functional recovery of the hindlimb 
following transection of the spinal cord in adult rats (Kaneko et al., 2006).  
1.1.3.5 The inflammatory and immune response after SCI 
Following injury to the CNS, an immune response is initiated recruiting microglia, 
macrophages and activated astrocytes to the site of impact. Both microglia and 
astrocytes are known support cells within the CNS aiding homeostatic neuronal 
function (Elkabes et al., 1996; Reviewed in Walz, 2000; Christopherson et al., 2005; 
Magistretti, 2011; Suzuki et al., 2011). However, after injury these cells can secrete a 
number of inhibitory proteins, including chemokines and cytokines (Yang et al., 
2004). In addition, in vitro research has shown nitric oxide and peroxynitrite are 
released by microglia in response to pathological conditions, both of which contribute 
to a neurotoxic and harmful environment (Kaushal et al., 2007). Furthermore, if the 
blood-brain barrier is compromised after injury, the release of these inhibitory proteins 
results in recruitment of leukocytes, such as neutrophils and monocyte-derived 
macrophages, to the injury site further exacerbating the area. This range of inhibitory 
pro-inflammatory proteins are produced in response to ligands binding to toll-like 
receptors (TLRs) and P2 purinoceptors expressed on the surface of glial and neuronal 
cells (Reviewed in Burnstock and Knight, 2004; Olson and Miller, 2004). TLR ligands 
include ECM proteins, such as the proteoglycan biglycan (Schaefer et al., 2005), 
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hyaluronan-derived oligosaccharides (Termeer et al., 2002), and heat shock proteins 
(Reviewed in Asea, 2008) secreted from damaged and apoptotic cells (Willis et al., 
2005; Lehnardt et al., 2007). Ligands for P2 purinoceptors are the nucleotide-
associated proteins, purines and pyrimidines, and signalling via this receptor can result 
in microglia activation, microglial migration towards the injury site (Haynes et al., 
2006; Ohsawa et al., 2007) and phagocytosis (Koizumi et al., 2007). In response to 
this, inhibition of P2 signalling has been shown to promote repair and functional 
recovery following acute thoracic SCI in adult rats (Wang et al., 2004). 
Research into TLR signalling has shown that it is directly linked to the inflammatory 
response associated with both PNS (Boivin et al., 2007) and CNS injury (Babcock et 
al., 2006; Kigerl et al., 2007). However, the mechanisms underlying TLR signalling 
are not fully understood as research has also shown it may actually be beneficial after 
CNS and PNS injury. For example, activation of macrophages and TLR downstream 
signalling can promote regeneration and may be essential for recovery of function after 
PNS nerve injury (Perrin et al., 2005; Boivin et al., 2007). Similarly, agonists of TLR 
can promote clearance of myelin debris by stimulating macrophages and microglia 
activity (Vallières et al., 2006), axonal sprouting (Chen et al., 2008b) and axonal 
regeneration (Yin et al., 2003). Moreover, injecting TLR agonists such as zymosan 
into SCI sites has resulted in improved DRG regeneration, however the regeneration 
is not sustained as there is a simultaneous increase in neurotoxicity (Gensel et al., 
2009). Research has further suggested the immune response may also have a beneficial 
role in CNS injury, acting to prevent further damage (Faulkner et al., 2004; Myer et 
al., 2006). For example, Myer and colleagues demonstrated neurodegeneration 
worsened after moderate cortical stab injury in mice where astrocytes had been 
conditionally ablated (Myer et al., 2006). Similarly, conditional deletion of reactive 
astrocytes at the injury site resulted in reduced infiltration of macrophages and 
increased neural degeneration after two different types of lumbar SCI, a longitudinal 
stab injury and a crush injury, in transgenic mouse models (Faulkner et al., 2004). 
Furthermore, these animals were unable to repair the leaky blood-brain barrier after 
injury and showed reduced motor recovery compared to control animals (Faulkner et 
al., 2004), highlighting the beneficial role activated astrocytes have at the injury site.  
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Other studies have shown macrophages can adopt two different morphologies, M1 and 
M2, in response to cytokines within the lesioned environment (Stout et al., 2005). Out 
of these two phenotypes, the M2 phenotype is thought to be anti-inflammatory and 
able to promote long-distance axon outgrowth in vitro (Kigerl et al., 2009).  
Currently, acute SCI patients can be administered glucocorticoids, such as 
methylprednisolone or naloxone, to reduce the inflammatory response which have 
shown to improve functional recovery (Bracken et al., 1992), however this treatment 
can be accompanied by a wide range of risks including respiratory infections and 
pneumonia (Reviewed in Hurlbert, 2014) and more recent research has questioned the 
efficacy of methylprednisolone (Evaniew et al., 2015). It is clear that the underlying 
pathways associated with TLR signalling and macrophage activation require further 
investigation before anti-inflammatory treatments can be considered safe and effective 
for promoting neuroregeneration. However, it is also clear that many inflammatory 
proteins have a dual role, on one hand adding to or adversely affecting the inhibitory 
injured environment and on the other, promoting regeneration and preventing further 
damage. This therefore suggests suppressing or dampening the immune system may 
not be entirely beneficial.  
1.1.4 Intrinsic factors inhibiting CNS repair 
Alongside the inhibitory extracellular environment created after injury, mature 
mammalian neurons have reduced capabilities for regeneration (Muramatsu et al., 
2009; Reviewed in Eva et al., 2012). This means that any successful treatment for SCI 
would need to address both the extrinsic and intrinsic obstacles. During development, 
the CNS is more prone to regenerate due to the plastic nature of the immature nervous 
system. Therefore, research on regeneration of the mature CNS has focused on 
reinstating the intrinsic signalling pathways, associated with the developing CNS in 
order to promote plasticity and regeneration after injury. Some target proteins of 
interest include, phosphatase and tensin homolog (PTEN), mammalian target of 
rapamycin (mTOR), suppressor of cytokine signalling 3 (SOCS3), Rho/ Rho-
associated kinase (ROCK) and cAMP (Reviewed in Chew et al., 2012). Alongside the 
changes in these proteins, growth-promoting receptors within the mature CNS, 
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including tropomyosin-related kinase (Trk) and integrin receptors, are downregulated 
illustrating further gaps in signalling pathways that are viable targets for repair. 
1.1.4.1 The PTEN/mTOR pathway 
The tumour suppressor protein, PTEN, converts phosphoinositide 3,4,5-triphosphate 
(PIP3) to phosphatidylinositol 4,5-bisphosphate (PIP2), within the phosphoinositide 
3-kinase (PI3-K) pathway. Downstream of PIP3 is Akt (protein kinase B), which can 
promote cell survival and axon growth via downstream effectors, including inhibition 
of glycogen synthase kinase 3-β (GSK3-β) and activation of mTOR activity. For 
example, activation of mTOR can promote cell growth via increased expression of 
growth-associated protein-43 (GAP-43). Therefore, the reduction of PTEN activity 
will result in increased PIP3 activity, increased mTOR expression and thus cell growth 
making the PTEN/mTOR pathway a target for CNS regeneration (Park et al., 2008; 
Ning et al., 2010; Mao et al., 2013; Ohtake et al., 2014). Furthermore, research has 
shown conditional deletion of PTEN in the nervous system can promote regeneration 
of the optic nerve (Park et al., 2008) and the CST in mice following injury (Liu et al., 
2010; Du et al., 2015). 
1.1.4.2 The JAK/STAT pathway  
A further target for enhancing intrinsic axonal repair is deletion of SOCS3. This is 
responsible for inhibiting the janus tyrosine kinases/signal transducers and activators 
of transcription (JAK/STAT) pathway (Reviewed in Krebs and Hilton, 2001). 
Specifically, STAT3 phosphorylation via this pathway can result in neurite outgrowth 
and regeneration (Schwaiger et al., 2000; Miao et al., 2006; Bareyre et al., 2011) and 
inhibition of this pathway via SOCS3, which is upregulated after CNS injury, prevents 
neurite outgrowth (Miao et al., 2006; Park et al., 2014). Increasing STAT3 activity has 
been shown to promote regeneration within the CNS and PNS (Bareyre et al., 2011; 
Lang et al., 2013; Mehta et al., 2016). For example, following unilateral 
pyramidotomy in mice, sustained STAT3 activity using adeno-associated virus 
resulted in remodelling of CST axons and functional recovery of the forelimb after 
injury (Lang et al., 2013). Similarly, deletion of SOCS3, thereby removing the 
negative regulation on the JAK/STAT pathway, promoted axonal outgrowth and 
regeneration within the optic nerve after a crush injury in adult mice (Smith et al., 
2009). SOCS3 deletion can also stimulate dendritic growth within white matter tracts 
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of the spinal cord and prevent demyelination after complete thoracic SCI in adult rats 
(Park et al., 2015). In addition, dual deletion of SOCS3 and PTEN has resulted in 
greater regeneration of the optic nerve (Sun et al., 2011) and sprouting of the CST (Jin 
et al., 2015) than deletion of either alone suggesting targeting both intrinsic pathways 
may result in enhanced regeneration.  
STAT3 activation has also been implicated in the proliferation of astrocytes and glial 
scar formation after SCI (Herrmann et al., 2008; Wanner et al., 2013). Although the 
glial scar is thought to be inhibitory to repair and many experimental treatments target 
the removal of glial scar components, research has also shown it has a protective role. 
For example, ablation of the glial scar via STAT3 KO does not promote spontaneous 
regrowth after severe crush of the mouse thoracic spinal cord (Anderson et al., 2016). 
Rather, it can promote spread of inflammation and axonal degeneration (Wanner et 
al., 2013). Together this research suggests modulation of the JAK/STAT pathway may 
have a number downstream effectors targeting multiple aspects of SCI 
pathophysiology.  
1.1.4.3 Rho GTPases  
The family of Rho GTPases are involved in modulation of the cell cytoskeleton and 
axongenesis, three of which are of particular interest in regeneration, namely RhoA, 
Rac1 and Cdc42. This is because each can promote actin and microtubule 
reorganisation stimulating axonal growth, guidance and migration by a number of 
effector proteins and pathways including PI3-K and mitogen-activated protein kinase 
(MAPK). Both Rac1 and Cdc42 are involved in lamellipodial and filopodial extension 
during growth cone formation (Brown et al., 2000; Sayyad et al., 2016). Following a 
lesion of the adult rat thoracic CST, delivery of constitutively active Rac1 and Cdc42 
within a hydrogel bridge alongside brain-derived neurotrophic factor (BDNF), 
promoted axonal regeneration of CST axons through the lesion site (Jain et al., 2011). 
Specifically, this combination of treatments resulted in reduction of CSPGs and 
reactive astrocytes at the lesion site and promoted regrowth of injured CST axons 
within the glial scar. Furthermore, Rac1 has been implicated in axonal guidance with 
Rac1 KO mice displaying defects in corticothalamic and thalamocortical pathways 
(Chen et al., 2007).  
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Largely, Rho GTPases promote growth cone formation via reorganisation of the actin 
cytoskeleton however other GTPases including Rho and the ROCK pathway have the 
opposite effect and act to promote growth cone collapse (Dergham et al., 2002; 
Monnier et al., 2003; Joset et al., 2010). Research has shown Nogo-A signalling via 
NgR can promote growth cone collapse via RhoA signalling (Niederöst et al., 2002; 
Joset et al., 2010). Inhibiting Rho signalling in vitro with either C3 transferase, a Rho 
inhibitor, or Y27632, a ROCK inhibitor, can promote growth of rat primary cortical 
neurons cultured on inhibitory substrates including CSPGs and myelin (Dergham et 
al., 2002). Similarly, inhibiting the Rho signalling pathway can promote regeneration 
after CNS injury (Lehmann et al., 1999; Dergham et al., 2002; Fehlings et al., 2011). 
For example, following thoracic CST lesioning, injection of Rho signalling inhibitors, 
either C3 transferase or Y27632, at the lesion site promoted regrowth of CST fibres 
beyond the injury site. It also significantly improved motor function demonstrated in 
the open field locomotor test after just 24 hours of treatment thought to be due to 
treatment-induced localised axonal sprouting (Dergham et al., 2002). Interestingly, 
this study identified inhibition of Rho using C3 transferase provided a better 
regenerative outcome than inhibition of ROCK using Y27632, suggesting Rho may 
initiate a downstream cascade, independent of ROCK, acting to prevent regeneration 
(Dergham et al., 2002).  
1.1.4.4 Integrins 
One further group of proteins that are of particular interest in axonal regeneration are 
integrins. Integrins are a family of transmembrane receptors involved in mediating 
cell-cell and cell-matrix adhesions. Within the nervous system they are involved in 
neurodevelopment, promoting neurite outgrowth and axonal elongation, but their 
expression is downregulated as the CNS matures. Research has shown overexpression 
of integrin subunits can promote neurite outgrowth in the presence of their ligand in 
vitro (Condic, 2001; Andrews et al., 2009). Furthermore, reintroducing integrin 
subunits into the CNS can stimulate axonal regeneration after injury (see section 1.2 
for further discussion on integrins).  
1.1.4.5 Trk receptors 
Alongside integrins, expression of another group of transmembrane receptors, Trk 
receptors, do not have a high enough expression to promote regeneration within the 
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adult mammalian CNS (Lu et al., 2001; Kwon et al., 2004). There are three subclasses 
of Trk receptors (TrkA, TrkB and TrkC) which bind a number of neurotrophic 
proteins, such as BDNF and nerve growth factor (NGF) resulting in modulation of cell 
survival and neurite outgrowth (Reviewed in Huang and Reichardt, 2003). Similar to 
integrins, there is a lack of Trk receptors in the adult CNS, specifically the receptor for 
BDNF, TrkB, located within the projections from adult CST axons (Lu et al., 2001). 
Indeed modulation of BDNF and TrkB has shown to be promising targets for 
promoting regeneration (Cheng et al., 2002; Song et al., 2008; Hollis et al., 2009). For 
example, increasing TrkB expression using lentivirus in rat corticospinal motor 
neurons in vivo, resulted in increased axonal outgrowth following a subcortical lesion 
in rats (Hollis et al., 2009). Furthermore, these TrkB-expressing cells located within 
the motor cortex were able to project towards a BDNF-secreting graft located in the 
C3 region of the spinal cord (Hollis et al., 2009). This suggested the trafficking 
mechanisms for TrkB were still active within axons of the CST and holds promise for 
future modulation of intrinsic signalling mechanisms for CNS repair.  
1.1.4.6 Ephs and ephrins 
Other intrinsic signalling proteins of note are the transmembrane receptor tyrosine 
kinases, ephs, and their ligands, ephrins, which form complexes with one another and 
work to modulate the cell cytoskeleton, thereby altering neurite outgrowth, migration 
and cell proliferation (Reviewed in Goldshmit et al., 2006). However, after SCI injury 
in the adult rat, a number of the EphA family of receptors are upregulated (Willson et 
al., 2002; Goldshmit et al., 2004; Fabes et al., 2006) and work to promote growth cone 
collapse (Willson et al., 2002). Using a blocking peptide, the activity of these 
receptors, such as EphA4 which is known to be upregulated within the CST after injury 
(Fabes et al., 2006), can be inhibited. This has proved to be a promising target for 
promoting CNS regeneration in rodents, resulting in increased sprouting of injured 
axons into the lesion site as well as improved functional recovery (Fabes et al., 2007; 
Goldshmit et al., 2011).  
1.1.5 Treatment and current research for SCI 
After SCI, some axons attempt to regenerate via axonal sprouting and dendritic 
remodelling however environmental and intrinsic challenges still remain suggesting 
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further intervention is required to achieve robust functional recovery. Currently there 
are no pharmacological or surgical treatments that will repair spinal cord axons and 
fully restore function. The aim of pharmacological treatments is therefore to reduce 
inflammation and pain with patients often receiving physiotherapy and rehabilitation. 
As mentioned earlier, patients can be prescribed methylprednisolone in an attempt to 
reduce inflammation, however it can result in some serious side effects and its clinical 
efficacy is not widely accepted (Bracken et al., 1998; Evaniew et al., 2015). Other 
types of pharmacological treatments currently prescribed include non-steroidal anti-
inflammatories, such as ibuprofen, calcium channel blockers, such as nimodipine, and 
opioid antagonists, such as naloxone. In the UK, prescription of high dose 
methylprednisolone, nimodipine and naloxone to SCI patients is not recommended for 
neuroprotection due to side effects associated with them (National Institute for Clinical 
Excellence, 2016). Pharmacological treatments are therefore limited but most often 
patients will receive extensive physiotherapy and rehabilitation. In recent years new 
clinical trial data has emerged from patients receiving epidural stimulation. This 
involves a small electrode being surgically placed onto the dura mater of the spinal 
cord. While this is not yet a mainline treatment as testing involved only a few patients, 
encouraging results were observed, such as stimulating muscles in the lower limbs to 
allow individuals who previously could not stand to stand unassisted (Reviewed in 
Edgerton and Harkema, 2011; Rejc et al., 2015). 
Current research for treatment of SCI in animal models is largely focused around three 
aspects: digestion of the glial scar and removal of inhibitory signalling, including 
removal of Nogo-A and other myelin-associated proteins; reinstating growth-
promoting signalling; and cell transplantation. For example, the inhibitory 
environment created at the lesion site harbours a number of proteins preventing axonal 
repair, including CSPGs, myelin-derived inhibitory proteins and semaphorins. 
Arguably some of the most promising studies have focused on targeting these proteins 
using various routes, such as removal or inhibition of these proteins. Specifically, 
studies have included use of monoclonal antibodies against Nogo-A (Caroni and 
Schwab, 1988; Brösamle et al., 2000; Liebscher et al., 2005), using ChABC enzyme 
to digest the glycosaminoglycan sugar chains of CSPGs (Bradbury et al., 2002; García-
Alías et al., 2009) or increasing the phagocytic activity of macrophages to enhance 
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clearance of inhibitory proteins at the lesion site (Vallières et al., 2006). Implemented 
individually, these treatments do not always result in extensive regrowth or restoration 
of function (Vallières et al., 2006). Therefore a combination of treatments may result 
in a greater level of repair and functional recovery (Zhao et al., 2013), suggesting that 
to enable robust repair multiple aspects of SCI pathophysiology should be targeted.  
Experimental approaches towards enhancing repair post-SCI have offered great 
advancements in this field. Yet, arguably, the technique with the most universal 
application is cell replacement. Replacing lost and injured cells may promote 
remyelination or provide new neuronal networks for axonal guidance. Cell therapy has 
focused on transplantation of various cell types including, but not limited to, 
oligodendrocytes, SCs, astrocytes and neural stem cells (NSCs). However, considering 
the nature of the inhibitory environment created after injury, it is not surprising that 
transplanted cells can react differently in an injured spinal cord environment compared 
to uninjured controls (Sontag et al., 2014). Research has shown that the lesioned 
environment can have a major impact on grafted NSCs, altering cell proliferation, 
survival, differentiation and engraftment into the host tissue (Sontag et al., 2014). 
However, when stem cell grafts are used in conjunction with ChABC for treatment of 
SCI in rodent models, greater survival and integration of grafted cells is observed 
(Karimi-Abdolrezaee et al., 2010). This strengthens the case for combination therapies 
for SCI, targeting multiple aspects for repair. Furthermore, grafted cells can be 
modified prior to transplantation to express a variety of different factors including 
fluorescent tags or specific growth-promoting proteins, the latter of which equips the 
cells with the necessary tools to adapt to and thrive within the injured environment. 
Nevertheless, cell transplantation also has its limitations, namely in terms of triggering 
an immune response. However with this in mind, recent research from a clinical trial 
in stroke patients revealed the neuroprotective effects of a stem cell transplant 
outlasted the survival of the cells (Steinberg et al., 2016) likely due to secretion of 
neurotrophic factors. This study is promising for the field of neuroregeneration and 
suggests long-term cell survival and immunosuppression after cell transplant may not 
be necessary to induce CNS repair.  
It has been suggested that only 10-15% of fibres need to regenerate to restore function 
(Reviewed in Dietz and Curt, 2006), therefore providing hope that axonal repair is 
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possible using stem cell transplants if given the correct guidance, support and 
environment. Cell therapy could promote regeneration by creating a bridge or a bypass 
for new regenerating neurons to navigate the injury site and restore connections. 
Whether this is required in combination with pharmacological agents to modify the 
inhibitory lesion site or modification of cells prior to transplant is yet to be fully 
determined. It is clear that both extrinsic and intrinsic mechanisms are preventing 
regeneration after SCI and therefore future research and treatments must tackle both 
of these aspects if robust functional regeneration is to be achieved. 
  




1.2.1 Integrin function and structure 
Integrins are heterodimeric transmembrane receptors expressed by all cells within the 
body except red blood cells. They govern a wide range of cell-cell and cell-matrix 
interactions, including cell motility, migration, adhesion, proliferation and survival 
(Letourneau and Shattuck, 1989; Miyamoto et al., 1995; Reviewed in Jones and 
Walker, 1999; Gardiner et al., 2005). They are involved in a number of physiological 
processes including nervous system development, aiding cell growth and neural 
plasticity (Reviewed in Reichardt and Tomaselli, 1991; Reviewed in Clegg et al., 
2003; Huang et al., 2006; Reviewed in Denda and Reichardt, 2007), immune system 
functioning (Reviewed in Zhang and Wang, 2012), regeneration of the PNS ( Werner 
et al., 2000; Gardiner et al., 2005), as well as the progression of cancer (Reviewed in 
Lu et al., 2008). However, one function of integrins that is of particular interest for 
CNS regeneration is their ability to promote neurite outgrowth and plasticity within 
the developing brain (Reviewed in Gupton and Gertler, 2010; Harper et al., 2010) as 
well as after injury (Tan et al., 2012; Cheah et al., 2016). 
Integrins are comprised of an α and a β subunit with currently 24 recognised 
heterodimers, consisting of 18 α and eight β subunits (Hynes, 2002). Integrin subunits 
are glycoproteins and bind to each other via non-covalent bonds. The combination of 
different integrin subunits, and particularly the α subunit, confers the ECM binding 
specificity, with many integrins binding more than one ligand. The heterodimers can 
be categorised into four subdomains including collagen receptors, laminin receptors, 








Figure 1.3 Integrin subunits and their binding partners. Integrins consist of an α and a β subunit of 
which there are currently 24 recognised heterodimers in mammals. The integrin heterodimer confers 
the binding specificity to the ECM ligand, with some subunits able to bind more than one partner, 
however they can be categorised in four distinct subgroups. These include collagen receptors, laminin 
receptors, RGD receptors and leukocyte-specific receptors. Figure modified from Hynes, 2002. 
 
Structurally, integrin receptors have a large extracellular domain that allows the 
receptors to interact and bind different components of the ECM including 
proteoglycans, glycoproteins and growth factors (Reviewed in Kim et al., 2011), 
which in turn activate intracellular signalling cascades resulting in cell adhesion and 
motility (Reviewed in Zhao and Guan, 2011; Reviewed in Danen, 2013; Reviewed in 
Moreno-Layseca and Streuli, 2014). The ectodomain of integrin receptors essentially 
act as gateways by which the cells communicate with and respond to the external 
environment. The cytoplasmic domain, in comparison, is much smaller and interacts 
with components of the cell cytoskeleton via adaptor proteins, including actin, 
vinculin, paxillin, kindlin and talin (Reviewed in DeMali et al., 2003; Rose et al., 2003; 
Humphries et al., 2007; Reviewed in Calderwood et al., 2013). Integrins bind their 
ligands with a relatively low affinity, however in response to this, there are usually 
high levels of integrin expression at the cell surface. This characteristic allows 
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integrins to act as guardians of cell movement interacting with a number of ECM 
molecules aiding in cell migration through the ECM (Figure 1.4).  
 
 
Figure 1.4 Structure of an integrin heterodimer. The integrin heterodimer consists of an α subunit 
(blue) binding non-covalently to a β subunit (green). Each consists of a large extracellular domain, a 
transmembrane domain that spans the lipid bilayer and a small cytoplasmic domain. The ligand binding 
site is located within the globular head of the α subunit. This site, termed the metal ion-dependent 
adhesion site, is controlled by the concentration of calcium and magnesium ions. The intracellular 
domain of the β subunit binds to integrin activators as well as adaptor proteins linking the integrin 
receptor with the cell’s cytoskeleton components, such as actin. 
 
1.2.2 Integrin activation and signalling  
As discussed above, integrin heterodimers can bind a wide variety of ECM ligands, 
however to do so they must first be activated. Integrin receptors can have two basic 
states of activation and following analysis of its crystal structure (Xiong et al., 2003), 
more is now known about this two-state model. Integrins are bi-directional signallers 
via ‘inside-out’ and ‘outside-in’ signalling. Due to the basal inactivation state of 
integrins in the bent conformation, they require activation before they can bind 
proteins in the extracellular domain. When integrins are in their inactive form they 
take on a bent appearance, bending the head of the extracellular compartment towards 
the cell surface (Figure 1.5, A). Binding of activator proteins, such as talin and kindlin 
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(Moser et al., 2009; Tan et al., 2012; Cheah et al., 2016), to the cytoplasmic domain 
of the β subunit instructs both integrin subunits to straighten out exposing the 
extracellular ligand binding site (Takagi et al., 2002). This conformational change is 
termed ‘inside-out’ signalling (Figure 1.5, B) and results in high-affinity ligand 
binding (Takagi et al., 2002). Once this conformational change has occurred, an ECM 
ligand can bind to the recognition site located on the α subunit resulting in intracellular 
signalling, termed ‘outside-in’ signalling (Figure 1.5, C) (Takagi et al., 2002). 
 
 
Figure 1.5 Inside-out and outside-in signalling via integrin receptors. Integrins must be activated to 
induce modification of the cell’s cytoskeleton. They exist on the cell surface in an inactive state with 
the head of each subunit bent down towards the cell membrane (A). Integrin activators, such as talin 
and kindlin, bind to the cytoplasmic domain of the β subunit to induce a conformational change in the 
integrin receptors, allowing both subunits to straighten out and exposing the ligand binding site located 
on the globular head of the α subunit (B). This is a process termed inside-out signalling. This 
conformation change allows the integrin receptor to bind an ECM ligand promoting intracellular 
signalling pathways that result in modification of the cell’s cytoskeleton, gene expression, cell 
proliferation and survival (C). This is termed outside-in signalling. 
 
Ligand binding to the α subunit is governed by Ca2+ and Mg2+ ions present in the 
extracellular globular domain of the α subunit, known as the metal ion-dependent 
adhesion site (Lee et al., 1995). These different divalent cations will confer different 
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specificities as well as affinities and can be used to modify integrin activation status in 
culture to keep the receptor in a high-affinity ligand binding state (Reviewed in Zhang 
and Chen, 2012).  
Integrin activation can also be modified using integrin activators, such as kindlin or 
talin. Talin is a cytoskeletal protein usually found within the cytoplasm of mammalian 
cells and consists of a 4.1, ezrin, radixin, moesin (FERM) domain and a rod domain 
(Figure 1.6, A). In newly forming cell-cell adhesions, the F3 subdomain of the FERM 
domain within the N-terminal region of talin binds to the cytoplasmic region of  
b integrin subunits, to ‘switch-on’ the integrin into the active state (Calderwood et al., 
1999, 2002; Di Paolo et al., 2002; Wegener et al., 2007). Within this F3 subdomain 
there is a phosphotyrosine binding (PTB) site that binds to specific tyrosine residues 
within the cytoplasmic domain of b subunits (Wegener et al., 2007). The talin  
c-terminal tail can bind to the actin cytoskeleton which therefore allows talin to act as 
a linking protein between b integrin cytoplasmic domains and the actin cytoskeleton, 




Figure 1.6 Structure of integrin activators talin and kindlin. Talin and kindlin are two integrin 
activators able to bind the cytoplasmic domain of the β subunit to stimulate a conformational change in 
the receptor and allow exposure of the ECM ligand site (inside-out signalling). Talin consists of a FERM 
domain, which binds to the β subunit, and a rod domain, which binds to actin, thereby linking integrin 
activity to the cell cytoskeleton (A). Kindlin also contains a FERM domain with a pleckstrin homology 
domain within the F2 subdomain, and also binds to the β subunit to promote inside-out signalling (B). 
Following activation via kindlin and talin, a conformational change in the integrin receptor results in a 
high affinity for ligand binding. Figure adapted from Moser et al., 2009. 
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Like talin, kindlin contains a FERM domain that binds the integrin β subunit to 
promote integrin activation (Figure 1.6, B) (Rogalski et al., 2000) which modulates 
the actin cytoskeleton indirectly by interacting with linking kinases including integrin-
linked kinase (Fukuda et al., 2014). There are three kindlin isoforms, -1, -2 and -3, 
however it is the effect of kindlin-1 on integrin activation to promote axonal 
regeneration which has most appeal. For example, overexpression of kindlin-1 in 
sensory neurons can enhance axonal growth in the presence of inhibitory CSPG 
proteins in vitro, but overexpression of kindlin-2 cannot (Tan et al., 2012). Further to 
this, activation of exogenously expressed integrins alongside kindlin-1 can promote 
sensory axon recovery through integrin-mediated signalling after dorsal root crush in 
adult rats (Cheah et al., 2016). Unfortunately, kindlin-1 is not expressed within the 
mammalian CNS (Ussar et al., 2006; Tan et al., 2012) and therefore presents a further 
obstacle for repair of the CNS after injury.  
As integrins are involved in cell adhesion and cell-cell interactions they are recruited 
to nascent adhesion sites. This is a process called integrin clustering, which has 
recently been discovered to be mediated by talin and focal adhesion kinase (FAK), a 
scaffolding protein, which together form a protein complex (Reviewed in Calderwood, 
2004; Wegener et al., 2007; Zhang et al., 2008; Reviewed in Myers et al., 2011). This 
complex interacts with integrins and as more integrins cluster at the membrane, more 
cytoskeletal components, such as actin, are recruited to the membrane resulting in 
dynamic changes to the cytoskeleton. In this way, cells are able to respond to the ECM 
by extending integrin-containing filopodia allowing movement of the cell. FAK can 
form other protein complexes within nascent adhesions including Src tyrosine kinase 
(Schaller et al., 1994) and paxillin, a focal adhesion-associated signalling protein, to 
promote and regulate cytoskeleton assembly and cell protrusion (Choi et al., 2011). 
As a result of integrin activation and outside-in signalling, a number of intracellular 
pathways can be activated including PI3-K, Src kinase and MAP kinase resulting in 
modulation of the cytoskeleton and cell adhesion and growth (Reviewd in Jones and 
Walker, 1999; Reviewed in Moreno-Layseca and Streuli, 2014). Furthermore, 
integrins can also promote cell proliferation through activation of cyclin-dependent 
kinases (Cdks), specifically Cdk4/6 and Cdk2, which are involved in advancement of 
the cell cycle beyond G1 (Reviewed in Schwartz and Assoian, 2001). Further 
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downstream effectors include Rho GTPases which have been implicated in cell 
migration and adhesion (Reviewed in Schwartz and Shattil, 2000) as well as axonal 
outgrowth and regeneration. Specifically, inhibition of Rho GTPases results in 
increased axon outgrowth (Lehmann et al., 1999; Dergham et al., 2002; Winton et al., 
2002; Hiraga et al., 2006). For example, Rho inhibition in cultured rat 
pheochromocytoma-12 (PC12) cells (Lehmann et al., 1999) and in cultured primary 
cortical neurons (Dergham et al., 2002) promoted neurite extension when cultured on 
an inhibitory myelin substrate. Similarly in vivo, inhibition of Rho prompted regrowth 
of axons within the injured optic nerve in adult rats (Lehmann et al., 1999) and in CST 
axons after thoracic spinal cord lesion in mice (Dergham et al., 2002).  
In order for cells to respond to the ECM, integrins embedded within the cell membrane 
must be internalised and trafficked to newly forming sites of adhesion (Roberts et al., 
2001; Woods et al., 2004). These receptors are recycled via endocytosis controlling 
the expression of integrins at the cell membrane (Reviewed in Bridgewater et al., 2012; 
Reviewed in Paul et al., 2015), yet the causative and underlying processes that govern 
integrin recycling are not fully understood. For this reason, the endocytic pathway is 
of great interest as changes in the recycling and trafficking of integrins will directly 
alter cell growth and motility. Research has shown integrins can be internalised by 
both clathrin-dependent and clathrin-independent mechanisms (Reviewed in Paul et 
al., 2015), and active and inactive integrins are recycled through short- and fast-loop 
pathways respectively (Arjonen et al., 2012). Specifically, integrin recycling and 
trafficking is mediated via small GTPases, including Rab and Arf (Dunphy et al., 2006; 
Eva et al., 2012; Mendoza et al., 2013; Chen et al., 2014). Integrins expressed on the 
cell membrane are internalised into early endosomes where they either follow a short-
loop recycling pathway, mediated by Rab4, which involves direct transport of the 
integrin back to the cell membrane, or a long-loop recycling pathway, mediated by 
Rab11 and Arf6, which involves transport of the integrin to the perinuclear recycling 
compartment before transport back to the cell membrane (Reviewed in Caswell and 
Norman, 2006). In this way, integrins can mediate a rapid response to the ECM 
resulting in cell motility and migration. 
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1.2.3 Integrins and CNS regeneration 
As discussed earlier, integrin expression within the mammalian CNS is high during 
embryogenesis and development, resulting in proliferation, synaptogenesis, axonal 
elongation, axonal guidance and neuroplasticity. However, as the CNS matures, a 
number of integrin subunits are downregulated resulting in reduced ability for axonal 
growth (Condic, 2001). This change in integrin expression is thought to be an 
important contributing intrinsic factor in the prevention of CNS regeneration after 
axonal injury and there is now a large body of research highlighting the use of integrins 
in promoting CNS regeneration (Werner et al., 2000; Ekström et al., 2003; Gardiner 
et al., 2005; Andrews et al., 2009; Tonge et al., 2012; Cheah et al., 2016). After injury 
in the PNS, integrin subunits are upregulated in both sensory (Ekstrom et al., 2003; 
Gardiner et al., 2005) and motor (Werner et al., 2000) neurons. Yet the same 
compensatory mechanism of integrin expression is not mimicked in the mature CNS 
after injury.  
Increasing integrin expression after injury presents a number of benefits, as not only 
are integrins linked to increased cell survival (Reviewed in Vachon, 2011), their 
increased expression has been linked to increased growth cone formation and 
regeneration within the PNS (Reviewed in Previtali et al., 2001). Furthermore, 
integrins have the ability to interact with the inhibitory components of the lesion site, 
specifically CSPGs and TN-C. For example, in the presence of CSPGs, immature 
neonatal, but not mature adult, CNS axons have the ability to extend neurites (Condic, 
2001; Blackmore and Letourneau, 2006). This greater regenerative ability is thought 
to be due to the high expression of integrins within immature CNS neurons. In fact, 
embryonic neurons have the ability to upregulate integrin expression in the presence 
of inhibitory stimuli, including the CSPG, aggrecan, whereas mature neurons do not 
(Condic et al., 1999). However, if integrin heterodimers, such as α1β1 and α5β1, are 
overexpressed using exogenous gene transfer, neurite outgrowth from adult DRG 
neurons successfully occurs in the presence of CSPGs, producing outgrowth similar to 
that of embryonic neurons (Condic, 2001).  
During development, neurons have high levels of cAMP that are reduced upon 
maturation (Cai et al., 2001). Furthermore, there is a large body of research showing 
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integrin activation and intracellular cAMP levels can greatly alter growth cone motility 
and neurite extension. For example, when embryonic chick DRGs are cultured on low 
levels of laminin, basal integrin activation suppresses cAMP activity, which in turn 
facilitates Rho-GTPase-mediated growth cone motility. If integrins are activated 
(using Mn2+) or intracellular cAMP levels are increased (with Sp-cAMP, a cAMP 
analog) Rho-GTPase-mediated growth cone motility is also increased. However, if 
both are increased at the same time, integrin subunits are internalised which results in 
subsequent growth cone collapse (Lemons and Condic, 2006). Furthermore, this 
interaction is dependent upon the cell substrate as this outcome was only observed 
when cells were cultured on low concentrations, but not high concentrations of laminin 
or fibronectin (Lemons and Condic, 2006). In line with this and as discussed in section 
1.1.3.3, after injury a number of inhibitory proteins are upregulated after injury, such 
as Nogo-A, resulting in growth cone collapse (Joset et al., 2010) however 
reintroduction of cAMP has shown to have significant potential for stimulating neurite 
outgrowth in dorsal column axon (Qiu et al., 2002) and DRGs (Joset et al., 2010).  
To add to this complex issue, after axonal injury, there are a number of upregulated 
inhibitory proteins that can interfere with and inhibit integrin signalling preventing 
neurite outgrowth, including CSPGs (Tan et al., 2011) and myelin-associated proteins 
(Hu and Strittmatter, 2008). For example, Nogo-A signalling, and specifically the N-
terminal domain, amino-Nogo, can prevent integrin-mediated neurite outgrowth 
within COS-7 cells when cultured on fibronectin substrate in vitro (Hu and 
Strittmatter, 2008). However, this inhibition from amino-Nogo appears to be selective 
for specific integrin heterodimers including α4β1, α5β1, and αvβ3. Increasing 
activation of integrin subunits, such as β1, using Mn2+, selective activating antibodies 
or integrin activators such as kindlin-1, can overcome Nogo- or CSPG-mediated 
inhibitory signalling (Hu and Strittmatter, 2008; Tan et al., 2011; Cheah et al., 2016). 
This suggests that if integrin expression were increased after CNS injury, they would 
also need be activated to allow them to overcome the inhibitory environment.  
Furthermore, recent research has suggested the trafficking of integrin subunits, such 
as the α6, α9 and β1 subunits, within the adult CNS can be both age and region 
dependent with integrin transport restricted in adult CST and rubrospinal tract axons 
(Andrews et al., 2016). This is in contrast to the free movement of integrins in 
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embryonic CST axons and adult sensory and DRG axons (Andrews et al., 2016). As 
discussed earlier, trafficking of integrins is mediated by small GTPases. Specifically 
in vitro studies have shown that within the axons of the mature CNS, integrins are 
transported back to the cell soma via the GTPase Arf6 (Franssen et al., 2015), yet 
modulation of Rab11/Arf6 coupling, specifically Arf6 inactivation, can reinstate 
integrin trafficking in the anterograde direction in primary cortical neurons in vitro 
(Franssen et al., 2015). Furthermore, the axon initial segment (AIS) acts as a barrier 
of integrin transport within mature CNS axons, yet disruption of ankyrin-G within the 
AIS, restores integrin anterograde trafficking (Franssen et al., 2015). The reason for 
this exclusion of integrins in mature CNS axons is not fully understood, however it is 
widely accepted to be an evolutionary trait. As the mammalian CNS matures, it no 
longer requires widespread expression of growth-promoting proteins and therefore 
they are downregulated and trafficked out of axons back to the cell soma. It seems that 
even though increasing integrin expression can promote neurite outgrowth, there are 
both regional and age-dependent differences in the trafficking of integrins into the 
axonal compartment presenting a further complication for repair of the CNS.  
1.2.4 TN-C signalling through the a9b1 integrin heterodimer 
A number of downregulated integrin subunits have been researched for their ability to 
induce neurite outgrowth and axonal regeneration including α1 (Condic, 2001); α4 
(Vogelezang et al., 2001), α5 (Condic, 2001; Tonge et al., 2012) and α9 (Andrews et 
al., 2009). Of particular interest is the capacity of integrins to interact with components 
of the lesioned environment and specifically the ability of the α9β1 heterodimer to 
promote neurite outgrowth when bound to the glycoprotein TN-C (Andrews et al., 
2009).  
1.2.4.1 TN-C 
As discussed earlier, TN-C is one of the main ECM constituents of the CNS highly 
expressed during embryonic and neonatal development (Götz et al., 1997; Schweitzer 
et al., 2005). It is secreted by astrocytes and radial glial cells and is one of the growth-
promoting proteins associated with growth cone formation within the developing 
cerebral cortex (Götz et al., 1997), with fibronectin (Sheppard et al., 1991) and 
proteoglycans (Bignami et al., 1992) also being implicated in this process. 
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Additionally, it is also highly upregulated after CNS injury as it is secreted mainly by 
reactive astrocytes into the lesion site and surrounding area (Zhang et al., 1997; Tang 
et al., 2003; Andrews et al., 2009).  
Four tenascin isoforms have been identified including, TN-C, TN-R, TN-X and TN-
W, which differ in the number of epidermal growth factor-like (EGF-L) repeats and 
fibronectin type III (FNIII) domains they contain (Figure 1.7). The first isoform 
characterised was TN-C, which has nine different splice variants identified in humans 
(A1, A2, A3, A4, B, AD1, AD2, C and D) (Reviewed in Joester and Faissner, 2001). 
The TN-C protein is comprised of six protein monomers linked by disulphide bridges, 
forming a hexameric protein structure (Figure 1.7, A). Each monomer comprises a 
tenascin assembly (TA) domain/cysteine-rich heptad repeats, EGF-L repeats, FNIII 




Figure 1.7 Structure of TN-C. TN-C structure forms a hexabrachion, consisting of six protein 
monomers joined by disulphide bridges (A). Each monomer contains a TA domain/cysteine-rich heptad 
repeats, EGF-L repeats, FNIII domains and a FG globe located on the C-terminal (B). The FNIII 
domains can give rise to nine different splice variants; A1, A2, A3, A4, B, AD1, AD2, C and D. Figure 
modified from Jones and Jones, 2000. 
 
TN-C, located on chromosome nine in humans, is expressed within most tissues, 
including the brain, during embryonic and neonatal development (Bartsch et al., 
1992b; Götz et al., 1997; Schweitzer et al., 2005); however, within the brain 
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expression rapidly decreases with age (Bartsch et al., 1992a). During post-natal 
development in the somatosensory cortex, TN expression in deep layers five and six 
is reduced before upper layers with all TN expression diminished after postnatal day 
15 (Mitrovic et al., 1994). However, some regions of the adult brain are reported to 
maintain a basal expression of TN-C including the olfactory bulb, retina, and areas of 
the cerebellum (Bartsch et al., 1992a, 1992b; Miragall and Dermietzel, 1992; Bartsch 
et al., 1994). 
From KO mouse studies, research has shown TN-C is important for development and 
structure of the somatosensory and motor cortices (Irintchev et al., 2005). For example, 
cell densities within TN-C KO mice differed and although they displayed less 
GABAergic parvalbumin interneurons, overall KO mice had a larger proportion of 
neurons and astrocytes than controls. Furthermore, they also displayed aberrant 
dendritic morphology from pyramidal neurons in the motor and somatosensory 
cortices compared to control mice. Likewise, TN-C KO mice showed increased firing 
within the somatosensory cortex, likely due to the reduced inhibitory input from 
parvalbumin interneurons (Irintchev et al., 2005). With help from KO studies, the role 
of TN-C in neuronal plasticity has become clearer over the past decade, highlighting 
the contribution of TN-C in regulation of L-type voltage-gated channels to modify 
synaptic plasticity (Evers et al., 2002) and hippocampal learning and plasticity 
(Strekalova et al., 2002). Many of these contributions could potentially be explained 
by TN-C binding to integrins and subsequent ion channel activity via intracellular 
signalling (Gall et al., 2003).  
Research has shown TN-C can bind to two specific integrin receptors, α7β1 (Mercado 
et al., 2004) and α9β1 (Yokosaki et al., 1994) to promote neurite outgrowth. 
Specifically, α9β1 binds to the third FNIII repeat on TN-C (Yokosaki et al., 1994) via 
a specific three amino acid motif arginine-alanine-alanine (RAA) (Yokosaki et al., 
1998). This is unique as integrins commonly bind to a ligand recognition site 
containing the amino acid sequence, RGD (Reviewed in Hynes, 1987). TN-C can also 
induce neurite outgrowth by binding to other receptors including contactin, belonging 
to the immunoglobulin family (Rigato et al., 2002; Michele and Faissner, 2009). 
However, because α9 integrin when bound to β1 can interact with the inhibitory 
components of the lesioned CNS environment, specifically TN-C, to promote neurite 
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outgrowth, its expression and regulation is a promising area of research for axonal 
regeneration. 
1.2.4.2 The a9b1 integrin heterodimer 
The α9 subunit binds non-covalently with the β1 integrin subunit, forming the α9β1 
heterodimer (Palmer et al., 1993). The heterodimer is expressed in many mammalian 
cells including endothelial cells, muscle cells, and neutrophils (Palmer et al., 1993; 
Tarui et al., 2001; Vlahakis et al., 2005; Staniszewska et al., 2007). This expansive 
tissue expression profile may explain why this heterodimer can bind a diverse range 
of ligands including NGF, vascular adhesion molecule 1, osteopontin, 
thrombospondin, vascular endothelial growth factor, and TN-C (Smith et al., 1996; 
Yokosaki et al., 1998; Taooka et al., 1999; Vlahakis et al., 2005; Staniszewska et al., 
2007, 2008). It has also been implicated in a number of diseases including 
angiogenesis (Vlahakis et al., 2007), respiratory failure (Huang et al., 2000) and 
granulopoiesis (Chen et al., 2006).  
In contrast to β1, which has many binding partners, the α9 subunit only binds to the 
β1 subunit (Figure 1.3). The α9 integrin subunit is highly expressed during embryonic 
and neonatal development (Cohen et al., 1986; Lefcort et al., 1992; Condic, 2001) and 
is developmentally downregulated in the adult CNS. The α9 subunit is comprised of 
1,006 amino acids, which is split into an extracellular domain (947 amino acids), 
transmembrane domain (26 amino acids) and an intracellular domain (33 amino acids) 
(Palmer et al., 1993). Even though the α9 integrin intracellular domain is short in 
comparison to the extracellular domain, it is reportedly required for activation and 
associates with a number of intracellular signalling proteins including Src tyrosine 
kinase, inducible nitric oxide synthase (Gupta and Vlahakis, 2009), FAK, the adaptor 
protein p130Cas and Rho GTPases, including Rac1 (Gupta and Vlahakis, 2009). 
Upon TN-C binding to α9β1 integrin, it can promote cell migration, but this is 
dependent upon the adaptor protein, paxillin, binding to the α9 cytoplasmic domain 
(Young et al., 2001). Paxillin is a focal adhesion-associated signalling protein which 
links the integrin subunit with the cell cytoskeleton and other focal adhesion proteins 
including FAK and vinculin which further promotes binding of talin and actin to 
promote cell motility (discussed in section 1.2.2). 
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In summary, within the adult CNS the expression of α9β1 integrin subunit is 
developmentally downregulated. This integrin receptor however can modulate cell 
cytoskeleton activity to produce neurite outgrowth when bound to TN-C which is 
upregulated after injury. Increasing expression of α9β1 in vitro and indeed in DRG 
neurons in vivo can promote regeneration and neurite outgrowth. However, in an SCI 
environment where TN-C is upregulated, the a9b1 integrin subunit is not transported 
down axons of the adult CST (Andrews et al., 2016). This is thought to be due to 
reduced anterograde trafficking from small GTPases (Franssen et al., 2015; Andrews 
et al., 2016). Furthermore, inhibitory proteins at the lesion site inactivate integrins, yet 
research has shown that activation of integrins can overcome this. For the α9β1 
integrin to promote regeneration of the CST, it must firstly be expressed at or 
transported to the lesioned environment to interact with the upregulated TN-C and 
promote regrowth through the glial scar, whether that be by modulation of intrinsic 
signalling pathways, such as inactivation of Arf6 (Franssen et al., 2015) or use of cell 
transplantation, such as neural progenitor cells (NPCs). Yet as the literature has 
demonstrated, this is only the first step, and it is likely further modification will be 
required, such as integrin activation or ECM inhibition, to enable a9b1 integrin 
expression to remain present and activated at the lesion site to stimulate recovery. 
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1.3 Cell transplantation 
1.3.1 General background on cell transplantation after CNS injury  
Currents treatments for SCI are limited, however current research has offered up many 
potential therapies in the field of cell transplantation. Cell replacement is now widely 
accepted as a promising tool to help promote repair within the injured CNS. By 
replacing cells that have been lost or damaged due to an injury, there is hope cell 
transplants can aid axonal repair, regrowth, guidance, axonal sprouting, plasticity as 
well as stimulate remyelination. Following research, a number of cell types have been 
identified as potential candidates for cell replacement, each targeting a different aspect 
of SCI pathophysiology. These include oligodendrocyte precursor cells (OPCs), SCs, 
olfactory ensheathing cells (OECs), astrocytes, mesenchymal stem/stromal cells 
(MSCs), and neural stem and progenitor cells (NSPCs) (Reviewed in Tetzlaff et al., 
2011).  
Primarily, research has focused on physiological and functional outcomes following 
in vivo cell transplantation for SCI. These include cell survival, functional integration, 
migration, growth-promoting properties, and evidence of restoration in sensory, motor 
or autonomic function. The question remains as to how transplanted cells promote 
regeneration. The answer to this lies in the number of downstream effects occurring 
after cell transplantation including neurotrophin secretion, modulation of the immune 
response, axonal sprouting, enhancement of axonal guidance and restoration of 
myelination. Early clinical trial data has shown promising results for cell 
transplantation, including OECs and SCs, in SCI (Féron et al., 2005; Mackay-Sim et 
al., 2008; Saberi et al., 2011; Tabakow et al., 2013). Furthermore, tissue grafts have 
also been trialled in rat SCI models for CNS repair for example grafts of human 
embryonic spinal cord into immunodeficient rats with acute or chronic SCI (Wictorin 
and Björklund, 1992; Akesson et al., 2001) and although grafts can extend both 
caudally and rostrally from the lesion site, no significant functional improvements 
were demonstrated in these studies. 
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Cell transplants can be autologous, allogenic or xenogeneic. Autologous 
transplantation takes cells from one individual to be transplanted into the same 
individual, i.e. the host and donor are the same, negating the need for 
immunosuppression and hopefully reducing the likelihood of immune-mediated 
rejection. An allogenic transplant is where the recipient receives donor cells from the 
same species but the donor is not genetically identical to the host. This is the most 
common type of transplant in humans and requires immunosuppression. A xenograft 
is transplantation of cells from one species to a different species, for example 
transplant of human cells into a rat model, where immunosuppression is required to 
prevent graft rejection.  
1.3.2 The immune response following cell transplantation after CNS 
injury 
Following xenogeneic transplant, a host immune response is elicited against the donor 
cells. This largely consists of an upregulation of activated microglia and astrocytes, 
proliferation of activated T-cells and potential for infiltrating lymphocytes. Alongside 
this a vast number of chemokines and cytokines are secreted from these cells which 
further add to the inflammatory cascade (Reviewed in Hoornaert et al., 2017). This 
results in reduced graft survival and therefore immunosuppressant drugs are often used 
to prolong transplant survival. Alternatively, research studies may use neonatal 
transplant models to avoid immune-mediated rejection of transplants (Ideguchi et al., 
2010; Mattis et al., 2014).  
Research has shown transplantation of some cell types can actually modulate the host 
immune response and promote a pro-regenerative environment. For example, grafted 
mouse NPCs into the mouse spinal cord after either subacute or early chronic thoracic 
injury promoted a pro-regenerative environment by reducing the activation of pro-
inflammatory M1 macrophages and increasing the expression of regenerative genes 
including Nos2 (Cusimano et al., 2012). Even though only 10% of grafted cells 
survived 6 weeks post-transplant, the NPCs remained undifferentiated and clustered 
around the injury site, but were able to promote remyelination and functional recovery 
after subacute, but not chronic thoracic injury. Furthermore, this study identified a 
therapeutic window of opportunity for repair after less severe subacute injury as cells 
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were transplanted either 7 or 21 days post subacute injury with functional recovery 
only observed following the former. These results suggest that firstly, the type of cell 
used in transplantation studies may be a large factor in repair after SCI where certain 
cell types, such as NPCs, producing dual effects, such as stimulating remyelination as 
well as altering the immune response. Secondly, cell transplantation alone may not be 
able to promote functional recovery in more chronic injuries which likely requires 
further pharmacological intervention.  
One alternative to transplanting cells is to transplant the conditioned medium, which 
can contain secreted neurotrophins (Cantinieaux et al., 2013). Conditioned medium 
from bone marrow-derived MSCs promoted functional recovery of motor skills just  
4 days after thoracic contusion injury in the adult rat reducing the likelihood of cell 
rejection. Furthermore, these functional improvements are comparable to bone 
marrow-derived MSC grafts after spinal contusion (Karaoz et al., 2012) providing 
support for the beneficial effects of secreted neurotrophic factors in regeneration. 
Although this method of treatment resulted in no changes in gliosis or axonal 
regeneration when compared to controls, it did reduce neuronal apoptosis, increased 
angiogenesis and reduced the size of the lesion site, thereby promoting a pro-
regenerative environment. Similarly, conditioned media containing exosomes, such as 
those from primary rat SC-derived exosomes, can promote neurite outgrowth in rat 
mechanically-injured DRG explant cultures in vitro and stimulate regeneration of the 
rat sciatic nerve after a crush injury in vivo (Lopez-Verrilli et al., 2013). These 
mechanisms provide potential cell-free alternatives for bypassing the immune 
response to enable repair after injury. 
1.3.3 Types of cells used in transplant for research of SCI 
1.3.3.1 Transplant of oligodendrocytes and SCs after SCI 
One of the main issues preventing regeneration after injury is the distinctive and drastic 
demyelination and Wallerian degeneration of severed or injured axons (Totoiu and 
Keirstead, 2005). Promoting remyelination by transplanting cell types, such as 
oligodendrocytes and SCs, is one of the main goals of cell replacement therapy for 
SCI. Oligodendrocytes are the main myelinating cell of the CNS and transplants of 
OPCs can promote remyelination after CNS and spinal injury (Bambakidis and Miller, 
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2004; Cao et al., 2010; Chen et al., 2015; Sun et al., 2013). For example, following 
contusion of the thoracic spinal cord in adult rats, transplant of adult OPCs expressing 
ciliary neurotrophic factor (CNTF), which supports the survival and generation of 
oligodendrocytes (Barres et al., 1993, 1996), differentiated into oligodendrocytes in 
vivo and promoted remyelination which resulted in recovery of hindlimb function 
when assessed using the Basso, Beattie, Bresnahan (BBB) locomotor scale after injury 
(Cao et al., 2010). Similarly, mouse embryonic stem cell (ESC)-derived OPC grafts 
promoted remyelination and functional recovery following radiation-induced SCI in 
adult rats (Sun et al., 2013) and hypoxic-induced brain injury in neonatal rats (Chen et 
al., 2015), thus exhibiting pro-regenerative effects across a wide range of CNS injuries.  
Unlike, the CNS, the PNS has an intrinsic capacity to regenerate after injury, in part 
owing to the presence of SCs (Reviewed in Jessen and Mirsky, 2016), the myelinating 
cells of the PNS. The ability for SCs to promote remyelination of the CNS was 
discovered in the early 1980s (Duncan et al., 1981) and since then SC transplantation 
has been of great interest in the field of SCI repair. Research shows SC grafts can 
prompt axonal remyelination, improve conductance and enhance repair in the CNS 
after injury (Honmou et al., 1996; Xu et al., 1997; Kohama et al., 2001; Takami et al., 
2002; Pearse et al., 2004; Sparling et al., 2015). Furthermore, SC grafts alone can 
promote functional repair of hindlimb movements, assessed using the BBB locomotor 
scale (Takami et al., 2002). Literature suggests SCs may have better functional 
outcomes when used as a co-treatment, for example with cAMP or matrices (Pearse et 
al., 2004; Hurtado et al., 2006; Pearse et al., 2007). Transplant of SCs alone show that, 
although regeneration can occur, it is restricted and does not go much further than the 
lesion site (Montgomery et al., 1996; Shields et al., 2000) as transplanted SCs do not 
migrate out of the glial scar (Andrews and Stelzner, 2007). In contrast, after SCI 
endogenous SCs migrate long distances to invade the lesion site to aid axonal repair 
and remyelination (Guest et al., 2005; Reviewed by Zhang et al., 2013). This process 
of migration can also be enhanced using transplant of other cell types, including 
exogenous SCs and OECs (Ramer et al., 2004; Zhang et al., 2013). This body of 
research formed the basis for the start of clinical trials using SC grafts for SCI 
treatment (Saberi et al., 2011).  
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1.3.3.2 Transplant of OECs after SCI 
OECs are located within the olfactory bulb and olfactory mucosa working to aid 
guidance and elongation of olfactory axons going from the PNS to the CNS ( Graziadei 
and Graziadei, 1979; Doucette, 1991). Similar to SCs, OECs have the ability to 
promote regeneration of PNS axons and therefore their ability to promote regeneration 
of the CNS has also been investigated (Ramón-Cueto and Nieto-Sampedro, 1994; Li 
et al., 1997; Ramón-Cueto et al., 1998; Reviewed in Mackay-Sim and St John, 2011). 
Regenerative characteristics of OECs include secretion of neurotrophins, including 
NGF and BDNF (Woodhall et al., 2001; Lipson et al., 2003), expression of adhesion 
proteins, including neural cell adhesion molecule (NCAM) (Miragall et al., 1988) and 
secretion of laminin, known for its axonal guidance and outgrowth properties (Ramón-
Cueto and Nieto-Sampedro, 1992). Research has shown OEC grafts are able to 
promote physiological axonal regeneration after crush of the dorsolateral funiculus 
within the adult rat cervical spinal cord shown by increased sprouting into the lesion 
site and reduction of reactive astrocytes around the lesion (Ramer et al., 2004). This 
result may have been enhanced by the ability of OECs to stimulate endogenous SC 
infiltration to the injury site (Ramer et al., 2004; Zhang et al., 2013), further adding to 
the pro-regenerative environment.  
Research has suggested functional recovery after OEC grafts in SCI models can be 
limited. For example, following transplant of OECs into an adult rat thoracic contusion 
SCI model, no hindlimb functional recovery was observed following assessment using 
the BBB locomotor scale (Takami et al., 2002). In contrast, OEC grafts in combination 
with rehabilitation involving treadmill step training were able to promote hindlimb 
functional regeneration after complete thoracic transection in adult rats (Kubasak et 
al., 2008). Recent encouraging research in humans has demonstrated OEC transplants 
can induce functional movements in a previously paraplegic individual following 
transplant into the injured thoracic spinal cord (Tabakow et al., 2014). The autologous 
OEC graft also contained olfactory nerve fibroblasts and was combined with a 
peripheral nerve graft alongside rigorous physical rehabilitation. As a result, the 
patient’s sensory, motor and autonomic function improved, progressing from Grade A 
to Grade C on the American Spinal Injury Association (ASIA) impairment scale with 
the patient showing an increase in muscle mass within the left thigh, return of reflex 
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activity within the Achilles tendon and an increase in bladder sensation (Tabakow et 
al., 2014).  
1.3.3.3 Transplant of astrocytes after SCI 
Astrocytes are known to have a crucial support role within the CNS, including 
metabolic support (Reviewed in Magistretti, 2011; Suzuki et al., 2011), promotion of 
synaptogenesis (Ullian et al., 2001, 2004; Christopherson et al., 2005) and secretion 
of neurotrophic factors (Bozoyan et al., 2012). However due to the understanding that 
reactive astrocytes are associated with inhibition of SCI regeneration, it is only in 
recent years that the regenerative potential of glial support cells, such as astrocytes, 
has been discovered with research now showing astrocyte grafts can promote repair of 
injured axons after SCI (Davies et al., 2006; Filous et al., 2010; Fan et al., 2012; Haas 
and Fischer, 2013).  
It has been suggested that immature glial-derived astrocytes hold a better regenerative 
capacity compared to glial precursors (Davies et al., 2006) or mature astrocytes (Filous 
et al., 2010). This may be due to the ability of immature astrocytes to overcome a 
CSPG-rich barrier in vitro (Filous et al., 2010). In addition, the methods used for 
differentiation of astrocytes from precursor cells, such as bone morphogenetic protein 
(BMP) and CNTF, can affect their regenerative ability, with transplant of BMP-
differentiated astrocytes resulting in better functional recovery after SCI (Davies et al., 
2008, 2011). Specifically, rats that received a graft of BMP-differentiated immature 
astrocytes improved faster when subjected to a grid-walk test compared to those that 
received a CNTF-differentiated astrocyte graft or a glial progenitor cell graft, 
promoting a discernible difference in behavioural recovery following unilateral 
transection of the dorsolateral funiculus (Davies et al., 2011). In contrast, subsequent 
research has shown transplant of human glial-restricted progenitors (hGRPs) from 
frozen stocks were compared to transplants of hGRP-derived astrocytes into cervical 
dorsal column lesion of adult rats (Haas and Fischer, 2013). Results show both have 
equal ability to promote axonal regeneration indicating hGRPs may not require in vitro 
differentiation before transplant. Furthermore, because these cells were from frozen 
stocks, this reduced the in vitro culture time for these cells before transplant and 
increases their potential for clinical application, however the full extent of their 
regenerative capacity has yet to be examined.  
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Astrocytes express a lower level of inhibitory CSPGs and a higher level of glial cell-
derived neurotrophic factor (GDNF) than other astrocyte subsets and other populations 
of glial precursor cells. This suggests astrocytes have an endogenous pro-regenerative 
capacity to survive in an inhibitory environment highlighting their potential for 
transplantation to promote repair after SCI (Davies et al., 2011). However, what is 
now also becoming clear is that grafted cells do not need to survive to promote a 
regenerative effect on the CNS. Davies and colleagues have also shown that the 
neuroprotective effects of transplanted astrocytes into the injured CNS outlast survival 
of the grafts (Davies et al., 2011) questioning the survival requirement of grafted cells. 
1.3.3.4 Transplant of MSCs after SCI 
Mesenchymal stem/stromal cells (MSCs), isolated from a number of sources, such as 
human bone marrow and adipose tissue, can be expanded in culture and differentiated 
into a variety of cell types including neuronal and glial cells (Sanchez-Ramos et al., 
2000; Woodbury et al., 2000; Kim et al., 2006; Radtke et al., 2009; Bae et al., 2011; 
Ma et al., 2011). MSCs have been researched for their use in regeneration for a number 
of different CNS conditions including multiple sclerosis (Yamout et al., 2010), 
Parkinson’s disease (Venkataramana et al., 2010) and SCI (Neuhuber et al., 2005; 
Cízková et al., 2006; Jung et al., 2009; Pal et al., 2009; Osaka et al., 2010; Xiong et 
al., 2017).  
How MSCs promote regeneration is not completely understood, however, research has 
shown MSC transplants can reduce the inflammatory response following ischaemic 
injury in mice (Ohtaki et al., 2008) and at the injury site following contusion SCI in 
rats (Abrams et al., 2009). Furthermore, intravenous injection of MSCs can reduce 
lesion size and increase expression of neurotrophins, such as BDNF, within the lesion 
site following thoracic contusion SCI in rats (Osaka et al., 2010), which is known to 
promote CST recovery after SCI (Jakeman et al., 1998; Sasaki et al., 2009). In fact 
whilst in culture, human MSCs can secrete a number of other neurotrophins alongside 
BDNF including NGF, vascular endothelial growth factor and hepatocyte growth 
factor, potentially encouraging the creation of a permissive environment for axonal 
repair (Chen et al., 2002). In addition, MSCs can promote angiogenesis after ischaemic 
injury (Toyama et al., 2009), axonal sprouting in a rat stroke model (Shen et al., 2006) 
and dorsal hemisection in a rat SCI model (Sasaki et al., 2009).  
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Within the past decade clinical trial data has emerged for MSC use after SCI in human 
patients (Callera and do Nascimento, 2006; Yoon et al., 2007; Saito et al., 2008) and 
even though functional improvements were observed in patients with an acute SCI, no 
improvements were observed in those with a chronic SCI (Yoon et al., 2007). One 
reason MSCs attract interest is because they can be used for autologous transplantation 
and therefore it is of great interest to explore their mechanisms and uses for 
regeneration after SCI as well as other neurologic conditions and diseases. 
1.3.3.5 Transplant of NSPCs after SCI 
NSPCs have the ability to self-renew and continuously proliferate until they 
differentiate into neuronal or glial cells. These attributes highlight the potential for 
their ability to promote regeneration after CNS injury where a number of different cell 
types are lost or injured. NSPCs can be either embryonic, active during embryogenesis 
and neurodevelopment, or adult, active in the certain areas of the mature CNS. The 
adult mammalian brain has a small proportion of NSPCs, located within the 
subventricular zones and the hippocampus (Reviewed in Ma et al., 2009). In rodents, 
NSPCs have also been identified within the spinal cord (Johansson et al., 1999; Horner 
et al., 2000). 
A large body of research has now shown transplantation of NSPCs promotes 
regeneration and functional recovery after SCI (Ogawa et al., 2002; Cummings et al., 
2005; Karimi-Abdolrezaee et al., 2006; Bonner et al., 2011; Lu et al., 2012b; Kadoya 
et al., 2016). For example, following complete transection of the thoracic (T3) spinal 
cord in rats, grafted embryonic rat NSCs promoted recovery when embedded in a fibrin 
matrix alongside growth factors (Lu et al., 2012b). Specifically, the grafted NSCs were 
able to project long-distances both caudal, reaching L1, and rostral to the lesion site, 
reaching C4, within the spinal cord. These projecting fibres were observed within host 
white matter tissue and were myelinated by rat host oligodendrocytes, likely leading 
to the enhanced electrophysiological recovery observed and improvements in hindlimb 
function assessed using the BBB open field locomotion test (Lu et al., 2012b). 
Myelination of grafted mouse NSCs was also observed following transplant into a rat 
subacute SCI model, however this myelination was due to approximately 50% of 
mouse grafted cells differentiated into myelinating oligodendrocytes in vivo post-
transplantation (Karimi-Abdolrezaee et al., 2006), however this did result in functional 
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recovery when animals were assessed using grid-walking and footprint analysis. In 
contrast, myelination of transplanted rat NPCs has been supported by recent research 
showing 24% of axons extending from transplanted rat NPCs can become myelinated 
by host rat oligodendrocytes in rat models of cervical SCI (Hunt et al., 2017). 
Interestingly, this myelination was dependent on the axon diameter, and in particular 
axons with a larger diameter were preferentially myelinated over smaller diameter 
axons (Hunt et al., 2017). Together this research indicates host rat oligodendrocytes 
may be able to promote myelination of projections extending from rat, but not mouse 
NSPCs. If transplanted NPC-derived neurons within the injured spinal cord are to 
promote functional recovery, the ability of host oligodendrocytes to myelinate grafted 
axons will be important for long-term sustainable recovery.  
The underlying mechanisms of NPC-induced regeneration, like many cell grafts, are 
largely unknown, however NPCs are able to promote neurotrophin release at the site 
of SCI (Hawryluk et al., 2012), reduce lesion cavity size (Hong et al., 2014), promote 
remyelination (Karimi-Abdolrezaee et al., 2006) and modify the immune response 
(Cusimano et al., 2012). However, the means by which NSPCs promote regeneration 
likely depends upon the differentiation status of the cells both before and after 
transplant. The differentiation status of NSPC transplants and the associated 
regenerative outcome has also come under debate with research suggesting NSCs must 
be differentiated into a neuronal lineage before transplantation to promote repair. 
NSCs transplanted into a contused thoracic (T8) rat spinal cord were restricted to a 
glial phenotype, while NSCs transplanted into an uninjured control favoured 
differentiation into a neuronal phenotype suggesting the inhibitory environment 
prevented the NSCs differentiation into a neuronal phenotype (Cao et al., 2002). 
Indeed, research has shown transplanting a mixed population of neuronal-restricted 
progenitors (NRPs) and glial-restricted progenitors (GRPs) into a dorsal column lesion 
of the rat spinal cord, promoted formation of relay connections between grafted and 
host cells across the lesion site (Bonner et al., 2011). Furthermore, this combination 
of cells was previously shown to overcome a CSPG-rich inhibitory environment to 
promote axon growth in hippocampal cultures (See et al., 2010). However, in addition 
to their benefits, use of NSCs pose some challenging questions including their ability 
to form colonies elsewhere in the brain via migration and induce aberrant signalling 
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(Steward et al., 2014). This research adds to the growing debate highlighting that if 
cell replacement and specifically replacement of neuronal connections is an aim of 
NSPC transplants after SCI, differentiating cells into a neuronal lineage before 
transplantation is of high importance. 
1.3.4 Use of stem cells for CNS repair: ESCs vs iPSCs 
First characterised almost 20 years ago (Thomson et al., 1998), human embryonic stem 
cells (hESCs) start life within the inner mass of mammalian blastocysts (Figure 1.8). 
Blastocyst formation is an early stage of embryo development which has raised ethical 
concerns surrounding the use of hESCs in research. Because stem cells can 
differentiate into all three germ layers (Evans and Kaufman, 1981) and therefore any 
cell type, their therapeutic potential for modelling disease and replacing damaged cells 
is endless. However, because of the limitation of this cell source as well as the ethical 
issues surrounding ESC use, researchers sought alternative mechanisms and sources. 
A breakthrough came in 2006 which radically changed the field of stem cell research. 
This Nobel Prize winning work was carried out by John B. Gurdon and Shinya 
Yamanaka, who discovered that somatic cells could be dedifferentiated to a pluripotent 
state with expression of just four transcription factors, Oct3/4, Sox2, Klf-4 and C-Myc 
(Takahashi and Yamanaka, 2006; Takahashi et al., 2007). Cells within this pluripotent 
state were then able to differentiate into any somatic cell and were therefore termed 
induced pluripotent stem cells (iPSCs). As with ESCs, iPSCs have self-renewal and 
proliferative properties, resulting in an endless supply of stem cells, which can be 
produced by dedifferentiating any somatic cell type, such as fibroblasts. The discovery 
of this groundbreaking technique has resulted in widespread use of iPSCs in vitro, 
analysing gene and protein expression, and also in vivo, examining their capabilities 
and functions in modelling and treatment of human diseases, with the eventual hope 
of personalised medicine. As a result, stem cell transplantation has become a viable 
possibility in the treatment of a wide range of CNS conditions and diseases, including 
Parkinson’s disease, cancers, multiple sclerosis, Alzheimer’s disease, stroke and SCI.  
 





Figure 1.8. Differences in culture of ESCs and iPSCs. ESCs originate within the fertilised egg  
(a zygote), which develops into a ball of cells termed a blastocyst. The inner cell mass of the blastocyst 
contains pluripotent ESCs, which can be harvested for in vitro and in vivo experimentation. In contrast, 
iPSCs can be derived from any cell type, such as a fibroblast, which can be virally modified to express 
four transcription factors, (also termed Yamanka factors) including Oct3/4, Sox2, Klf4 and c-Myc. Once 
expressed, the fibroblast dedifferentiates into a pluripotent state comparable to the pluripotent state of 
ESCs. At this stage both ESCs and iPSCs can differentiate into any of the three germ layers, mesoderm, 
ectoderm or endoderm, and therefore any cell type within the body. Figure modified from Zhu et al., 
2011. 
 
There is however concern that use of iPSC-derived cells are not equivalent to ESC-
derived cells and cannot replace ESCs. While there are a number of aspects in which 
both ESCs and iPSCs are similar, including self-renewal, proliferative potential and 
morphology, there are also some distinct differences associated with genome integrity, 
gene expression and proliferative regulation (Baker et al., 2007; Chin et al., 2009; 
Mayshar et al., 2010). As a result, questions remain about the therapeutic potential of 
iPSCs.  
Specifically, the genomic integrity of iPSCs has come into question with research 
highlighting loss of genomic stability following both dedifferentiation and 
Using human iPSC-derived neural progenitor cells to increase integrin expression in the CNS 
45 
 
differentiation (i.e. reprogramming) (Mayshar et al., 2010). When stem cells are 
maintained in culture, they are exposed to a different environment than an in vivo 
environment and are kept in an unnatural proliferative state. Research has shown that 
over time this progressive selective pressure on iPSCs can introduce chromosomal 
abnormalities resulting in the cell adopting a continuous growth rate (Mayshar et al., 
2010). Karyotypic abnormalities have however been identified in both ESCs ( Draper 
et al., 2004; Baker et al., 2007) and iPSCs (Kim et al., 2009; Mayshar et al., 2010) as 
a result of in vitro culture adaptation. Genomic aberrations have been identified in 
chromosome 1, chromosome 9 (Kim et al., 2009) and chromosome 12 (Mayshar et al., 
2010) in iPSCs. Chromosome 9 has been linked with germ cell tumours ( Reuter, 2005; 
Looijenga et al., 2006), and abnormalities in chromosome 12, particularly trisomy, can 
result in upregulation of cell cycle-associated genes, as well as increased expression 
of pluripotency genes, such as NANOG and growth differentiation factor 3 (GDF3) 
(Mayshar et al., 2010). Within ESCs, karyotypic abnormalities have also been 
identified in chromosome 12 (Draper et al., 2004; Baker et al., 2007), as well as 
chromosome 17 (Baker et al., 2007; Mayshar et al., 2010), which has been linked with 
cancers including neuroblastomas (Łastowska et al., 2002) and breast cancer 
(Tirkkonen et al., 1998). The abnormalities discussed could be due to a number of 
aspects of stem cell culture. Differences in oxygen concentration between in vitro and 
in vivo environments, which can result in abnormal shortening of telomeres (von 
Zglinicki et al., 2000), or the enzymatic passaging of cells in bulk using trypsin, which 
can induce stress and result in chromosomal abnormalities in early cell passages 
(Mitalipova et al., 2005). Together these results suggest both ESCs and iPSCs can 
contain aberrant karyotypes some of which may confer increased growth rate and 
tumorigenicity, all of which are important factors when considering stem cell 
transplantation.  
Research has also shown that early-passage iPSCs have a different gene expression 
profile to ESCs, with iPSCs expressing more genes involved in differentiation 
compared to ESCs (Chin et al., 2009). Furthermore, this distinct gene expression 
pattern was conserved between mouse and human iPSCs derived from a number of 
different cells types. Yet, with increased passage of iPSCs in culture, the gene 
expression profile becomes more similar to ESCs (Chin et al., 2009). These karyotypic 
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changes result in either, potential changes in chromosomes involved in tumour 
formation, or increased cell cycle protein expression, resulting in uncontrollable 
proliferation, another major concern when using stem cells in vivo.  
1.3.5 ESC and iPSC and cell derivatives in CNS transplantation 
When considering stem cell-based therapies in humans, it is likely that stem cells or 
stem cell-derived cells will be either pre-differentiated, to reduce the presence of 
undifferentiated cells and minimise the risks associated with uncontrollable 
proliferation, or preconditioned in vitro prior to transplant to enhance the cells ability 
to survive in vivo (Reviewed in Khatiwala and Cai, 2016). The type of pre-
conditioning is likely to vary depending on the cell type and the injury/disease for 
which the treatment is targeting, but could include prior differentiation into a specific 
cell lineage, such as neuronal or glial cell, or exposure to certain culture conditions, 
such as hypoxia to promote cell survival (Stacpoole et al., 2011).  
Nonetheless research has demonstrated successful transplantation of undifferentiated 
stem cells which differentiated after transplant in vivo with minimal karyotypic 
changes identified (Bjorklund et al., 2002; Park et al., 2005). Within the field of CNS 
injury, embryonic-derived cells have shown promise with the ability to differentiate 
into cortical neurons in vitro (Gaspard et al., 2008) which functionally integrate into 
the host mouse brain after transplant (Espuny-Camacho et al., 2013). Furthermore, 
research has demonstrated transplanted ESCs can differentiate in vivo, for example 
into dopaminergic neurons, when transplanted into the striatum of rodent models of 
Parkinson’s disease (Bjorklund et al., 2002; Park et al., 2005). However, direct 
transplantation of undifferentiated stem cells is associated with risks, including tumour 
formation, and therefore for clinical application differentiation of stem cells prior to 
transplant will most likely be required. Indeed, ESCs have been successfully 
differentiated prior to transplantation into a number of cell types including OPCs and 
NPCs prior to transplant. For example, ESC-derived OPCs promoted remyelination 
and repair after SCI (Keirstead et al., 2005; Sharp et al., 2010) and ESC-derived NPCs 
injected into the deep layers of the mouse cerebral cortex were able to further 
differentiate in vivo into pyramidal neurons (Ideguchi et al., 2010). Research has also 
shown that following transplantation of pre-differentiated neurons derived from ESCs 
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into the rat neonatal brain, donor axons are able to follow host white matter tracts 
(Denham et al., 2012).  
Similarly, research has demonstrated iPSC-derived cells are beneficial in animal 
models of CNS and spinal injury (Nori et al., 2011; Tornero et al., 2013; Lu et al., 
2014). Not only are iPSC-derived cortical neurons capable of forming functional 
synapses in vitro (Shi et al., 2012a, 2012b), transplants of human iPSC-derived NPCs, 
which have been induced in vitro to develop into cortical neurons, can integrate within 
the injured cortex, promote recovery and restore function following stroke-induced 
injury in the rat somatosensory cortex (Tornero et al., 2013). Tornero and colleagues 
also transplanted un-fated hiPSC-NPCs as a control into the same injury model. 
Following transplant analysis of both un-fated and fated hiPSC-NPCs at the graft site, 
results showed the number of un-fated cells was almost double that of cortically-fated 
cells at the graft site. This was due to a higher proportion of proliferative cells indicated 
by positive Ki67 expression within the un-fated cell graft. These results suggest that 
although no tumour formation was observed within this study, un-fated cells have a 
higher risk of tumour formation due to the increased proliferation rate and implies over 
time tumour formation may occur. Despite this reduction in the number of cortically 
fated cells, functional recovery of the forelimb was comparable between the two 
groups and while no functional differences were observed in regeneration, the fated 
cells were able to extend higher density projections within the host brain (Tornero et 
al., 2013). Collectively these results suggest cortically-fated hiPSC-derived NPCs may 
be better suited to clinical applications than un-fated equivalents.  
One of the main advantages iPSCs have over ESCs is their potential for autologous 
transplantation, thereby evading the host immune response, allowing for further graft 
integration. Other than skin fibroblasts, there are a number of different cell types being 
investigated for generation into iPSCs including keratinocytes, melanocytes, cord 
blood cells and adipose tissue-derived stem cells (Reviewed in Khazaei et al., 2014). 
This type of personalised medicine is however both time-consuming and costly as cells 
would need to be tailor made to match the patient, so alternative easier methods for 
producing patient-specific cell types need to be found. One potential avenue may be 
the creation of iPSC banks which contain stem cells from donors screened for specific 
human leukocyte antigens which match a large percentage of the population 
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(Reviewed in Cyranoski, 2012; Baghbaderani et al., 2015; Reviewed in Solomon et 
al., 2015; Holmqvist et al., 2016).  
1.3.6 Transplantation of stem cell-derived NSPCs for repair of CST 
axons  
One of the key pathways within the spinal cord which governs communication of both 
sensory and motor information between the brain and the rest of the body is the CST. 
This projects from the cerebral cortex through the brain and down the spinal cord 
(Figure 1.9). Research has shown CST axons have a reduced capacity to regenerate 
(discussed in section 1.1.4) compared to the reticulospinal, raphespinal and 
propriospinal tracts (Xu et al., 1995; Vavrek et al., 2007; Lu et al., 2012a; Lee et al., 
2013). After injury there can be spontaneous sprouting and recovery of CST axons 




Figure 1.9 Neuroanatomical location of the corticospinal pathway in humans and rats. Within 
humans (A) and rats (B, C) the CST, one of the main sensorimotor pathways in the brain, follows a 
similar pathway. The descending CST originates within layer V of the sensorimotor cortex where axons, 
mainly from pyramidal neurons, project towards and bundle within the corona radiata projecting into 
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the internal capsule. They then extend down towards the cerebral peduncles within the midbrain. From 
there the fibres extend into the brain stem into the ventral pons and pyramids within the medulla before 
crossing at the pyramidal decussation located at the caudal medulla, where the axons then enter the 
spinal cord. Around 80-85% of fibres cross over at the pyramidal decussation where fibres originating 
in one hemisphere cross over to control the opposite side of the body. These fibres go on to form the 
lateral CST which synapse with cells within the ipsilateral anterior horn. The remaining 10-15% of 
uncrossed fibres carry on to form the anterior CST which projects down the spinal cord and cross over 
to the contralateral spinal cord once they reach the spinal level they are innervating. The point at which 
they cross is termed the anterior white commissure located within the anterior spinal cord and they 
synapse within the anterior horn. Figure A modified from Waxman, 2010, figures B and C modified 
from Welniarz et al., 2015. 
 
Transplantation of stem cell-derived NSPCs has tremendous potential to promote 
repair following CST injury by replacing damaged cells, re-connecting neuronal 
circuitry, modulating the immune response or secreting growth-promoting proteins in 
both rodent and non-human primate SCI models (Ideguchi et al., 2010; Nori et al., 
2011; Cusimano et al., 2012; Kobayashi et al., 2012; Lu et al., 2012b, 2014; Kadoya 
et al., 2016; Lu et al., 2017). For example, 9 days following moderate cervical spinal 
cord contusion in adult immunosuppressed marmosets, human iPSC-derived NSCs 
were transplanted into the lesion site (Kobayashi et al., 2012). Results showed grafted 
cells survived up to 12 weeks in vivo (longest time point analysed), promoted 
angiogenesis, axonal regeneration and neurotrophin release, whilst also preventing 
axonal demyelination. However, in contrast to recent research in rats (Hong et al., 
2014) the lesion size was not reduced. Together these outcomes resulted in significant 
motor recovery of both upper and lower limbs following assessment in the open field, 
bar grip and cage climbing tests (Kobayashi et al., 2012). This work also highlighted 
the lack of tumour formation within these un-fated iPSC-derived NSCs reinforcing 
their potential for clinical application.  
Furthermore, significant CST regeneration has been observed following 
transplantation of multipotent rat NPCs (derived from embryonic spinal cord) into the 
rat spinal cord 2 weeks after complete thoracic (T3) transection (Kadoya et al., 2016). 
Specifically, regenerating fibres were observed within the NPC graft and beyond the 
lesion site, with host axons forming synaptic connections with grafted cells (Kadoya 
et al., 2016). In contrast and contradictory to previous research, grafts of SCs or MSCs 
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secreting neurotrophic factors were unable to induce regrowth of CST axons within 
the same injury model which suggests the regenerative effects were specific to NPCs 
(Kadoya et al., 2016). Results from this study also showed NPC grafts reduced the 
presence of reactive astrocytes at the graft-host interface, adding a further potential 
mechanism by which NPCs can promote regeneration. Interestingly, this work 
demonstrated that for NPCs to exert a regenerative effect, they need to be in contact 
with injured CST axons, signifying potential ligand-receptor interactions (Kadoya et 
al., 2016). 
Moreover, Kadoya and colleagues suggested that the tissue origin of transplanted 
NPCs impacts the ability of endogenous CST axons to regenerate (Kadoya et al., 
2016). For example, NPCs derived from embryonic spinal cord were able to promote 
regrowth of endogenous CST fibres into the lesion site compared to NPCs derived 
from embryonic telencephalon which resulted in no CST axons penetrating the graft 
site. Similarly, when human iPSC-derived NPCs were injected into the same injury 
model, results showed extensive CST regrowth into the lesion site, but only if the 
hNPCs were caudalised (Kadoya et al., 2016). Therefore, endogenous CST axons are 
capable of regeneration, however it appears the origin and location of the graft can 
significantly impact the regenerative outcome. This finding is of particular interest, 
especially when considering use of iPSC-derived cells which can originate from a 
number of different somatic cell types. For the most part the cells used by Kadoya and 
colleagues in this instance were derived from embryonic tissue; however, they did 
repeat the experiment with human iPSC-derived NPCs, which were able to promote 
significant CST regeneration and strengthened the potential of iPSC-based 
regeneration (Kadoya et al., 2016).  
Previous work from Lu and colleagues (Lu et al., 2012b) has shown that rat iPSC-
NSCs as well as human NSCs within a fibrin matrix containing growth factors can 
overcome the inhibitory environment created after injury and therefore this treatment 
does not need to be combined with further treatments targeting the inhibitory ECM. 
Perhaps these cells have the ability to combat this inhibitory milieu. Indeed, research 
has shown NSPC grafts are able to reduce the inflammatory response after thoracic 
contusion in mice and reduce the activation of M1 macrophages (Cusimano et al., 
2012). However, the full extent of iPSC-derived NPC on regeneration has not yet been 
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uncovered, but the differentiation of NPCs into different cell types, including neuronal 
and glial phenotype, will likely decipher the regenerative impact and outcome. 
Nevertheless, stem cell-derived cells can be pre-differentiated or set onto a particular 
differentiation pathway prior to transplantation. In these situations, where cells have 
been forcefully guided towards a specific neuronal phenotype, the gene expression 
within these cells must be carefully considered to prevent unwanted projections to off-
target neuroanatomical regions. For example, for grafted cells to project subcortically 
and selectively within the CST, analysis of the expression profile, including expression 
of chicken ovalbumin upstream promoter transcription factor interacting protein 2 
(Ctip2) (Arlotta et al., 2005; Chen et al., 2008a) and neuropilin-1 (Sano et al., 2017) 
is required. Before cells can be considered for transplant the expression profile of cells 
needs to be fully examined and expression of genes, outside of those expressed within 
the target area, may need to be masked or knocked down. Similarly, the method of 
differentiation of ESC-derived NPCs in culture prior to transplant can have a 
noticeable effect on the gene expression (Ideguchi et al., 2010). ESC-derived NPCs 
were targeted to differentiate into a cortical neuron phenotype by either co-culturing 
them with mouse MS5 stromal cells in vitro or treatment with retinoic acid prior to 
transplantation into the neonatal cerebral cortex of mice. In culture, the NPCs grown 
on a MS5 feeder layer expressed a higher proportion of deep-layer cortical neuron 
markers, including Ctip2, compared to the cells that received the retinoic acid 
treatment. Furthermore, following transplant NPCs grown on MS5 feeder cells were 
able to project large fibre bundles within the descending CST compared to sparse 
fibres from retinoic acid-treated NPCs (Ideguchi et al., 2010). These results indicate 
the type of mechanism of neuronal differentiation can greatly affect the gene 
expression of cells, and although these cell types both differentiated into cortical 
neurons, the distinct profile expression of layer V is required in order for projections 
to extend large fibre bundles within the CST. Importantly this study demonstrated 
ESC-derived NPCs transplanted into the motor cortex of neonatal mice were able to 
project within the CST, as far as the cervical spinal cord (the furthest location 
analysed) only 2-3 weeks after transplantation (Ideguchi et al., 2010) indicating that 
these cells are capable of extending long-distance projections.  
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1.3.7 Combination of treatments likely to give best chance of 
functional recovery 
Although individually each type of cell transplant discussed above has promising 
regenerative potential and some are even able to evade or even modify the external 
environment, such as the inflammatory response, it is likely long-term robust 
functional regeneration will be achieved using a combination of treatments. 
Transplanting cells after CNS injury to either replace damaged cells or promote 
remyelination, alongside treatments which can modulate the inhibitory milieu, will 
likely address multiple obstacles associated with prevention of SCI repair. 
Regeneration of axons in general is impeded by the glial scar and inhibitory 
environment and therefore the best outcome may come from cell transplants used in 
co-treatments alongside modulatory agents of the ECM (Fouad et al., 2005; Filous et 
al., 2010; Kanno et al., 2015). For example, combining a cell graft containing 
myelinating SCs and OECs in conjunction with ChABC treatment resulted in better 
regeneration following complete SCI in adult rats compared to cell grafts alone or 
controls (Fouad et al., 2005). This approach attempted to address multiple aspects of 
SCI pathophysiology and resulted in remyelination and regrowth of damaged fibres 
through and caudal to the graft site and significant functional improvements in the 
forelimb and hindlimb following assessment using the BBB scale (Fouad et al., 2005). 
Similarly, when immature astrocytes were transplanted alongside ChABC into the 
lesion site, regeneration of sensory axons was observed within and caudal to the lesion 
site within host white matter tracts. However, beyond this, regeneration was restricted 
(Filous et al., 2010) suggesting further intervention to promote intrinsic growth 
promoting properties may be required.  
Indeed, increasing intrinsic growth-promoting properties, such as increasing TrkB 
(Fang et al., 2017) or integrin expression (Cheah et al., 2016), increasing BDNF 
secretion (Butenschön et al., 2016), increasing cAMP signalling (Pearse et al., 2004) 
or reducing PTEN activity (Lewandowski and Steward, 2014; Danilov and Steward, 
2015), within injured axons have shown promise in promoting regeneration in vivo. 
However, increasing the growth-promoting properties of some CNS axons, such as 
those within the CST, is hindered by the reduced trafficking of growth-promoting 
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proteins within these axons (Lu et al., 2001; Andrews et al., 2016). Promising results 
have come from research into the trafficking mechanisms which prevent integrin 
transport within the CST (Franssen et al., 2015), however this adds yet more 
complexity to combating the already complex SCI pathophysiology. Considering the 
vast number of inhibitory processes working to prevent axonal regeneration after SCI, 
it is likely a combination of treatments targeting multiple aspects, including the 
intrinsic inability of axons to repair, cell replacement, extrinsic inhibitory glial scar, 
inhibitory myelin-associated proteins and inflammation, will likely be required to 
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1.4 Project aims and objectives 
As integrins are downregulated within the CNS, here we aimed to increase integrin 
expression, specifically the α9 subunit, within the CST. As literature shows integrins 
are not trafficked within the mature CST (Andrews et al., 2016), therefore here we 
used iPSC-derived hNPCs as a vehicle to promote this expression within neonatal rats 
with the main aim of characterising the cells in vivo and assessing the integrin 
expression over time. In order to achieve this goal the project was divided into three 
major aims as detailed below.  
1. Characterisation of integrin expression and function in iPSC-derived hNPCs 
in vitro  
This aspect of the project examined the endogenous expression level of integrin 
subunits within iPSC-derived hNPCs. In particular, the expression levels of both α9 
and β1 was assessed; the two growth-promoting integrin subunits of interest. The 
hNPCs used within this project were derived from iPSCs and were treated so that when 
cultured, they differentiate into cortical neurons (Axol Bioscience). Additionally, 
using lentiviral methods, the aim was to overexpress the α9 integrin subunit within 
cells and assess its expression. Finally, the functionality of the overexpressed protein 
was determined and assessed for its ability to induce neurite outgrowth in vitro in the 
presence of TN-C.  
2. Transplant and survival of wild type (WT) iPSC-derived hNPCs in vivo  
The first in vivo component of the project investigated whether WT iPSC-derived 
hNPCs were able to survive and integrate following transplantation into the 
sensorimotor cortex of rodent hosts. This involved examining graft integration and 
survival at a number of different time points following the initial transplant. The area 
into which these cells were grafted was layer V of the sensorimotor cortex of neonatal 
rats, where the CST originates. This is one of the main pathways involved in motor 
control and skeletal muscle coordination. This aspect of the project aimed to examine 
the grafted cells in vivo to determine if they were able to project from the injection site 
within the CST to the spinal cord. Using IHC, we also characterised the cortical neuron 
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and progenitor marker expression of transplants and analysed the grafts for evidence 
of maturation over time  
3. Transplant and survival analysis of α9-expressing iPSC-derived hNPCs in 
vivo 
The survival and integration of grafted α9-expressing iPSC-derived hNPCs in vivo was 
investigated and the localisation of the integrin within these transplanted cells was 
determined. Using similar techniques as in the second aim above,  
integrin-expressing hNPCs were transplanted into the neonatal sensorimotor cortex. 
Cells were analysed at several different time points post-transplantation from 2 weeks 
up to 8 weeks. The results obtained from α9-eYFP hNPC transplants in regard to 
survival and growth were compared to the results from WT hNPC transplants.  
  









Chapter 2: General materials and methods 
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2.1 Preparation of solutions  
2.1.1 Preparation of PBS 
A 0.1 M (1X) phosphate buffered saline (PBS) solution was made using 1.0 M (10X) 
stock consisting of 160 g NaCl, 4 g KCl, 28.8 g Na2HPO4.2H2O, 4.8 g KH2PO4 and 
1.6 L distilled water (dH2O), topped up with dH2O to a final volume of  
2 L. To obtain a 0.1 M (1X) solution, 50 mL of 1.0 M stock was diluted with 450 mL 
dH2O. The 1X PBS solution was autoclaved for sterility before use and stored at room 
temperature (RT).  
2.1.2 PBS-Tween 20 
PBS-Tween was prepared by adding 100 µL of Tween-20 detergent (Sigma) to  
500 mL of 1X PBS solution (section 2.1.1) to obtain a 0.02% stock used for ICC 
(section 2.6.1) and IHC (section 2.8.1).  
2.1.3 Preparation of TBS 
A 10X tris-buffered saline (TBS) solution was prepared by adding 87.7 g NaCl and 
100 mL of 1 M Tris-HCl (pH 7.5) to 1 L of dH2O. The 1 M Tris-HCl was made by 
dissolving 121.1 g of Tris base (Sigma) in 800 mL of dH2O and adjusted to pH 7.5 
using concentrated HCl (Sigma). A 1X TBS solution was made by diluting 100 mL of 
10X TBS stock in 900 mL distilled H2O. 
2.1.4 TBS-Tween 20  
TBS-Tween was prepared by adding 1 mL of Tween-20 detergent (Sigma) to 1 L of 
1X TBS solution (section 2.1.3) to obtain a 0.1% stock used for western blotting (WB) 
(section 2.6.4). 
2.1.5 Preparation of LB broth  
Luria Bertani (LB) broth was prepared by dissolving 10 g LB powder (Sigma, L3022) 
in 500 mL dH2O and autoclaving before use. Once cooled to RT, antibiotic, either 
kanamycin or ampicillin (section 2.2.2), was added as required.  
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2.1.6 Preparation of LB agar plates 
Agar was prepared by dissolving Lennox LB powder containing agar (Sigma) in 1 L 
dH2O (as per manufacturer’s instructions) which was then autoclaved and left to cool 
to RT. The set agar was heated to allow the agar to melt and cooled slightly before 
adding antibiotic, either kanamycin or ampicillin (section 2.2.2). The agar was poured 
into 10 cm plates and left to set at RT before sealing with parafilm and storing at 4°C 
prior to use. 
 
2.2 Preparation and purification of plasmid DNA 
2.2.1 DNA transformation and culture inoculation 
Approximately 100 ng of the plasmid deoxyribonucleic acid (DNA) was added to a 
1.5 mL tube along with 50 µL of competent DH5α cells before being incubated on ice 
for 30 minutes. Following this, the 1.5 mL tube was placed at 42°C (in a heat block) 
for 45 seconds to heat shock the cells before returning the tube to ice. After heat 
shocking, 250 µL of pre-warmed to 37°C bacterial SOC medium (Invitrogen, 15544-
034) was added to the tube and placed in a 37°C shaking incubator for 1 hour at  
220 rpm. Following the incubation, between 50-100 µL of the bacterial solution was 
spread onto agar plates containing the necessary antibiotic (Table 2.1 and section 
2.2.2). Bacterial solution was allowed to air dry on plates for 15-30 minutes before 
incubating plates upside down at 37°C overnight. The following day an individual 
colony was picked using a sterile pipette tip and used to inoculate an 8 mL LB broth 
culture containing the corresponding antibiotic. The culture was placed at 37°C for  
12-16 hours in a shaking incubator at 220 rpm.  
If glycerol stocks were already available for certain DNA plasmids, a bacterial 
transformation was not required. In these instances, an 8 mL culture was inoculated 
using a sterile pipette tip which had been used to scrape the glycerol stock before being 
transferred into a 50 mL tube containing 8 mL LB broth and the relevant antibiotic 
(see Table 2.1 and section 2.2.2). The culture was incubated overnight for 12-16 hours 
in a shaking incubator set at 220 rpm at 37°C. At this stage, a glycerol stock was made 
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from the culture by transferring 500 µL of the bacterial media into a 1.5 mL tube along 
with 250 µL of a 50% glycerol (Fisher Scientific) in dH2O stock. The bacterial glycerol 
stock was stored at -80°C and used for future inoculations. Following this step, the 
plasmid DNA was purified from the remainder of the bacterial culture using a miniprep 
kit (section 2.2.3). 
In situations where a larger amount of DNA was required, for example multiple viral 
transductions, a larger culture was prepared. Initially, an 8 mL starter culture was 
inoculated either using an individual colony or a glycerol stock and incubated for 
approximately 8 hours at 37°C at 220 rpm. After 8 hours, approximately 1-2 mL of the 
original 8 mL culture was transferred to a larger culture of 200-300 mL LB broth with 
the appropriate antibiotic and incubated overnight (12-16 hours) at 37°C at 220 rpm. 
DNA was then purified out from the culture using a Macherey-Nagel Maxiprep kit as 
per manufacturer’s instructions (section 2.2.4). 
Table 2.1 Different plasmid DNA used and corresponding antibiotic resistance 









pSD16 (psPAX2) Ampicillin 
 
2.2.2  Ampicillin and kanamycin stocks 
A 100 mg/mL stock of ampicillin was prepared by dissolving 1 g of ampicillin sodium 
salt (Fisher, BP1760-5) in 10 mL dH2O. The solution was filtered through a 0.22 µm 
filter and syringe before storing at -20°C in aliquots. A working concentration of  
100 µg/mL was obtained by diluting the stock solution 1:1,000 in LB broth or LB agar.  
A 50 mg/mL stock of kanamycin was prepared by dissolving 0.5 g of kanamycin 
sulphate (GibcoTM, 11815-024) in 10 mL of dH2O. The solution was filtered through 
a 0.22 µm filter and syringe before storing at -20°C in aliquots. A working 
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concentration of 50 µg/mL was obtained by diluting the stock solution 1:1,000 in LB 
broth or LB agar.  
2.2.3 DNA plasmid purification using a miniprep kit 
Plasmid DNA purification from an 8 mL overnight culture was carried out using a 
Qiagen® Spin Miniprep Kit as per manufacturer’s instructions. Briefly, the bacterial 
culture was centrifuged at 3,500 rpm for 8 minutes at 4°C to pellet the cells. The 
bacterial supernatant was discarded and the pellet was resuspended in 250 µL of Buffer 
P1 and transferred to a microcentrifuge tube. Following this, 250 µL of Buffer P2, a 
lysis buffer, was added to the microcentrifuge tube and mixed by inverting the tube 
five times. After this, 350 µL of Buffer P3 was added to neutralise the lysate and the 
contents of the tube were mixed by inverting the tube a further five times before 
centrifuging the tube for 10 minutes at 13,000 rpm at RT in a benchtop centrifuge. The 
supernatant, which now contained the contents of the lysed cells including the DNA, 
was collected and transferred to a QIAprep spin column for purifying out the DNA. 
This spin column was subsequently centrifuged for 60 seconds at 13,000 rpm. The 
flow through in the collection tube was discarded and 750 µL of Buffer PE was added 
to the spin column which was again centrifuged for 60 seconds. The flow through was 
again discarded and the spin column inside the collection tube was centrifuged for  
60 seconds once more to remove any buffer remaining in the column and filter. The 
spin column was removed from the collection tube and transferred to an autoclaved 
1.5 mL tube for the final steps of eluting and collecting the purified DNA. To elute the 
DNA, 50 µL of double-distilled water (ddH2O) was added to the filter and left to stand 
for 5 minutes before centrifuging for 60 seconds. The concentration of DNA was 
measured using a NanoDrop 2000 spectrophotometer and DNA was stored at -20°C. 
2.2.4 DNA plasmid purification using a maxiprep kit  
Larger amounts of DNA were purified from the larger bacterial cultures using the 
Macherey-Nagel NucleoBond® Xtra Maxi Plasmid DNA Purification Kit as per 
manufacturer’s instructions for high-copy plasmids. Briefly, the culture was 
transferred to a centrifuge bottle (Beckman) and bacterial cells were pelleted by 
centrifugation at 6,000 rcf for 20 minutes at 4°C. The supernatant was discarded and 
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the cell pellet was resuspended in 12 mL Resuspension Buffer RES containing 
ribonuclease A. To lyse the cells, 12 mL of Lysis Buffer LYS was added to the 
suspension and the bottle was inverted five times and incubated at RT for 5 minutes. 
During this incubation, the NucleoBond® Xtra column and filter were equilibrated by 
slowly pipetting 25 mL Equilibration Buffer EQU onto the filter sides to saturate the 
entire filter. After the 5-minute incubation, the suspension was neutralised using  
12 mL Neutralisation Buffer NEU, which was added to the bottle before gently 
inverting five times to mix. The suspension was then added to the filter and allowed to 
flow through. The column was then washed with 15 mL of Equilibration Buffer EQU 
and allowed to flow through before removing and discarding the filter from the 
column. The column was subsequently washed with 25 mL Wash Buffer, which was 
allowed to flow through the column before transferring the column to a 50 mL 
collection tube. The DNA was eluted using 15 mL of Elution Buffer ELU which was 
added to the column and collected in the collection tube. Once the column emptied, it 
was removed and discarded and 10.5 mL of isopropanol was added to the collection 
tube and vortexed to precipitate the DNA from suspension. This was centrifuged for 
30 minutes at 15,000 rcf at 4°C to pellet the DNA. The supernatant was discarded and 
4 mL of 70% ethanol (EtOH) was added and the tube was centrifuged at 15,000 rcf for 
5 minutes at RT. The EtOH wash was discarded leaving behind the pellet in the bottle 
which was allowed to air dry for 15-30 minutes before dissolving the pellet in ddH2O 
by manually pipetting and transferring to a 1.5 mL tube. The concentration of DNA 
was measured using a NanoDrop 2000 spectrophotometer and DNA was stored  
at -20°C. 
 
2.3  Preparation of cell culture reagents, flasks, plates and coverslips 
2.3.1 Preparation of PDL  
A 10 mg/mL stock of poly-D-lysine (PDL) was prepared by resuspending 100 mg PDL 
hydrobromide powder (Sigma, P1149) in 10 mL tissue culture (TC)-grade dH2O. The 
PDL stock solution was aliquoted into 500 µL and kept at -20°C for long-term storage. 
PDL was used at a working concentration of 20 µg/mL by adding 15 µL of PDL stock 
to 7.5 mL TC-grade dH2O.  
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2.3.2 Preparation of PDL-coated flasks and coverslips 
In preparation for tissue culture, 5 mL PDL solution (20 µg/mL) was incubated in a  
T-75 flask for 1 hour at 37°C. Following incubation, the PDL was removed and the 
dishes were washed three times with sterile PBS before seeding cells at desired density. 
The same protocol applied for PDL-coated 13 mm glass coverslips (VWR). Glass 
coverslips were sterilised in 70% EtOH before being placed into a NuncTM 24-well 
plate (Thermo ScientificTM) and allowed to air dry. In each well, 500 µl of PDL 
solution was added and the plate was incubated for 1 hour at 37°C, after which the 
PDL was removed and coverslips washed three times with sterile PBS. Following use, 
PDL working solution was stored at 4°C and was re-used up to a maximum of  
10 times.  
2.3.3 Preparation of PLO  
A 10 mg/mL stock of poly-L-ornithine (PLO) was prepared by diluting 100 mg PLO 
(Sigma, P3655) in 10 mL TC-grade dH2O and stored in aliquots at -20°C. PLO was 
used at a working concentration of 20 µg/mL by diluting 20 µL of stock in 10 mL  
TC-grade dH2O.  
2.3.4 Preparation of NGF 
NGF was prepared by dissolving 1 mg NGF powder (Sigma, N2513) in 10 mL  
TC-grade dH2O to give a concentration of 100 µg/mL. Aliquots of 50 µL were kept at 
-80°C for long-term storage. 
2.3.5 Preparation of PEI 
A 1 mg/mL stock of polyethylenimine (PEI) solution was prepared by dissolving  
100 mg PEI (Polysciences, 239662) in 100 mL TC-grade dH2O by heating to 
approximately 80°C. The pH of the solution was measured and brought to pH 7.2 using 
HCl and filter sterilised using a 0.22 µm filter and syringe. The solution was stored in 
aliquots at -20°C for long-term storage or 4°C for short-term use. 
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2.3.6 Preparation of hexadimethrine bromide/polybrene 
A 2 mg/mL stock solution was prepared by adding 0.002 g Hexadimethrine bromide 
(Sigma, H9268) to 1 mL TC-grade dH2O. The solution was filter sterilised using a 
0.22 µm filter and syringe and stored at -20°C in aliquots. 
 
2.4 Culture of cell lines  
2.4.1 Thawing of tissue culture cell lines  
All cell lines, retinol pigmented epithelial (RPE) cells, rat pheochromocytoma-12 
(PC12) cells and human embryonic kidney (HEK) 293T cells, were thawed using the 
same protocol. A vial of cells was taken from liquid nitrogen and placed on dry ice 
before thawing in a 37°C water bath. The contents of the vial were then transferred to 
a 15 mL tube along with 9 mL of the appropriate warmed media before being pelleted 
by centrifugation at 1,000 rpm for 3 minutes. The media was aspirated from the tube 
leaving the cell pellet which was resuspended in 10 mL of media before being 
transferred to a NuncTM T-75 culture flask (Thermo ScientificTM). Flasks were placed 
in a 37°C incubator with 5% CO2. 
2.4.2 Culture of RPE cells 
RPE cells were cultured in NuncTM T-75 flasks (Thermo ScientificTM) at 37°C with 
5% CO2 and grown in complete Dulbecco’s Modified Eagle Medium/Nutrient Mixture 
F-12 (DMEM/F12, GibcoTM) containing 10% fetal bovine serum (FBS, Seralabs) and 
1% penicillin and streptomycin (PS, 5000 U/mL Pen; 5000 µg/mL Strep, GibcoTM). 
Media was prepared under sterile conditions and filtered using a 0.22 µm filter. Cells 
were split when approximately 70-80% confluent using 0.05% trypsin- 
ethylenediaminetetraacetic acid (EDTA) (GibcoTM) (section 2.4.6). In preparation for 
collecting lysates for WB, RPE cells were plated onto uncoated NuncTM 6-well tissue 
culture plates (Thermo ScientificTM) at a density of 2 x105 cells per well. For analysing 
cells using immunocytochemistry (ICC), RPE cells were grown on uncoated glass  
13 mm diameter coverslips (VWR, 631-0149) in NuncTM 24-well tissue culture plates 
(Thermo ScientificTM) at a density of 4 x104 cells per well. In preparation for collection 
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of WB lysates, RPE cells were plated onto uncoated NuncTM 6-well plates (Thermo 
ScientificTM).  
2.4.3 Culture of HEK293T cells 
HEK293T cells, which express the SV40 T antigen, were cultured in NuncTM T-75 
flasks (Thermo ScientificTM) in a 37°C incubator with 5% CO2. Cells were cultured in 
complete Dulbecco’s Modified Eagle Medium (DMEM, GibcoTM) containing 10% 
FBS (Seralabs) and 1% PS. Media was prepared under sterile conditions and filtered 
using a 0.22 µm filter. When around 70-80% confluent, cells were split using 0.05% 
trypsin-EDTA (section 2.4.6). In preparation for transfection of viral plasmids 
HEK293T cells were plated onto 10 cm tissue culture plates at 4 x106 the day before 
transfection (sections 2.4.9 and 2.4.10). 
2.4.4 Culture of rat proliferating PC12 cells  
Proliferating rat PC12 cells were maintained on a substrate of 20 µg/mL PDL diluted 
in TC-grade dH2O (section 2.3.2). Proliferating PC12s were cultured in proliferation 
media containing 10% horse serum (Sigma, H1270), 5% FBS (Seralabs) and 1% PS 
(GibcoTM) in DMEM (GibcoTM). Cells were split at 70-80% confluency using 0.05% 
trypsin-EDTA (section 2.4.6). Media was prepared under sterile conditions and filtered 
using a 0.22 µm filter. In preparation for collection of cell lysates, proliferating PC12 
cells were seeded onto 20 µg/mL PDL-coated 6-well dishes. For analysing cells using 
ICC, PC12 cells were plated on 13 mm PDL-coated glass coverslips. 
2.4.5 Differentiation of rat PC12 cells 
For differentiating, PC12 cells were plated onto double-coated dishes of 20 µg/mL 
PDL and 10 µg/mL laminin (Sigma, L2020). The laminin was diluted in PBS and 
incubated with the PDL-coated dishes overnight at 37°C. The laminin was 
subsequently removed and plates were washed three times with PBS. Differentiating 
PC12s were cultured in differentiation media containing DMEM (GibcoTM), 1% FBS 
(Seralabs), 1% insulin, human transferrin and selenous acid (ITS+) supplement (BD 
Life Sciences, 354352), 1% PS (GibcoTM) and 100 ng/mL NGF (Sigma). For analysing 
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cells using ICC, PC12 cells were plated on 13 mm PDL-laminin-coated glass 
coverslips. 
2.4.6 Passaging tissue culture cell lines 
PC12 cells were passaged using 0.05% trypsin-EDTA (GibcoTM) diluted in PBS. 
Culture media was removed from cells and adherent cells were washed gently with  
5 mL PBS. Following the wash, trypsin-EDTA (GibcoTM) diluted in PBS was added 
to the flask and incubated at 37°C for 3-5 minutes to detach cells. Once cells had 
detached from the flask they were pipetted into a single cell suspension and transferred 
to a 15 mL tube along with 6 mL of the appropriate media, (proliferation media for 
PC12s and complete DMEM/F12 for RPE and compete DMEM for HEK293T cells). 
The cells were pelleted by centrifugation at 1,000 rpm for 3 minutes at RT. The 
supernatant was aspirated from the tube leaving the cell pellet. Cells were counted 
using a haemocytometer, split and seeded at the desired density. 
2.4.7 Live cell imaging 
To assess cell survival during culture cells were imaged using a Leica DM IL LED 
fluorescence inverted microscope and an Axiovert 40 CFL inverted microscope 
equipped with an Axiocam ICm1 camera (Zeiss).  
2.4.8 Transient transfections of PC12 cells and hNPCs  
PC12 cells were transfected with either a plasmid containing the human α9 integrin 
sequence tagged with enhanced yellow fluorescent protein (α9-eYFP) or a plasmid 
containing enhanced green fluorescent protein (eGFP), using GeneJammer (Agilent), 
PEI (Sigma) or JetPrime (Polyplus). For each reagent, proliferating PC12 cells were 
approximately 70-80% confluent at the time of transfections. Transfections carried out 
in a 6-well plate if cells were to be used for lysates and in 24-well plate with coverslips 
if cells were to be used for ICC. All of the transfection details can be found in Table 
2.2 with all volumes and concentrations given per well. The buffer used for 
GeneJammer and PEI was serum-free optiMEM and for JetPrime it was the JetPrime 
dilution buffer. 
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Table 2.2 Summary of transfection reagents and protocols  
Transfection 




Amount of DNA 
per well (ng) 
Final volume of 
transfection mix 
(µL) 
GeneJammer 6 -well 6.0 2,000 100 24-well 1.2 400 20 
PEI 6-well 15.0 3,750 150 24-well 3.0 750 30 
JetPrime 6-well 4.0 2,000 200 
 
2.4.9 Production of third generation LV  
HEK293T cells were grown in complete DMEM (10% FBS and 1% PS in DMEM) on 
10 cm plates. For preparation of viral supernatant HEK293T cells were plated out at a 
density of 4 x106 the night before use. The following day, HEK293T cells were given 
fresh complete DMEM 2 hours before transfection. Cells were transfected using a 
4:2:1:1 ratio of the four lentiviral (LV) plasmids (Table 2.3), using 1 mg/mL PEI. The 
cells were transfected with the four LV plasmids, including the two LV packaging 
plasmids pMDLg/pRRE (Addgene, 12251) and pRSV/REV (Addgene, 12253), the 
envelope expressing plasmid pMD2.G (Addgene,12259) and the LV transfer plasmid 
either LV-α9-eYFP or LV-farnesylated green fluorescent protein (fGFP). 
The required volume of DNA from each of the four plasmids was added to 500 µL 
pre-warmed optiMEM along with 65 µg PEI. The transfection was briefly mixed by 
pipetting before vortexing for 10 seconds. The mix was incubated for 15-30 minutes 
at RT before adding dropwise to the 10 cm plate of HEK293T cells. The plate was 
gently tilted back and forth to ensure even coverage of the transfection mix before 
incubating for 24 hours at 37°C in a class two incubator. All viral work from this point 
was carried out in a class two tissue culture hood and incubator. After 24 hours, media 
was replaced with 5 mL fresh complete DMEM and incubated for a further 24 hours 
at 37°C. After this incubation (48 hours after the initial transfection) viral media was 
collected and filter sterilised using a 0.45 µm filter and stored at 4°C. Another 5 mL 
of fresh media was added to each plate before incubating for a final 24 hours at 37°C. 
Media was collected and filter sterilised as above. Viral supernatant was stored at 4°C 
for short-term use or aliquoted into 1 mL microcentrifuge tubes and stored at -80°C 
for long-term storage.  
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Table 2.3 Viral plasmids used in third generation LV 
3rd generation LV 
plasmids Plasmid name Ratio 
Amount required/10 
cm plate 
Transfer vector LV- α9-eYFP 4 10 µg LV-fGFP 
Packaging plasmid #1 pMDLg/pRRE 2 5 µg 
Packaging plasmid #2 pRSV-REV 1 2.5 µg 
Envelope plasmid pMD2.G 1 2.5 µg 
 
2.4.10 Production of second generation LV  
Similar to third generation LV production, HEK293T cells were plated out at a density 
of 4 x106 the night before use. The following day cells were transduced with the three 
second generation LV plasmids (Table 2.4) using TransIT® LT-1 transfection reagent 
(Mirus). Briefly, TransIT® LT-1 reagent was diluted in 1.5 mL pre-warmed optiMEM 
(GibcoTM) and incubated for 20 minutes at RT. Different volumes of TransIT® LT-1 
were used for different sizes of transfer plasmids and used at a ratio of 200 base pairs: 
1 µL of TransIT® LT-1. After the 20-minute incubation, the required volume of DNA 
from each of the three plasmids was added to the transfection mix and incubated at RT 
for 30 minutes before adding dropwise to the 10 cm plate of HEK293T cells. Plates 
were tilted gently before incubating for 24 hours at 37°C. After 24 hours, the media 
was replaced on the HEK293T cells with 4 mL fresh complete DMEM. After a further  
24-hour incubation, the viral supernatant was collected and filter sterilised through a 
0.45 µm filter and stored at 4°C. This was replaced with another 4 mL of complete 
DMEM for a further 24-hour incubation. After this time the viral supernatant was 
collected, filtered and stored at 4°C for short-term use or aliquoted into 1 mL 
microcentrifuge tubes and stored at -80°C for long-term storage. 
Table 2.4 Plasmids used in production of second generation LV 
2nd Generation viral 
plasmids Plasmid name 
Amount required/10cm 
plate 
Transfer vector LV- α9-eYFP 10 µg LV-fGFP	 6.5 µg 
Packaging plasmid psPAX2 (pSD16) 5 µg 
Envelope plasmid pMD2.G-VSV.G 2.1 µg 
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2.4.11 Transduction of PC12 cells with second or third generation LV 
In preparation for viral transduction, proliferating PC12 cells were plated onto a  
6-well plate the night before at a density of 2 x105. PC12 cells were transduced with  
1 mL/well of viral supernatant, either second or third generation, containing 2 µg/mL 
polybrene. Viral media was incubated with cells for 4 hours at 37°C before washing 
cells once with fresh media and replacing with fresh complete DMEM. Cells were 
incubated at 37°C and monitored daily for cell death. Media was replaced with fresh 
complete DMEM when required. Cells were kept in culture until for 4-9 days until 
taken for cell lysates (section 2.6.4), split onto coverslips or used for neurite outgrowth 
assays (section 2.6.2).  
2.4.12 Transduction of hNPCs with second generation LV 
hNPCs were transduced with second generation LV supernatant 72 hours after 
thawing. As with the PC12 cells, hNPCs were transduced with 1 mL/well of viral 
supernatant containing 2 µg/mL polybrene. Viral media was incubated with cells for 
4 hours at 37°C before removing the spent media, washing cells once with fresh media 
and replacing with Axol Neural Maintenance Medium. Cells were incubated at 37°C 
and were monitored for cell death. Media was changed as required, usually every  
24-48 hours. Cells were kept in culture for a further 4-5 days until they were either 
collected for transplantation (section 2.5.6 and 2.7.1), taken for cell lysates (section 
2.6.4), split onto coverslips for ICC (section 2.5.4) or used for neurite outgrowth assays 
(section 2.6.2).  
2.4.13 Cryopreservation of tissue culture cell lines 
Proliferating PC12, RPE and HEK293T cells were frozen and stored in liquid nitrogen 
when around 70-80% confluency. Media was removed from cells and washed with 
sterile PBS, before adding 3-4 mL 0.05% trypsin-EDTA (GibcoTM) diluted in PBS to 
the flask. The flask was incubated at 37°C for 3-5 minutes to allow cells to dissociate. 
Once cells had detached from the flask they were pipetted into a single cell suspension 
and transferred to a 15 mL tube along with 6 mL of the appropriate media, 
(proliferation media for PC12s, compete DMEM/F12 for RPEs and complete DMEM 
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for HEK293T cells). The cells were pelleted by centrifugation at 1,000 rpm for  
3 minutes at RT. The supernatant was aspirated from the tube leaving the cell pellet. 
Cells were frozen down in a freezing media containing 90% FBS (Seralabs) and 10% 
dimethyl sulfoxide (DMSO, Fisher Scientific, BP231-100). The freezing media was 
prepared under sterile conditions and filtered using a 0.22 µm filter (Millipore, 
SLGP033RS) and 10 mL syringe before use. The cell pellet was resuspended in the 
desired amount of freezing media and subsequently aliquoted into 1 mL cryovials 
(Thermo ScientificTM, 363401) for freezing. The cryovials were transferred to a 
polystyrene box and placed at -80°C for 3-6 days before transferring to liquid nitrogen 
for long-term storage.  
 
2.5 Culture of iPSC-derived hNPCs 
2.5.1 Preparation of media and components 
hNPCs were cultured in Axol Neural Maintenance media (Axol Bioscience) 
supplemented with Neural Maintenance Supplement (Axol Bioscience). The 
supplement was aliquoted into 750 µL aliquots and stored at -80°C. Media was 
aliquoted into 50 mL aliquots and stored at 4°C. One vial of supplement was thawed 
when required to add to one 50 mL tube of media.  
2.5.2 Preparation of tissue culture plates 
Human iPSC-derived NPCs (Axol Bioscience) were maintained on 6-well tissue 
culture dishes coated with 20 µg/mL PLO and 10 µg/mL laminin (Sigma, L2020). 
Plates were incubated with PLO diluted in TC-grade dH2O for 2 hours at 37°C. 
Following incubation, the PLO was removed and plates were washed three times with 
TC-grade dH2O before being incubated with 10 µg/mL laminin diluted in TC-grade 
dH2O overnight at 37°C. The following day the laminin was removed and plates were 




Using human iPSC-derived neural progenitor cells to increase integrin expression in the CNS 
71 
 
2.5.3 Thawing and maintenance of iPSC-derived hNPCs 
Frozen cell stocks were slowly thawed in a 37°C water bath and added to a 15 mL tube 
with 9 mL Neural Maintenance Medium (Axol Bioscience). Cells were pelleted by 
centrifugation at 1,000 rpm for 3 minutes at RT. The supernatant was discarded and 
the cell pellet was carefully resuspended in Neural Maintenance Medium (Axol 
Bioscience) supplemented with media supplement (Axol Bioscience) and 1 µL/mL 
Axol Sure Boost (1,000X, Axol Bioscience). Cells were counted using a 
haemocytometer and plated at a density of 50,000 cells/cm2 with 1.5 mL media onto 
PLO-laminin coated 6–well plates. The cells were incubated for 2 hours at 37°C, after 
which the medium was replaced with fresh Neural Maintenance Medium 
supplemented media supplement and 1 µL/mL Axol Sure Growth (1,000X, Axol 
Bioscience). The medium was replaced every 2 days with Neural Maintenance 
Medium and media supplement until the cells were removed from the dish after  
8-9 days in culture for transplantation (section 2.7.1), lysate collection (section 2.6.4) 
or for viral transduction (section 2.4.12). 
2.5.4 Passaging of iPSC-derived hNPCs 
hNPCs were passaged using StemPro Accutase (GibcoTM). Spent media was aspirated 
from plates and cells were gently washed once with sterile 1X PBS before adding  
1 mL of Accutase to each well of a 6-well plate and incubating at 37°C for 3-5 minutes 
to allow cell dissociation. Cells were then collected and transferred to a 15 mL tube 
with 9 mL of Axol Neural Maintenance media. The cells were pelleted by 
centrifugation at 1,000 rpm for 3 minutes at RT. Supernatant was removed and cells 
were resuspended in 1 mL of media for counting using a haemocytometer. For viral 
transduction or ICC analysis cells were plated at a density of 50,000 cells/cm2 onto 
PLO and laminin double coated plates or acid-washed coverslips.  
2.5.5 Preparation of acid-washed glass coverslips 
Glass coverslips were washed in hot dH2O with glassware detergent in a beaker, and 
sonicated for 30 minutes in a water bath. The coverslips were then rinsed four times 
with ddH2O and sonicated once more in ddH2O for 15 minutes. Coverslips were then 
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submerged in 1 M HCl, and heated to 50-60°C for 4-6 hours in a designated fume 
hood. The beaker was shaken every 30 minutes to ensure an even acid wash and to 
stop the coverslips from sticking together. Following the incubation time, coverslips 
were allowed to cool to RT before being washed three times with ddH2O to remove 
any residual HCl and sonicating once more in ddH2O for 30 minutes. Following this, 
the coverslips were washed twice more in 70% EtOH and sonicated for 15 minutes in 
EtOH after each wash. The coverslips were then autoclaved for sterility. Before use, 
coverslips were washed in 70% EtOH and allowed to air dry before coating with PLO 
and laminin for plating cells.  
2.5.6 Preparation of iPSC-derived hNPCs for transplant 
For transplantation, cells were collected as described in section 2.5.4 and resuspended 
at 100,000 cells/µL in Axol Neural Maintenance media and supplement with 1 µL/mL 
Sure Boost (Axol Bioscience) in a 1.5 mL tube.  
 
2.6 Cell culture analysis  
2.6.1 Analysis of cells in vitro using ICC 
To visualise expression of specific proteins, cells were analysed using ICC. Media was 
removed from wells and cells were washed with 1X PBS before fixing with  
4% paraformaldehyde (PFA) for 10 minutes at RT. Cells were subsequently washed 
three times with 1X PBS. To block non-specific staining and permeabilise cells, 
coverslips were incubated with 10% goat serum (Sigma) or 10% donkey serum 
(Sigma) and 0.4% Triton-X100 (Sigma) in PBS on parafilm for 20-60 minutes at RT. 
Following the blocking step, cells were incubated with primary antibodies (see Table 
2.5) diluted in the same blocking solution at 4°C overnight. The following day, the 
primary antibody was removed and cells were rinsed three times with 1X PBS 
containing 0.02% tween-20 before incubation with AlexaFluor secondary antibodies 
in 1X PBS (see Table 2.6) for 2 hours at RT. Cells were then washed a further three 
times with PBS before staining the nuclei with 4’,6’-diamidino-2-phenylindole 
(DAPI) (Thermo ScientificTM, 62248, 1:10,000) in PBS for 10 minutes at RT. Cells 
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were washed a further three times with 1X PBS before being mounted onto slides with 
FluorSave (Calbiochem). Slides were imaged using a Leica D5500 epifluorescent 
microscope equipped with a DFC550 digital camera (Leica).  
Table 2.5 List of all primary antibodies used in ICC and IHC 
Antibody Species Dilution Supplier Cat No. ICC IHC 
BDNF Polyclonal, rabbit 1:200 1:200 Abcam AB72439 
Ctip2 Monoclonal, rat 1:500 1:500 Abcam AB18465 
Ctip2 Polyclonal, rabbit 1:500 1:500 Abcam Ab70453 
DAPI ---- 1:10,000 1:10,000 Thermo ScientificTM 62248 
DCX Polyclonal, rabbit 1:500 1:500 Abcam AB18723 
GFAP Polyclonal, rabbit 1:750 1:500 DAKO ZO33429-2 
GFP Polyclonal, rabbit 1:1,000 1:1,000 Invitrogen A11122 
HuNu Monoclonal, mouse ---- 1:500 Millipore MAB1281 
Iba-1 Polyclonal, rabbit 1:500 1:500 Wako 019-19741 
Ki67 Monoclonal, mouse 1:100 1:100 Novus Biologicals NBP2-22112 
MBP Monoclonal, rabbit 1:50 1:50 Cell signalling D8X4Q 
hNCAM Monoclonal, mouse ---- 1:200 Santa Cruz, Insight sc-106 
Oct4 Polyclonal, rabbit 1:500 ---- Abcam Ab18976 
Tbr1 Polyclonal, rabbit 1:200 1:400 Abcam AB31940 
TN-C Monoclonal, rabbit 1:250 1:250 Abcam ab108930 
TrkB Polyclonal, rabbit 1:1,000 1:1,000 Santa Cruz Biotechnology SC-12 
VGlut 1 Polyclonal, Guinea Pig 1:500 ---- Synaptic Systems 135 304 
WFA ---- ---- 1:200 Sigma L1516 
α9-integrin Polyclonal, rabbit 1:1,000 ---- Pierce (Thermo ScientificTM) PA5-27771 
βIII-tubulin Monoclonal, mouse 1:1,000 1:1,000 Sigma T8660 
βIII-tubulin Polyclonal, rabbit 1:1,000 1:1,000 Covance MRB-435P 
β1-integrin Monoclonal, mouse 1:500 ---- BD Transductions 610467 
 
Table 2.6 List of all secondary antibodies used for ICC and IHC 
Antibody Dilution Supplier Cat. No. 
ICC IHC 
Goat anti-mouse AlexaFluor 488 1:1,000 1:750 Invitrogen A21121 
Goat anti-mouse AlexaFluor 568 1:1,000 1:750 Invitrogen A11004 
Goat anti-rabbit AlexaFluor 488 1:1,000 1:750 Invitrogen A11008 
Goat anti-rabbit AlexaFluor 568 1:1,000 1:750 Invitrogen A11011 
Goat anti-rat AlexaFluor 488 1:1,000 1:750 Invitrogen A11006 
Donkey anti-guinea pig 
AlexaFluor488 1:1,000 ---- 
Jackson 
Immunoresearch 706-545-148 
Donkey anti-mouse AlexaFluor 568 1:1000 ---- Invitrogen A21202 
Streptavidin 488 ---- 1:250 Invitrogen S32354 
Streptavidin 568 ---- 1:250 Invitrogen S11226 
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2.6.2 Neurite outgrowth assay 
Neurite outgrowth assays were performed on Permanox© 8-well chamberslides 
(Thermo ScientificTM). Differentiating PC12s were grown on a substrate of 20 µg/mL 
PDL (section 2.3.2) and 10 µg/mL chicken TN-C (Millipore) and the hNPCs were 
grown on 20 µg/mL PLO and 10 µg/mL chicken TN-C or varying concentrations of 
human TN-C (Millipore): 1 µg/mL, 5 µg/mL, 10 µg/mL, 15 µg/mL, 20 µg/mL,  
25 µg/mL or 30 µg/mL. The dishes for hNPCs were prepared as in section 2.5.2. Cells 
were plated onto coated chamberslides at a density 5x104/well. The cells were 
incubated for 72 hours at 37°C, following PBS wash and fixation with 4% PFA for  
10 minutes at RT. The PFA was then removed and cells were washed three times with 
sterile PBS and stored at 4°C in preparation for staining.  
2.6.3 Neurite outgrowth statistical analysis 
Neurite outgrowth was analysed at 72 hours post-plating of cells onto TN-C. For ICC 
analysis, cells were first incubated in blocking buffer (0.1 M PBS containing 10% goat 
serum (Sigma) and 0.4% Triton-X100 (Sigma)) before being stained with GFP 
(1:1,000) and βIII-tubulin (1:1,000) (Table 2.5) diluted in the same blocking solution 
overnight at 4°C. After incubation, the cells were washed three times with PBS-T 
before incubation with the secondary antibodies AlexaFluor goat-anti rabbit 488 and 
AlexaFluor goat-anti mouse 568, 1:1,000 (Table 2.6) for 2 hours at RT. The cells were 
subsequently washed twice more with PBS-T before using DAPI at 1:10,000 diluted 
in PBS for 10 minutes at RT. Following two more washes with PBS-T, a coverslip was 
placed onto the slide using FluorSave (Calbiochem) and imaged using a Leica 
DM5500 fluorescent microscope. Analysis was performed using NeuronJ, an ImageJ 
add on (Meijering et al., 2004), and statistical analysis was performed using Microsoft 
Excel and Prism 5 GraphPad software. For each condition a total of 30 axons were 
measured in microns using NeuronJ. One replicate consists of one vial of cells using 
one chamberslide (with two wells/condition) and a total of 30 cells were counted per 
condition for each replicate. Comparisons between the data sets were analysed using 
one-way analysis of variance (ANOVA) (non-parametric) and Tukey post hoc to 
determine statistical significance.  
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2.6.4 Western blot protocol 
2.6.4.1 Protein preparation 
Cell lysates were collected on ice from confluent hNPCs, PC12 or RPE cultures using 
1X radioimmunoprecipitation assay (RIPA) buffer (from a 5X stock containing 
250mM Tris, 750mM NaCl, 5% NP-40 and 2.5% sodium deoxycholate) supplemented 
with 25X complete protease inhibitor (PI, Roche, 11873580001) at a volume of  
100 µL per well of a 6-well plate. Briefly, media was removed and cells were gently 
washed with 1X PBS. PBS was removed before adding the RIPA and PI solution 
followed by an incubation at RT for 1 minute. Cells were removed from the dish using 
a cell scraper, collected into a 1.5 mL microcentrifuge tube and incubated on ice for  
15 minutes. Following incubation, the cells were centrifuged at 13,000 rcf at 4°C for 
15 minutes. The supernatant was transferred to a fresh microcentrifuge tube and 
sample protein concentration was determined using a bicinchoninic acid (BCA) assay 
(section 2.6.4.2). Cell lysates were stored at -80°C.  
2.6.4.2 Determining protein concentration using a BCA assay  
Protein concentration was determined using a BCA assay kit (Thermo ScientificTM) 
and the protocol was followed as per manufacturer’s instructions. Briefly, protein 
samples were diluted 1:10 with RIPA buffer and 10 µL of each were plated into a  
96-well plate. Each sample was run in triplicate. Samples were run against a serial 
dilution (eight samples) of bovine serum albumin diluted in RIPA buffer ranging from 
0 mg/mL up to 2 mg/mL, with 10 µL per well. Each standard was run in triplicate. The 
kit reagents of solution A and solution B were mixed in a ration of 1:50 with  
200 µL of this solution was added to each well. The plate was incubated at 37°C for 
30-45 minutes before reading absorbance at 570 nM wavelength on a plate reader. A 
standard curve was produced using the absorbance readout from the protein standards 
and the concentration of protein samples were determined from this information.  
2.6.4.3 Sample preparation and running of WB 
Cell lysates (20 µg of protein per well for cell lines and 40 µg for hNPC samples) were 
separated by electrophoresis on a 4-12% bis-tris pre-cast gel (Invitrogen). Diluted 
samples with NuPAGETM loading dye (Thermo Fisher) were heated to 90°C for  
10 minutes before loading and were run alongside a PageRuler Plus Prestained protein 
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ladder (Thermo Fisher, 26619). The gel was run at 200 V, 120 mA and 25 W for  
40 minutes with 1X NuPAGETM 3-(N-morpholino)propanesulfonic acid (MOPS) 
sodium dodecyl sulfate (SDS) running buffer (Thermo ScientificTM, NP0001) diluted 
in dH2O, before being transferred to a nitrocellulose membrane (GELifesciences) and 
at 25V, 125mA and 17W for 90 minutes with 1X NuPAGETM transfer buffer (Thermo 
ScientificTM, NP0006). Following transfer, the membrane was processed for 
immunolabelling. 
2.6.4.4 WB membrane staining 
The nitrocellulose membrane was incubated for 1 hour in 5% milk powder (Marvel) 
in 0.1% TBS-T at RT on a shaker to block non-specific binding. Primary antibodies 
were then diluted in 5% milk powder in 0.1% TBS-T at desired concentration  
(Table 2.7). A β-actin antibody (Sigma) was used to assess equal loading of protein 
per well. The blot was incubated with the primary antibody overnight at 4°C on a 
shaker. Following this, the primary antibody was removed and stored at -20°C. 
Primary antibodies were reused up to a maximum of three times before using fresh. 
Following this, the blot was washed three times each for 10 minutes with  
0.1% TBS-T on a shaker followed by incubation with secondary antibody for  
45 minutes at RT. The secondary antibodies (Table 2.7) were used at a dilution of 
1:15,000 and diluted in 3% milk powder (Marvel) in 0.1% TBS-T. Following this, the 
blot was washed three times for 10 minutes each with 0.1% TBS-T before analysis.  
Table 2.7 List of primary and secondary antibodies used in analysis of WB 
Primary antibodies 
Antibody Species Dilution Supplier Cat. No. 
GFP Polyclonal, rabbit 1:1,000 Invitrogen A11122 
α9-integrin Polyclonal, rabbit 1:1,000 Pierce (Thermo ScientificTM) PA5-27771 
β-actin Monoclonal, mouse 1:10,000 Sigma A5441 
β1-integrin Monoclonal, mouse 1:1,000 BD Transductions 610467 
Secondary antibodies 
HRP-Mouse Goat anti-mouse 1:15,000 Invitrogen A16072 
HRP-Rabbit Goat anti-rabbit 1:15,000 Invitrogen A16096 
 
2.6.4.5 WB analysis 
WBs were analysed using chemiluminescence. Enhanced chemiluminescence (ECL) 
detection reagents (GE Healthcare) were mixed and used immediately in a 1:1 ratio as 
per manufacturer’s instructions. The imaging reagents were continuously pipetted over 
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the membrane for 4-5 minutes before imaging using the LAS-3000 Lite imaging 
system (Fuji). 
 
2.7 Transplant of iPSC derived-hNPCs and tissue fixation 
2.7.1 Neonatal cerebral cortex transplants of WT and α9-expressing 
hNPCs 
All procedures were carried out under the Project Licence number 60/4472 and 
Personal Licence number IC71C2B2B, conformed to the UK Animals (Scientific 
Procedures) Act (1986) and were approved by the Animal Welfare Ethics Committee 
of the University of St Andrews.  
The transplant procedure for both WT hNPCs and α9-eYFP-expressing hNPCs 
followed the same protocol. Cells were removed from the dish after 8-9 days in culture 
(section 2.5.6). Newborn Sprague Dawley rat pups were injected between postnatal 
day 0-2 (P0-2), using hypothermic anaesthesia. For the anaesthesia, each pup was 
anaesthetised on ice for 3-5 minutes until they had stopped moving, after which they 
were transferred to a platform, also containing ice to maintain anaesthesia during 
surgery. Animals were injected either unilaterally or bilaterally in two specific sites 
with 100,000 cells per site (1 µL/injection site) for the predicted neonatal sensorimotor 
cortex (Altman and Bayer, 1995) (Table 2.8). Following analysis of initial tissue 
batches, coordinates for subsequent batches were adjusted to improve accuracy of 
injection (detailed in Table 2.8). Animals were placed beneath a stereotaxic frame and 
injected using a Hamilton syringe with an attached custom made 30-gauge stainless 
steel needle (ESSLAB UK). Cells were injected manually over the course of 1 minute. 
Following the transplant animals were transferred to a pre-warmed cage to recover. 
Once the entire litter had undergone surgery and woken up, they were returned to the 
cage with the mother. Pups were monitored closely for 48-72 hours post-surgery to 
assess any sign of rejection from the mother.  
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Table 2.8 Stereotaxic coordinates and overview of each batch of transplants 
*   Surgery carried out by Dr Melissa Andrews 
** Batch 5 pups were rejected by mother following transplant and cannibalised  
A-P: Anterior-posterior; M-L: Medial-lateral; D-V: Dorsal-ventral 
 
2.7.2 Neural tracing experiments 
2.7.2.1 Preparation of BDA solution  
A 100 mg/mL stock solution was prepared by dissolving 10 mg biotinylated dextran 
amine (BDA) powder (10,000 molecular weight, Invitrogen D1956) in 100 µL Axol 
Neural Maintenance media. Solution was prepared fresh for use.  
2.7.2.2 BDA tracing in vivo  
Two litters were grafted with hNPCs that included 5% BDA (one WT hNPCs  
batch 12 and one α9-eYFP-expressing hNPCs batch 11). When resuspending cells for 
transplant, instead of using 100% Axol Neural Maintenance media containing Sure 
Boost, 50% of the re-suspension solution consisted of the 100 mg/mL BDA stock 
solution, giving a final BDA concentration of 50 mg/mL. The 50% media contained 
2000X Sure Boost to compensate.  
2.7.3 Solutions for perfusion 
2.7.3.1 Preparation of 0.2 M sodium phosphate buffer 
Two stock solutions were produced consisting of 27.8 g sodium phosphate monobasic 











Injection site #1 
(mm) 
Injection site #2 
(mm) 
A-P M-L D-V A-P M-L D-V 
1* WT hNPCs Unilateral, Left 15 -1.0 1.0 -0.7 -0.5 1.0 -0.7 
2 WT hNPCs Unilateral, Left 11 -1.0 1.0 -0.7 -0.5 1.0 -0.7 
3 WT hNPCs Bilateral 13 -1.0 1.0 -0.5 -1.0 -1.0 -0.5 
4 WT hNPCs Bilateral 11 -1.0 1.0 -0.5 -1.0 -1.0 -0.5 
5** WT hNPCs Bilateral 11 -1.0 1.0 -0.5 -1.0 -1.0 -0.5 
6 WT hNPCs Bilateral 14 -1.0 1.0 -0.45 -1.0 -1.0 -0.45 
7	 α9-hNPCs	 Unilateral, Right	 14	 0.0	 1.5	 -0.5	 1.0	 1.5	 -0.5	
8 α9-hNPCs Bilateral 4 0.0 1.5 -0.5 0.0 -1.5 -0.5 
9	 α9-hNPCs	 Unilateral, Right	 15	 0.0	 1.5	 -0.5	 1.0	 1.5	 -0.5	
10	 α9-hNPCs	 Bilateral	 15	 0.0	 1.5	 -0.5	 0.0	 -1.5	 -0.5	
11	 α9-hNPCs + BDA	 Unilateral, Right	 11	 0.0	 1.5	 -0.4	 1.0	 1.5	 -0.4	
12	 WT hNPCs +BDA	 Unilateral, Right	 14	 0.0	 1.5	 -0.4	 1.0	 1.5	 -0.4	
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dibasic stock (Na2HPO4, Sigma) in 1 L dH2O. A 0.2 M sodium phosphate buffer was 
prepared by adding 81% sodium phosphate monobasic stock and 19% sodium 
phosphate dibasic stock. Both the monobasic and dibasic stock solutions were kept at 
RT.  
2.7.3.2 Preparation of 0.9% saline solution 
Equal parts dH2O and 0.2 M sodium phosphate buffer were combined before adding 
0.9% NaCl. The pH of the solution was measured and adjusted to pH 7.4 using HCl 
and NaOH, and then filtered using 11 µm Whatman® filter paper (Sigma) and a 
porcelain Büchner funnel. The solution was stored at RT before use and was prepared 
no earlier than 48 hours before perfusion.  
2.7.3.3 Preparation of 4% PFA solution 
An 8% PFA solution was prepared by dissolving PFA powder (Fisher) in dH2O at  
60-65°C using a stir plate and a magnetic stir bar. The solution was cooled to RT and 
2-4 mL of 10 M NaOH was added to increase the pH to fully dissolve the PFA. Equal 
parts 8% PFA solution and 0.2 M sodium phosphate buffer were mixed to give a final 
4% PFA (in 0.1 M buffer) solution. The pH of the solution was measured and adjusted 
to pH 7.4 using HCl and NaOH, and then filtered using 11 µm Whatman® filter paper 
(Sigma) and a porcelain Büchner funnel. The solution was stored at 4°C before use 
and was prepared no earlier than 48 hours before perfusion.  
2.7.4 Tissue perfusion and sectioning 
Sprague Dawley rats were administered an overdose of sodium pentobarbital and 
perfused transcardially using saline solution followed by 4% PFA at one of five 
different time points following transplantation (Table 2.9). The brain and spinal cord 
from each animal were removed and post-fixed in 4% PFA solution for 48 hours at 
4°C before being transferred to a 30% sucrose solution in 1X PBS for 48-72 hours for 
cryoprotection. Cryoprotection was verified when the brain had sunk to the bottom of 
the storage tube when held in a vertical position. Using a sliding microtome (Leica) 
and dry ice, brain tissue was cryo-sectioned in the coronal or sagittal plane at 40 µm 
thickness and stored in 0.05% sodium azide (Sigma) in 1X PBS in a NuncTM 48-well 
plate (Thermo ScientificTM) at 4°C until processed for staining. 
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Table 2.9 Number of pups perfused at each time point post-transplantation 
Type of graft 
received 
Tissue collection time points post-transplant 
2 weeks 4 weeks 6 weeks 7 weeks 8 weeks Total 
No. of pups with 
WT hNPC grafts 17 16 17 15 13 78 
No. of pups with 
α9-hNPC grafts 13 12 12 11 11 59 
Total 30 28 29 26 24 137 
 
2.8 IHC analysis of hNPC transplants 
2.8.1 IHC of free-floating tissue 
Brain tissue was analysed using fluorescent immunohistochemistry (IHC). Tissue 
sections were first washed in 1X PBS in a NuncTM 24-well plate (Thermo ScientificTM) 
for 5 minutes before non-specific staining was blocked by incubation in blocking 
buffer containing 10% goat serum (Sigma) and 0.4% Triton-X in 1X PBS for 2 hours 
at RT. The tissue was then incubated with primary antibody diluted in blocking 
solution overnight at 4°C. The primary antibodies used are detailed in Table 2.5. 
Specifically, to assess graft survival and hNPC projections, human-specific markers 
including human nuclear antigen (HuNu) and human neural cell adhesion molecule 
(hNCAM) were used. To assess exogenous α9 integrin expression in α9-eYFP-
expressing hNPCs, an anti-GFP antibody (Invitrogen) was used. Following primary 
antibody incubation, tissue sections were washed three times for 10 minutes each with 
0.02% Tween-20 in PBS. For certain antibodies (specifically TN-C), pre-treatment 
with 0.03% hydrogen peroxidase diluted in PBS for 30 minutes at RT before primary 
antibody incubation was required. Sections were rinsed once with 1X PBS before 
continuing with blocking and primary antibody incubation. Tissue was subsequently 
incubated at RT for 2 hours with fluorescently-tagged secondary antibodies of the 
corresponding species. All secondary antibodies were used at 1:750 diluted in 1X PBS 
and are detailed in Table 2.6. Tissue was washed after the secondary antibody 
incubation using 0.02% Tween-20 in PBS before staining nuclei using DAPI (Thermo 
ScientificTM, 62248) at 1:10,000 diluted in PBS for 10 minutes at RT. For staining of 
PNNs tissue sections were incubated with biotinylated Wisteria floribunda agglutinin 
(WFA) diluted in PBS (Table 2.5) for 2 hours at RT before incubation with streptavidin 
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488 or 568 diluted 1:250 in PBS for 1 hour at RT. Tissue was subsequently stained for 
DAPI. To analyse BDA expression tissue was incubated with streptavidin 488 or 568 
(Table 2.6) diluted 1:250 in PBS for 2 hours at RT before staining with DAPI. Sections 
were washed a further three times with PBS before mounting onto 0.25% gelatine-
coated slides (section.2.8.2). Mounted tissue was covered and allowed to air dry for 
approximately 1 hour at RT before mounting coverslips (VWR) using FluorSave 
(Calbiochem). Coverslips were dried at RT for a minimum of 1-2 hours before 
imaging. Slides were stored at 4°C and covered to protect from the light. Slides were 
imaged using a Leica D5500 epifluorescent microscope equipped with a DFC550 
digital camera (Leica). Initially, every one in six to eight tissue sections of the 
sensorimotor cortex was analysed for presence of an hNPC bolus and hNCAM-
positive projections. Subsequent tissue sections were analysed either rostral or caudal 
to this depending on where positive HuNu or hNCAM staining was observed. This 
continued until no further positive staining was detected. In this way the projections 
were mapped, taking images and creating brain maps by hand for each animal. Images 
were analysed and scale bars were added using ImageJ software. 
2.8.2 Preparation of gelatin-coated slides  
Gelatin was prepared fresh for each use by dissolving, 0.5 g gelatin from porcine skin 
(Sigma) in 500 mL dH2O at 56°C over a period of 5-10 minutes. The solution was then 
removed from the heat to cool to RT before adding 0.25 g chromium potassium 
sulphate. Slides were dipped in and out of the gelatin solution for 1 minute, making 
sure there were no air bubbles between or on the slides, before being left to air dry at 



























Chapter 3: In vitro expression and functional 
analysis of integrin and cell-specific protein 
expression in iPSC-derived hNPCs 
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3.1 Introduction and aims  
Both neurite and axonal growth are highly dependent upon cellular interactions with 
the surrounding ECM. Neurons communicate and respond to environmental stimuli 
via growth-promoting transmembrane receptors, such as integrins. These interactions 
result in reorganisation of the cytoskeleton to modulate axon growth, guidance and 
elongation. Each integrin heterodimer can bind to different extracellular ligands. The 
α9β1 heterodimer binds the glycoprotein TN-C, the main ECM component of the 
mammalian CNS, which is also upregulated following CNS injury. However, as the 
mammalian CNS matures there is a reduced expression of integrins in neurons, 
including α9. This is likely to be due to the reduced requirement for developmental 
proteins within the mature CNS. In both cell culture and after SCI, it has been shown 
that α9 integrin binding to TN-C promotes neurite outgrowth and extension, as has 
been demonstrated by overexpression of the α9 integrin subunit in rat PC12 cells and 
DRGs (Andrews et al., 2009). Increasing integrin expression within the CNS has 
previously been investigated with regard to axonal regeneration and protein 
localisation; however, this research showed exogenously expressed α9 integrin is not 
transported down the axons of the mature CST (Andrews et al., 2016). Therefore, here 
we suggest hNPCs could be used as a vehicle to increase exogenous expression of 
integrins within the CNS.  
The aim of this chapter was to characterise hNPCs in vitro before transplantation into 
neonatal rat sensorimotor cortex. Our interests mainly focused on analysing 
endogenous expression of both the α9 and β1 integrin subunits, as well as developing 
and optimising a protocol for overexpressing the α9 subunit within hNPCs using 
initially transient transfection and followed by LV for constitutive expression. We 
utilised LV to overexpress α9 integrin in both rat PC12 cells to confirm the results of 
others (Andrews et al., 2009), followed by overexpression in hNPCs. In both cases we 
investigated neurite outgrowth when grown on TN-C with protocol optimisation 
initially in PC12 cells before moving to the hNPCs. Overexpression was confirmed 
using ICC and WB, and outgrowth was analysed using neurite outgrowth assays. To 
gain further insight into their general protein expression profile, additional ICC was 
carried out on hNPCs to analyse expression of deep-layer cortical neuron markers, 
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further growth-promoting proteins, as well as examine the presence of other cell types 
within the cultures.  
  




3.2.1 Transient transfection  
Proliferating PC12 cells were transfected with α9-eYFP and eGFP plasmids, using 
GeneJammer (Agilent), PEI (Sigma) or JetPrime (Polyplus) (see section 2.4.8 and 
Table 2.2 for full protocol). PC12 cells were seeded onto PDL-coated 6-well plates or 
PDL-coated glass coverslips in 24-well plates (section 2.4.2) the day before 
transfection. WT PC12 cells were used as a transfection control, which received 
proliferation media and either no transfection reagent (n=3) or with transfection 
reagent only (n=1). Transfections were carried out in either a 6-well plate (cell lysates 
for WB) or a 24-well plate (with coverslips used for ICC analysis). Each transfection 
using GeneJammer and PEI was replicated (n=3) for each condition and JetPrime 
transfections for WB were repeated only once (n=1) since the GeneJammer 
outperformed the JetPrime from the start.  
3.2.2 Preparation of second and third generation LV 
See sections 2.4.9 and 2.4.10. 
3.2.3 Viral transduction of PC12 cells and hNPCs 
See sections 2.4.11 and 2.4.12.  
3.2.4 Western blot protocol 
The full western blot protocol is described in section 2.6.4. Briefly, cell lysates were 
collected and protein concentration was determined using a BCA assay kit (Thermo 
ScientificTM). For PC12 lysates, 20 µg of protein was loaded per well and 40 µg of 
protein per well for hNPC lysates. Cell lysates were separated via electrophoresis using 
a 4-12% bis-tris pre-cast gel (Invitrogen) and followed by transfer to a nitrocellulose 
membrane (Gelifesciences). The membrane was subsequently blocked for 1 hour at 
RT using TBS-T containing 5% milk powder (Marvel). It was then incubated with 
primary antibody overnight at 4°C with one or more of the following: α9 integrin, 
GFP, β1 integrin and β-actin (see Table 2.7 for full antibody details). Following 
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overnight incubation, the blot was washed three times with TBS-T and then incubated 
with secondary antibody, either horseradish peroxidase (HRP) goat anti-mouse or HRP 
goat anti-rabbit (Table 2.7), for 45 minutes at RT; which was used at a dilution of 
1:15,000 in TBS-T containing 3% milk powder. Membranes were analysed using 
chemiluminescence. ECL imaging reagents were pipetted over the membrane for  
4-5 minutes before imaging using an LAS-3000 Lite imaging system (Fuji).  
3.2.5 ICC analysis of PC12 cells and hNPCs in vitro 
For full ICC protocol, see section 2.6.1. Briefly, PC12 cells and hNPCs grown on 
coverslips were washed with PBS, fixed with 4% PFA for 10 minutes at RT and 
subsequently washed three times with PBS. The coverslips were then blocked for  
20 minutes using 10% goat or donkey serum and 0.4% Triton-X100 in 1X PBS and 
then incubated with primary antibody (see Table 3.1, full details in Table 2.5) at 4°C 
overnight. The coverslips were subsequently washed three times with PBS before 
being incubated with secondary antibody of the corresponding species (see Table 2.6) 
for 2 hours at RT. Coverslips were then washed a further three times with PBS before 
staining the nuclei with DAPI (1:10,000) in PBS for 10 minutes at RT. Coverslips were 
washed a further three times with PBS before being mounted onto slides. 
3.2.6 Neurite outgrowth analysis  
Neurite outgrowth assays are described in section 2.6.2 and 2.6.3. Differentiating 
PC12s were grown on a substrate of both 20 µg/mL PDL and 10 µg/mL chicken  
TN-C (Millipore) and the hNPCs were grown on 20 µg/mL PLO and 10 µg/mL 
chicken TN-C or varying concentrations of human TN-C (Millipore): 1 µg/mL,  
5 µg/mL, 10 µg/mL, 15 µg/mL, 20 µg/mL, 25 µg/mL or 30 µg/mL. Cells were plated 
onto coated chamberslides at a density of 5x104/well. The cells were incubated for  
72 hours at 37°C, followed by a PBS wash and fixation with 4% PFA for 10 minutes 
at RT. The PFA was then removed and cells were gently washed three times with PBS 
and stored at 4°C. Chamberslides were stained following the protocol for ICC (section 
2.6.1) with the primary antibodies GFP (1:1,000) and β-III tubulin (1:1,000) (Table 
3.1) and secondary antibodies, goat anti-rabbit AlexaFluor 488, goat anti-mouse 
AlexaFluor 568, donkey anti-guinea pig AlexaFluor 488 and donkey anti-mouse 
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AlexFluor 568 at 1:1,000 (Table 2.6) incubated for 2 hours at RT. Following imaging, 
analysis was performed using NeuronJ, Microsoft Excel and Prism 5 GraphPad 
software. For each condition a total of 30 axons were measured in microns using 
NeuronJ. Each assay was replicated a minimum of three times (see Tables 3.2 and 3.3), 
except for the hNPCs grown on 15 µg/mL, 20 µg/mL, 25 µg/mL or 30 µg/mL of human 
TN-C which were replicated once (n=1) due to time constraints. The results from each 
replicate are detailed in Table 3.2 for PC12s and Table 3.3 for hNPCs (full details of 
hNPC outgrowth assays in Appendix A). One replicate consists of one vial of cells 
using one chamberslide (with two wells/condition) and a total of 30 cells were counted 
per condition for each replicate. Comparisons between the data sets were analysed 
using one-way ANOVA (non-parametric) and Tukey post hoc to determine statistical 
significance. 
Table 3.1 Primary antibodies and dilutions used for ICC analysis 
Antibody Species ICC dilution 
BDNF Rabbit 1:200 
Ctip2 Rabbit 1:500 
DCX Rabbit 1:500 
GFAP Rabbit 1:750 
GFP Rabbit 1:1,000 
Ki67 Mouse 1:100 
MBP Rabbit 1:50 
Oct4 Rabbit 1:500 
Tbr1 Rabbit 1:200 
TN-C Rabbit 1:250 
TrkB Rabbit 1:1,000 
VGlut1 Guinea Pig 1:500 
α9 integrin Rabbit 1:500 
β1 integrin Mouse 1:500 
βIII-tubulin Mouse 1:1,000 
βIII-tubulin Rabbit 1:1,000 
  




3.3.1 Analysis of α9- and GFP-transfected PC12 cells by ICC and WB 
Overexpression of α9-eYFP and GFP was first achieved using transient transfection 
using two different reagents, GeneJammer and PEI, and results were analysed using 
ICC and WB. After staining cells for anti-GFP (Invitrogen), the ICC results indicate 
positive GFP staining in both the α9-eYFP (Figure 3.1, A and D) and GFP (Figure 3.1, 
B and E) transfected PC12s for both GeneJammer and PEI transfection reagents. The 
WT PC12 cells showed no positive staining for GFP (Figure 3.1, C and F). For WB, 
PC12 cells were also transfected using GeneJammer and PEI, however no bands were 
detected following staining for GFP and β-actin (data not shown). PC12 cells were 
subsequently transfected with α9-eYFP using JetPrime (Polyplus). From these 
transfection experiments, the overexpression of α9-eYFP was confirmed by WB 
(Figure 3.1, G) using the cell lysates from α9-eYFP PC12s (lane 2) and WT PC12 cells 
(lane 1). These lysates were run alongside lysates collected from WT RPE cells (Lane 
3), as a positive α9 integrin control. Following the transfer and blocking step, the blot 
was stained using anti-α9-integrin antibody and an anti-β-actin antibody. 
Chemiluminescence detection identified a band in lane 2 at approximately 150 
kilodalton (kDa) indicating α9-eYFP expression in PC12 cells and a band between 
100-130 kDa in lane 3 indicating endogenous α9 expression in RPE cells. No bands 
were observed for WT PC12 cells (lane 1), apart from one at approximately 42 kDa 
indicating β-actin which was observed in all lanes.  




Figure 3.1 Overexpression results following transient transfection of rat PC12 cells with α9-eYFP 
protein. Proliferating rat PC12 cells were transfected with either a α9-eYFP or a GFP plasmid using 
either GeneJammer (A-C), polyethylenimine (PEI, D-F) or JetPrime (G). Cells were fixed 72 hours 
post-transfection using 4% PFA and were stained using antibodies against GFP (Invitrogen) or  
βIII-tubulin (Sigma) along with a DAPI stain (Thermo ScientificTM). Both GeneJammer and PEI 
reagents resulted in transfection of the α9-eYFP plasmid detected by ICC and indicated by the white 
arrows highlighting the α9-eYFP positive cells (A and D). Transfection of GFP was also achieved using 
both GeneJammer and PEI reagents, indicated by the white arrows highlighting the GFP positive cells 
(B and E). No positive GFP staining was detected in WT cells (C and F) following PEI and GeneJammer 
transfections. Cells were also transfected using JetPrime reagent which was detected and confirmed 
using WB at approximately 150 kDa (G, lane 2). The endogenous level of α9 integrin was detected in 
WT RPE cells with a band between 100 and 130 kDa (G, lane 3). Lysates from WT PC12s were run in 
lane 1 and no observed bands were observed apart from β-actin at approximately 42 kDa which was 
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observed in each lane. Transfections and ICC were repeated three times, n = 3, WB repeated once, n 
=1. Scale bar in A-F = 100 µm. 
 
3.3.2 Overexpression of α9 integrin and GFP plasmids in PC12 cells 
using LV 
Stable expression of α9-eYFP and GFP in PC12 cells was trialled using third 
generation LV methods. Different concentrations of polybrene (hexadimethrine 
bromide) reagent were used to optimise and enhance transduction efficiencies. 
Following transduction, approximately 30-50% of cells detached from the dish, likely 
due to the cytotoxic effects of the polybrene. Results from WB show GFP expression 
was achieved using 0 µg/mL, 2 µg/ml and 4 µg/mL polybrene, but no α9-eYFP 
expression was observed under the same concentrations of polybrene (Figure 3.2, A). 
Equal β-actin bands were observed in all lanes at approximately 42 kDa and indicated 
equal protein loading per well. The blot in Figure 3.2 was the result from cells being 
incubated with viral supernatant for 4 hours. The experiment was also repeated with 
an overnight incubation of viral supernatant with the cells, however this did not alter 
the results (data not shown). Results from ICC confirmed this, as no positive GFP-
expression was observed in PC12 cells transduced with third generation LV-α9-eYFP 
viral supernatant and 2 µg/mL polybrene, following staining using an anti-GFP 
antibody (Figure 3.2, B and C).  
 




Figure 3.2 WB and ICC results following transduction of PC12 cells using third generation LV. 
Results show GFP expression was achieved using third generation LV methods with either 0, 2 or 4 
µg/mL of polybrene however no expression was observed for α9-eYFP. No expression of α9-eYFP or 
GFP was observed in WT PC12s (A, lane 1). Blot stained with anti-GFP (Invitrogen) and anti-β-actin 
(Sigma). WB lanes = 1: WT PC12, 2: LV-α9-eYFP PC12 (0 µg/mL PB); 3: LV-α9-eYFP PC12 (2 
µg/mL PB), 4: LV-α9-eYFP PC12 (4 µg/mL PB), 5: LV-fGFP PC12 (0 µg/mL PB), 6: LV-fGFP PC12 
(2 µg/mL PB), 7: LV-fGFP PC12 (4 µg/mL PB). ICC results shown no positive staining for GFP in 
PC12 cells that received LV-α9-eYFP third generation supernatant containing 2 µg/mL PB (B and C). 
Scale bar in B and C =100 µm. 
 
A second generation LV production and transduction protocol was trialled next and 
successful expression of LV-α9-eYFP was achieved (Figure 3.3). PC12 cells were 
transduced with two different LV-α9-eYFP plasmids (denoted ‘1.1.1’ and ‘2.2.1’) 
using second generation LV, and different volumes of viral supernatant, 1 mL, 2 mL 
or 3 mL with 2 µg/mL polybrene. Following WB analysis, a double band was observed 
at the expected 150 kDa in the lanes from cells which received the LV-1.1.1 -α9-eYFP 
plasmid (Figure 3.3, A lanes 1-3). Within these same lanes, bands at approximately 27 
and 37 kDa were also observed. No bands were detected at either of these molecular 
weights in the PC12 cells which received the LV-2.2.1-α9-eYFP plasmid (Figure 3.3, 
A lanes 4-6) or in the WT PC12 cells (Figure 3.4, A lane 7). Equal β-actin bands were 
observed in all lanes at approximately 42 kDa and confirmed equal protein loading per 
well. Results from ICC confirmed the α9-eYFP expression in cells that received 1 mL 
of LV-1.1.1-α9-eYFP viral supernatant and 2 µg/mL polybrene (Figure 3.3, B-E, ICC 
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results for other conditions not shown). Together these optimisation experiments 
resulted in the subsequent use of second generation LV supernatant using 1 mL LV 
(LV-1.1.1-α9-eYFP or LV-fGFP) in the presence of 2 µg/mL polybrene (Figure 3.4).  
 
Figure 3.3 Second generation LV results in expression of LV-α9-eYFP in the PC12 cell line. Two 
different LV-α9-eYFP plasmid preparations were tested using second generation LV production (1-1-1 
and 2-2-1) as well as different volumes of viral supernatant (1 mL, 2 mL or 3 mL) with 2µg/ml 
polybrene. The plasmid 1-1-1 LV-α9-eYFP produced the expected bands at approximately 150 kDa (A, 
lanes 1-3) and no obvious difference in protein expression was observed using either 1 mL (lane1),  
2 mL (lane 2) or 3 mL (lane 3) of viral supernatant. Furthermore, small faint bands were observed in 
these same lanes at around 27 kDa, which may be YFP degradation product. On the other hand, 
transduction of 2-2-1 LV-α9-eYFP did not result in any overexpression of the α9-eYFP protein 
following WB (A, lanes 4-6). No bands for α9-eYFP were detected in WT PC12 cells (A, lane 7). The 
WB membrane was stained for GFP and β-actin (Table 2.7). WB lanes = 1: LV α9-eYFP PC12 1-1-1 
(1 mL supernatant); 2: LV α9-eYFP PC12 1-1-1 (2 mL supernatant); 3: LV α9-eYFP PC12 1-1-1 (3 mL 
supernatant); 4: LV α9-eYFP PC12. 2-2-1 (1 mL supernatant); 5: LV α9-eYFP PC12. 2-2-1 (2 mL 
supernatant); 6: LV α9-eYFP PC12. 2-2-1 (3 mL supernatant); 6: WT PC12 cells. Overexpression of 
α9-eYFP using 1 mL of viral LV-1.1.1 α9-eYFP supernatant and 2 µg/mL supernatant in PC12s was 
confirmed using ICC (B-E). Using a GFP antibody, α9-eYFP could be detected along the PC12 cell 
surface (white arrows in B-E). Scale bar in B-C= 100 µm and D-E = 20 µm. 
 




Figure 3.4 Confirmation of second generation LV transduction of α9-eYFP and fGFP in 
proliferating PC12 cells using ICC and WB. Proliferating PC12 cells grown on PDL were transduced 
with second generation LV supernatant for either LV-α9-eYFP or LV-fGFP with 2µg/ml polybrene. 
Successful transduction and expression of the LV-α9-eYFP plasmid was achieved indicated by positive 
GFP staining (A) which co-labelled with βIII-tubulin (B) and DAPI (C). Positive staining shown for 
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GFP, following transduction with LV-fGFP supernatant (D) shown co-labelled with βIII-tubulin and 
DAPI (E, F). WT (untransfected) PC12 cells did not show positive staining when probed for GFP (G). 
Scale bar A-I = 100 µm. Following WB analysis (J), the overexpression of LV-α9-eYFP was detected 
in lane 1 at the approximately 150 kDa. Furthermore, the over expression of GFP control was detected 
in lane 2 at roughly 30 kDa. β-actin control staining indicated by the band at 42 kDa in each lane 
specified equal protein loading per lane.  
 
 
3.3.3  Functional analysis of α9-expressing PC12 cells on TN-C 
To assess if the overexpressed LV-α9-eYFP within the PC12s was functional, virally-
transduced cells were grown on 10 µg/mL chicken TN-C (Andrews et al., 2009) and 
neurites were measured using a neurite outgrowth assay. Measurements were taken 
from PC12 cells stained for βIII-tubulin. Fluorescent images were converted to black 
and white to allow for measurement analysis and neurite tracing using NeuronJ (Figure 
3.5, A-C). Examples of neurites measured are indicated by the black arrows in images 
Figure 3.5, A-C. Measurements from three replicate outgrowth assays, totalling 90 
measurements for each condition (α9-eYFP, GFP and WT) are shown in Table 3.2. 
Overexpressing LV-α9-eYFP in PC12s resulted in an average neurite outgrowth of 
135.36 µm (n=3) which was significantly longer, P<0.001, compared to neurite 
outgrowth from GFP-transduced PC12 cells (70.99 µm) and WT PC12 cells (75.21 
µm) (Figure 3.5, D). There was no significant difference in neurite outgrowth between 
the GFP-transduced and WT PC12 cells (Figure 3.5, D). From these results we can 
conclude that the overexpressed α9 integrin from the LV transduction of LV-α9-eYFP 
leads to expression of functional α9 protein.  
Table 3.2 Neurite outgrowth measurements taken from virally-transduced PC12 cells grown on 
chicken TN-C 
Repeat 
Average outgrowth in µm on 10 µg/mL chicken TN-C  
α9–PC12 GFP–PC12 WT PC12 
1 129.55 73.81 84.98 
2 128.63 69.69 63.40 
3 147.90 69.48 77.26 
 Average 135.36 70.99 75.21 
 St Dev. 10.87 2.44 10.94 
 SEM 6.27 1.41 6.31 




Figure 3.5 Overexpressing of α9 integrin subunit increases neurite outgrowth in PC12 cells when 
grown on chicken TN-C. PC12 cells transduced with α9-eYFP LV supernatant were able to put out 
neurites that averaged 135.36 µm in length, which was significantly longer than PC12 cells that 
expressed GFP, 70.99 µm, and WT PC12 cells, 75.21 µm. Scale bar in A-C = 200 µm. Neurite 
outgrowth analysed by one-way ANOVA and expressed as mean ± standard error of the mean (SEM), 
n=3, *** P < 0.001. 
 
3.3.4 Endogenous expression and LV overexpression of integrin 
within hNPCs  
Endogenous expression of both α9 and β1 integrin subunits within hNPCs was 
analysed using ICC and WB. Results showed hNPCs endogenously express β1 integrin 
(Figure 3.6) and α9 integrin (Figure 3.7, A, B, P and Q) subunits. ICC results showed 
that α9 was expressed within the cell body of the cultured hNPCs (Figure 3.7, A and 
B), whereas the β1 integrin appeared to be localised within the neurites and the cell 
body (Figure 3.6, A and B). Expression of endogenous α9 integrin in human young 
cerebral cortical neurons (hyCCNs, Axol Bioscience) further differentiated from the 
progenitor cells (hNPCs) were also examined. ICC results indicated these cells 
retained the α9 integrin expression into the early stages of neuronal development with 
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α9 present within neurites (Figure 3.7, C-D, white arrows). Research has previously 
shown some cells including PC12 cells can express and secrete TN-C into the ECM 
(Andrews et al., 2009). Our results indicated hNPCs expressed TN-C within the cell 
(Figure 3.7, E-F). To assess whether these cells would eventually secrete TN-C, further 
long-term monitoring of in vitro hNPCs would be needed.  
To confirm the ICC results, WB was carried out on WT hNPC lysates. Both integrin 
subunits were detected by WB but only after the protein concentration was increased 
from 20 µg/well to 40 µg/well. Firstly, expression of β1 integrin was observed, 
however the blots had to be exposed at a higher setting to visualise a band of the 
expected weight, 145 kDa (Figure 3.6, C and D, lanes 1 and 3). Endogenous β1 
expression was also observed in RPE cells at the same molecular weight (Figure 3.6, 
C and D, lane 2).  
The LV protocol developed for overexpression of LV-α9-eYFP and LV-fGFP in PC12 
cells was repeated in hNPCs. As noted with PC12 cells, approximately 40% of cells 
detached in the days following transduction until cells were collected for analysis by 
ICC or WB, prompting the use of a lower concentration of polybrene without 
compromising transduction efficiency. Cells were fixed using 4% PFA before staining 
for GFP with an anti-GFP antibody. Cells were immunopositive for GFP staining in 
both LV-α9-eYFP hNPCs (Figure 3.7, G-I) and LV-fGFP hNPCs (Figure 3.7, J-L), 
shown in cells co-labelled with βIII-tubulin. Furthermore, GFP and α9-eYFP 
expression was observed within both the cell body and extending the length of the 
neurites (Figure 3.7, G-L, white arrows). The WT hNPCs were negative for GFP 
expression (Figure 3.7, M-O) as expected. Lysates of LV-α9-eYFP hNPCs, LV-fGFP 
hNPCs and WT hNPCs were collected for WB analysis, which subsequently 
confirmed the ICC results. Nitrocellulose membranes were immunostained for GFP 
alongside β-actin antibodies (Figure 3.7, P and Q). Staining the membrane for GFP 
detected a band at around 150 kDa in lane 2 containing LV-α9-eYFP hNPC lysates 
(Figure 3.7, P) indicating α9-eYFP expression, and GFP was detected at around 27 
kDa in lane 3 containing LV-fGFP hNPC lysates (Figure 3.7, P). No protein bands at 
27 kDa were seen in lane 1 containing WT hNPC lysates. A single β-actin band was 
seen in each lane at the expected 42 kDa to confirm equal protein loading in each well.  




Figure 3.6 Endogenous expression of the β1 integrin subunit in hNPCs. Following ICC analysis 
hNPCs show expression of endogenous β1 integrin expression within the cell body and neurites (A, 
white arrows) which co-labelled with βIII-tubulin and the nuclear stain DAPI (B). Endogenous 
expression of the β1 integrin subunit was further confirmed using WB. When WT hNPC lysates were 
stained for β1 integrin subunit, bands were detected at around 130 kDa in lanes 1 and 3, containing WT 
hNPCs. Lane 2 contained WT RPE cells, which endogenously express β1 integrin to a much higher 
degree. The blot shown in C is at a low exposure setting and the β1 integrin bands in WT hNPCs are 
barely detectable (C). However, when the membrane is exposed to a higher setting (D), the endogenous 
β1 integrin expression within the WT hNPCs is evident and β-actin bands can be seen in each lane, at 
around 42 kDa indicating equal protein loading per well. Scale bar in A-B = 50 µm 
 
A separate blot was stained for α9 integrin to enable detection of endogenous protein 
levels in WT hNPCs alongside RPE cell lysates as a positive α9 integrin control 
(Figure 3.7, Q). A faint band at 114 kDa was observed in lanes 1 (WT hNPCs) and 2 
(LV-α9-eYFP hNPCs) (Figure 3.7, Q) indicating a low level of endogenous α9 
integrin. Overexpression of α9-eYFP was indicated by a 150 kDa band in lane 2 (LV-
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α9-eYFP hNPCs) indicating an overexpression of the α9 protein (Figure 3.7, Q). 
Together these results confirm our previous ICC results that hNPCs do express a low 
level of α9 integrin, however this expression can be increased using LV transduction.  




Figure 3.7 Endogenous expression of α9 and LV overexpression of α9-eYFP and GFP in hNPCs. 
Following ICC endogenous α9 integrin expression was observed within the cell bodies of the hNPCs 
(A-B, white arrows). Within hyCCNs, integrin expression was retained and detected within the neurites 
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(C and D, white arrows). ICC results indicate the hNPCs also express TN-C (E and F, white arrows). 
Overexpression of both the LV-α9-eYFP and LV-fGFP plasmids in hNPCs was confirmed by ICC (G-
O) and WB (P and Q). Using an anti-GFP antibody, the LV-α9-eYFP was detected in hNPCs following 
LV transduction (G) and co-labelled with βIII-tubulin and the nuclear marker DAPI (H and I). 
Overexpression of GFP was also detected using the same antibody (J) which also co-localised within 
βIII-tubulin-stained projections (K, white arrows) and with DAPI (L). No positive GFP expression was 
detected in WT hNPCs (M), but both the βIII-tubulin (N) and DAPI (O) were positive. Furthermore, 
overexpression of LV-α9-eYFP was detected using WB and staining for GFP antibody (P) and α9 
integrin antibody (Q). In lane 2, blot P and Q, containing lysates from LV-α9-eYFP hNPCs, an 
approximate 150 kDa band was detected indicating overexpression of the α9-eYFP protein, detected by 
both a GFP antibody (P) and an α9 integrin antibody (Q). Overexpression of GFP was detected in  
lane 3 (P) containing LV-fGFP hNPCs, at around 27 kDa and no bands except for β-actin was observed 
in lane 1 (P) which contained WT hNPCs. β-actin bands were visible in each lane, at around 42 kDa 
confirming equal protein loading per well. When staining for α9 integrin (Q), endogenous α9 expression 
was detected in WT hNPCs in lane 1 at around 114 kDa. This was the same molecular weight as in lane 
3 (Q), containing WT RPE cells, which endogenously express the α9 integrin subunit. WB lanes in P = 
1: WT hNPCs, 2: LV-α9-eYFP hNPCs, 3: LV-fGFP hNPCs. WB lanes in K = 1: WT hNPCs, 2: LV-
α9-eYFP hNPCs, 3: WT RPE cells. Scale bars in A, B, E and F = 20 µm, C and D, G-O = 50 µm. 
 
3.3.5 Expression of α9 integrin promotes neurite outgrowth in 
hNPCs when grown on TN-C 
To examine whether the overexpressed α9-eYFP protein was functional when 
expressed within hNPCs, neurite outgrowth was measured following the same protocol 
previously used for the PC12 cells. Following transduction using LV, α9-eYFP 
hNPCs, fGFP hNPCs and WT hNPCs were plated onto chamberslides coated with 
either chicken (10 µg/mL) (Figure 3.8) or human (1 µg/mL, 5 µg/mL, 10 µg/mL, 15 
µg/mL, 20 µg/mL, 25 µg/mL or 30 µg/mL) TN-C. Cells were grown on TN-C for 72 
hours before fixing with 4% PFA and subsequent ICC analysis. Neurite measurements 
were taken from βIII-tubulin-stained cells (Figure 3.8). Examples of neurites measured 
for each condition are highlighted by the white arrows in Figure 3.9. The averages 
from each replicate were pooled and combined (Table 3.3) and the final average was 
taken and plotted with SEM (Figure 3.10). The raw data from each replicate is detailed 
in Appendix A.  




Figure 3.8 Overexpression of α9 in hNPCs promoted neurite outgrowth when grown on chicken 
TN-C. When grown on 10 µg/mL chicken TN-C, WT hNPCs extended small neurites (E and F, white 
arrows), likely as a result of an endogenous integrin expression within these cells. Overexpression of 
α9 integrin in hNPCs using LV promoted a marked increase in neurite outgrowth (A and B, white 
arrows) on the TN-C substrate. Overexpression of GFP alone had no significant result on neurite 
outgrowth (C and D, white arrows). Scale bar A-F= 100 µm. 
 




Figure 3.9 Representative images from neurite outgrowth analysis of hNPCs grown on different 
species and concentrations of TN-C. Following LV transduction, LV-α9-hNPCs, LV-fGFP-hNPCs 
and WT hNPCs were grown on either 1 µg/mL human, 5 µg/ mL human, 10 µg/mL human or 10 µg/mL 
chicken TN-C. After 72 hours, cells were fixed and stained for βIII-tubulin (Tuj). Fluorescent images 
were converted to black and white in Image J, as these were better detected by the Neuron J software. 
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Table 3.3 Combined measurements taken from hNPC neurite outgrowth assays on different species and 
concentrations of TN-C 




Average outgrowth in µm 
α9 –hNPC GFP-hNPC WT hNPCs 
10 µg/mL Chicken TN-C  
1 10 days P=2 279.39 47.63 49.31 
2 10 days P=2 225.95 43.65 39.72 
3 10 days P=2 160.21 55.71 38.85 
4 27 days P=2 160.24 56.19 64.53 
5 27 days P=3 149.78 63.15 66.03 
6 10 days P=2 212.60 65.10 55.36 
 Average 198.03 55.24 52.30 
 St Dev 50.59 8.41 11.79 
 SEM 20.65 3.43 4.82 
1 µg/mL Human TN-C  
1 10 days P=2 234.75 49.44 52.30 
2 10 days P=2 250.31 46.72 40.85 
3 27 days P=2 130.79 75.05 75.87 
4 27 days P=3 120.97 95.83 95.53 
5 10 days P=2 192.83 50.35 54.03 
 Average 185.93 63.48 63.72 
 St Dev 58.81 21.39 21.83 
 SEM 26.30 9.57 9.76 
5 µg/mL Human TN-C  
1 10 days P=2 203.29 59.21 72.99 
2 10 days P=2 256.84 53.01 53.76 
3 27 days P=2                                                                                                                  126.05 90.29 74.76 
4 27 days P=3 124.45 89.56 83.65 
5 10 days P=2 193.80 132.98 124.79 
 Average 180.89 85.01 81.99 
 St Dev 56.19 31.78 26.29 
 SEM 25.13 14.21 11.76 
10 µg/mL Human TN-C  
1 10 days P=2 185.20 90.10 78.56 
2 10 days P=2 283.48 81.48 75.78 
3 27 days P=2 139.20 105.20 104.10 
4 27 days P=3 158.90 124.10 129.10 
5 11 days P=2 184.42 165.80 124.61 
6 10 days P=2 192.51 152.82 154.70 
  Average 190.62 119.92 111.14 
  St Dev 49.69 34.02 30.86 
  SEM 20.29 13.89 12.60 
15 µg/mL Human TN-C  
1 10 days P=2 177.35 162.76 144.19 
  St Dev 76.57 59.28 31.00 
  SEM 13.98 10.82 5.66 
20 µg/mL Human TN-C  
1 10 days P=2 187.95 183.12 176.68 
  St Dev 129.13 60.47 44.58 
  SEM 23.58 11.04 8.14 
25 µg/mL Human TN-C  
1 10 days P=2 191.50 155.65 240.89 
  St Dev 84.84 74.43 68.96 
  SEM 15.49 13.59 12.59 
30 µg/mL Human TN-C  
1 10 days P=2 190.30 229.38 183.6 
  St Dev 95.91 58.41 56.87 
  SEM 17.51 10.66 10.38 
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A significant difference in LV-α9-eYFP hNPCs outgrowth was observed for each 
condition (chicken 10 µg/mL, human 1 µg/mL, human 5 µg/mL and human 10 µg/mL) 
compared to both LV-fGFP hNPCs and WT hNPCs (Figure 3.10, A-D). Furthermore, 
when hNPCs were cultured on human TN-C, a significant increase in neurite 
outgrowth was observed with increasing concentrations of human TN-C (Figure 3.10, 
A-D and I), specifically in the GFP hNPCs, between those grown on 10 µg/mL chicken 
TN-C and the 10 µg/mL human TN-C (P<0.01) and also between those grown on 10 
µg/mL human TN-C and 1 µg/mL human TN-C (P<0.01). Additionally, a significant 
difference was observed between the WT hNPCs grown on 10 µg/mL human TN-C 
and 10 µg/mL chicken TN-C (P<0.01) and those grown on 1 µg/mL human TN-C and 
10 µg/mL human TN-C (P<0.05). No significant difference was observed between the 
four different LV-α9-eYFP hNPCs grown on any of the TN-C substrates.  
To assess this further, initial experiments were carried out using higher concentration 
of human TN-C (15, 20, 25 or 30 µg/mL). Results for 15 µg/mL and 20 µg/mL of 
human TN-C showed an increase in neurite outgrowth from the GFP-hNPCs and WT 
hNPCs, whilst outgrowth from LV-α9-hNPCs remained consistently high at around 
200 µm (Table 3.3 and Figure 3.10). These results were in line with the trend observed 
in 1-10 µg/mL, which demonstrated an increased concentration of human TN-C 
resulted in increased neurite length from both GFP and WT hNPCs. At higher 
concentrations of 25 µg/mL or 30 µg/mL human TN-C, expression from each of the 
three cell types (WT, α9-eYFP and GFP) did not follow the expected trend, however 
each of these latter experiments (15, 20, 25 and 30 µg/mL) was carried out only once 
and will need to be repeated to assess reliability (Table 3.3 and Figure 3.10). 




Figure 3.10 Increasing α9 integrin expression in hNPCs promotes neurite outgrowth when grown 
on different concentrations of chicken and human TN-C. Overexpressing α9-eYFP in hNPCs 
promoted significant neurite outgrowth when grown on 10 µg/mL chicken TN-C and on 1 µg/mL, 5 
µg/mL or 10 µg/mL of human TN-C compared to GFP-hNPCs and WT control hNPCs. (A-D and I). 
Furthermore, as the concentration of human TN-C increased from 1 µg/mL to 10 µg/mL the neurite 
outgrowth from both the GFP- and WT hNPCs increased (I). No significant difference was observed 
between the four different LV-α9-eYFP hNPCs grown on any of the TN-C substrates (I). When the 
concentration of human TN-C was increased further (15 µg/mL, 20 µg/mL, 25 µg/mL or 30 µg/mL), 
neurite outgrowth from the GFP-hNPCs and WT hNPCs also increased, however further repeats will 
be required to confirm this (E-H). Results were analysed by one-way ANOVA and expressed as mean 
± SEM (chicken 10 µg/mL n=6; human 1 µg/mL n=5; human 5 µg/mL n = 5; human 10 µg/mL n = 6; 
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human 15 µg/mL n = 1; human 20 µg/mL n =1; human 25 µg/mL n = 1 and human 30 µg/mL n = 1); 
*P<0.05, ** P<0.01, ***P<0.001. 
 
3.3.6 Further hNPC characterisation for cell-specific protein 
markers 
To gain further insight into the protein expression profile of hNPCs, ICC was 
performed for a number of cell-specific protein markers. These included analysing the 
cells for other phenotypes, examining deep-layer cortical neuron markers, assessing 
expression of other growth-promoting proteins, analysing potential neuronal 
phenotypes as well as assessing progenitor and prolific markers.  
Human NPCs (Axol Bioscience) were pre-programmed to become cerebral cortical 
neurons (CCNs) and therefore hNPC cultures would be expected to largely consist of 
a neuronal phenotype. Nevertheless, we analysed the cultures for other potential cell 
types that neural progenitors may differentiate into, including astrocytes and 
oligodendrocytes. Following staining for glial fibrillary acidic protein (GFAP), myelin 
basic protein (MBP) and βIII-tubulin, the hNPC cultures contained a small proportion 
of GFAP-positive cells indicative of astrocytes (Figure 3.11, B); however, there was 
no presence of MBP, a protein expressed by myelinating oligodendrocytes (Figure 
3.11, C). The cells that were stained for MBP were kept in culture for 21 days to allow 
for the potential development of myelin, however, MBP staining was not present 
within the culture at this time point. The majority of cells within the culture were  
βIII-tubulin-positive indicating a high proportion of the hNPCs had a neuronal 
phenotype as expected (Figure 3.11, A).  




Figure 3.11 WT hNPC cultures contained neuronal and astrocytic cells, but no MBP-positive 
oligodendrocytes. The hNPCs were pre-programmed to become CCNs, which was confirmed by ICC 
results as the majority of the culture expressed the neuronal marker βIII-tubulin (A). A small proportion 
of the culture was also positive for GFAP indicative of astrocytes (B), however no positive staining was 
observed in 21-day old cultures probed for myelin basic protein (MBP), a marker for oligodendrocytes 
(C). Scale bar in A-C = 100 µm.  
 
As the hNPCs were intended for transplantation into the deep layers of the rat 
sensorimotor cortex, the hNPCs were analysed for expression of deep-layer cortical 
neuron markers Ctip2 and T-box brain 1 (Tbr1) before being transplantated. Both of 
these neuronal markers are associated with the projection of neurons to subcortical 
targets. We found a high proportion, approximately 80%, of hNPCs expressed Tbr1 
(Figure 3.12, A-C) and Ctip2 (Figure 3.12, D-F), colocalising with the cell nucleus.  




Figure 3.12 hNPCs expressed deep-layer cortical neuron markers in vitro. The WT hNPCs were 
analysed for their expression of deep-layer cortical neuron markers, as this was the area that we targeted 
for transplantation. Two such markers include Tbr1 (A-C) and Ctip2 (D-E). ICC results show both were 
expressed within the nucleus of the hNPCs, which co-labelled with the nuclear stain DAPI (white arrows 
in B and E, respectively). Scale bars in A, B, D and E= 100 µm; C and F= 20 µm.  
 
For further characterisation into the developmental state of the cells, the hNPCs were 
analysed for their expression of the progenitor marker doublecortin (DCX). DCX is a 
protein expressed in immature neuronal cells and was anticipated to be highly 
expressed within these developing cells. Our ICC analysis confirmed that DCX was 
expressed and co-labelled with the βIII-tubulin-expressing cells (Figure 3.13, A-B).  
Alongside integrin expression, hNPCs were also found to express TrkB, a growth-
promoting receptor, involved in axonal elongation, as well as its ligand, BDNF, known 
for its growth-promoting properties (Reviewed in Binder and Scharfman, 2004). Both 
proteins were observed with punctate expression within the cell body and neurites 
(Figure 3.13, E, F and C, D, respectively). Moreover, as a high proportion of cortical 
projection neurons are excitatory glutamatergic neurons, presence of this phenotype 
using a vesicular glutamate transporter 1 (VGlut1) antibody was assessed. Human 
NPCs were found to express high levels of VGlut1 (Figure 3.13, G-H) and suggested 
the hNPCs had an excitatory phenotype.  




Figure 3.13 Further characterisation of hNPCs in vitro. Following ICC analysis, results show hNPCs 
expressed the progenitor marker DCX (A-B), the neurotrophin BDNF (C-D) and its receptor TrkB (E-
F) as well as the glutamate transporter VGlut1 (G-H). Scale bars A-B = 100 µm; C-F =20 µm and  
G-H = 50 µm.  
 
Furthermore, as these hNPCs have been pre-programmed to differentiate into CCNs, 
we would expect there to be very few cells maintaining the expression of stem cell 
markers, such as Oct4. Following ICC, hNPCs were immunopositive staining for Oct4 
(Figure 3.14, A-B). Oct4 is associated with undifferentiated cells, which does not align 
with our previous results. Research has suggested Oct4 expression is finely balanced 
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and overexpression of Oct4, can stimulate differentiation (Niwa et al., 2000), a 
characteristic which may explain the high expression level seen within the hNPCs. 
Conversely, hNPCs were also positive for the proliferation marker Ki67 (Figure 3.14, 
C-E), which is highly expressed in stem cells but also cancerous cells and its 
expression can be of concern when using stem cell-derived cells in vivo. 
 
 
Figure 3.14 hNPCs express stem cell and proliferation markers. hNPCs were positive for the 
transcription factor Oct4 (A, white arrows), a recognised stem cell marker, using an anti-Oct4 antibody. 
Within the hNPCs positive Oct4 expression was observed co-localising with the nuclear stain, DAPI  
(B, white arrows). Furthermore, the hNPCs were positive for Ki67 (C and D), a nuclear protein involved 
in cell proliferation and within the hNPCs this co-localised with DAPI (E, white arrows). Scale bars  
A-B = 100 µm; C= 50 µm and D-E =20 µm. 
 
The hNPCs were transplanted at around 8-9 days in culture. Prior to transplant, WT 
hNPCs cells were able to extend neurites in vitro (Figure 3.15, A white arrows) and 
neural rosette formation was observed (data not shown). Interestingly, after cells were 
maintained in culture for 21 days, mature fibre bundles were observed extending from 
boluses of WT hNPCs (Figure 3.15, C white arrows). These bundles appeared larger 
in size, suggesting the axon diameter may have grown in size or the axons were 
bundling together.  




Figure 3.15 WT hNPCs before and after transplantation. The hNPCs were transplanted after  
8-9 days in vitro (DIV). At this point cells were able to extend neurites (A, white arrows). Following 
transplantation, remaining cells were placed back into culture. WT hNPCs were able to extend neurites 
after being at RT for an extended period of time during the transplantation procedure (B, white arrows). 
When hNPCs were kept in culture for 21 days they displayed large fibre bundles projecting from hNPC 
boluses which suggested projections were bundling together or the axon diameter had grown (C, white 
arrows). Scale bar A-C= 250 µm.  
 
Finally, the hNPCs were analysed after transplantation to assess their viability and 
ability to extend neuronal projections following the transplantation protocol. 
Following the transplant procedure, the remaining WT hNPCs and α9-eYFP hNPCs 
were returned to cell culture to analyse the cell population used for transplants (Figure 
3.15, B and Figure 3.16, A). Cells extended axonal projections indicating both their 
viability as well as their ability to extend projections at the time of transplant, and up 
to a week following transplant, the longest time point analysed. Furthermore, the 
exogenous α9-eYFP expression was analysed 7 days post-transplant, indicating cells 
expressed α9-eYFP protein at the time of grafting (Figure 3.16, B-F). The α9-eYFP 
protein was detected within the neurites from these cells and also clustering within 
potentially newly forming growth cones (Figure 3.16, D-F).  
The hNPCs were also stained for presence of Rab11, a small GTPase involved in 
integrin trafficking/recycling (Eva et al., 2010; Franssen et al., 2015), microglia using 
an anti-ionised calcium binding adapter molecule-1 (Iba-1) antibody and synapse 
formation using an anti-postsynaptic density protein-95 (PSD-95) antibody, all of 
which were negative (data not shown). 
 





Figure 3.16 α9-hNPCs in culture including under the conditions of transplantation. Following 
collection for transplantation, remaining hNPCs were returned to culture and were able to extend 
neurites 7 days post-transplant (A, white arrows) (longest time-point analysed) indicating cell viability 
at the time of transplant. Furthermore, following ICC analysis excess LV-α9-eYFP hNPCs maintained 
expression of α9-eYFP (B-F). The α9-eYFP protein was detected within the neurites from these cells 
and also clustering within potentially newly forming growth cones (D-F). Scale bar in A= 250 µm; B 
and C = 50 µm; D = 15 µm; E = 5 µm; F = 2.5 µm. 
 
  




Integrins are involved in cell-cell and cell-matrix interactions. As the mammalian CNS 
matures, developmental proteins, such as integrins, involved in neuronal outgrowth 
and elongation are downregulated. As a result, the adult CNS is unable to repair or 
regenerate. The α9 integrin subunit forms a heterodimer with the β1 subunit and when 
expressed it can bind TN-C, the main ECM component of the CNS, highly expressed 
during development and also upregulated after a CNS injury (Zhang et al., 1997; Tang 
et al., 2003; Andrews et al., 2009). Furthermore, the environment created after CNS 
injury is characterised by a number of inhibitory molecules namely CSPGs and 
myelin-derived inhibitory proteins, such as Nogo-A, preventing regeneration. In an 
attempt to promote regeneration within the injured CNS, α9 integrin has been 
researched for its ability to promote repair after injury. Indeed, increasing α9 integrin 
expression in vivo using adeno-associated virus in DRG promotes axonal regeneration 
following a dorsal column crush injury (Andrews et al., 2009). However, recent 
research has demonstrated that exogenously expressed α9 integrin subunit is not 
trafficked into the axonal compartment within certain neuronal subtypes, including 
adult CST axons (Andrews et al., 2016). It is unclear why the integrin is inhibited from 
localising within those axons but it may be due to Rab11-Arf6 coupling promoting 
retrograde integrin transport and hence restricting expression of integrins to the 
somato-dendritic domain (Franssen et al., 2015). However, Andrews and colleagues 
(2016) also discovered integrin transport is present within developing CST axons. 
Together this research suggests a requirement for an alternative method to overexpress 
the α9 integrin subunit in order to promote repair and long-distance axonal 
regeneration within the adult CNS. One such alternative described in this work is using 
developmental hNPCs to act as a vehicle to reintroduce integrin into the mature CNS.  
In this chapter we have presented extensive in vitro characterisation of iPSC-derived 
hNPCs including demonstration of the endogenous levels of both the α9 and β1 
integrin subunits and the overexpression of the α9 subunit using both transient 
transfection and stable viral transduction. Additionally, we assessed the in vitro 
capacity of these cells to promote neurite outgrowth on TN-C. Furthermore, we 
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showed an increase in α9 integrin expression in hNPCs can have a significant effect 
on promoting neurite outgrowth when cells are cultured on TN-C.  
To confirm previously published work, a number of proof-of-principle experiments 
were performed using the α9-eYFP plasmid in the rat neuronal PC12 cell line. Firstly, 
transient transfection was used to overexpress the α9-eYFP protein to confirm 
overexpression within PC12s. Owing to the lack of commercially available antibodies 
for α9 integrin in vivo, the α9 plasmid had been tagged with eYFP. This allowed 
exogenous expression of α9 integrin to be easily detected using an anti-GFP antibody 
in vitro as well as in vivo. Alongside these transfections a GFP-only plasmid was used 
as a transfection control along with untransfected WT cells. The use of a GFP-only 
plasmid allowed us to ascertain that any functional effect coming from the α9-eYFP 
protein was due to the presence of the α9-integrin and not the transfection procedure. 
The results here indicate expression of either the α9-eYFP or GFP plasmid in PC12 
cells was achieved using either GeneJammer or PEI transfection reagents with similar 
efficiencies, and no GFP expression was observed within the WT PC12 cells, 
confirmed by ICC (Figure 3.1). For WB, expression was also assessed following 
GeneJammer and PEI transfections, however no bands were detected on the blots after 
probing for GFP and β-actin. This was considered to be a problem that occurred during 
the collection of cell lysates. The transfections and WB were repeated (n=3), and fresh 
cell lysis buffer was used for each replicate, however no bands were observed. One 
further transfection reagent, JetPrime, was used to transfect PC12 cells with the  
α9-eYFP plasmid. Following WB detection, an α9-eYFP band was observed at 
approximately 150 kDa. This was slightly higher than endogenous (untagged) α9, at 
around 114 kDa. The reason for this is due to the exogenous protein being tagged to 
eYFP which adds roughly another 26 kDa, causing the molecular weight of the protein 
to be increased (Figure 3.1).  
With transplantation experiments in mind, stable expression of the α9-eYFP protein 
was assessed using third generation LV. The LV system is a commonly used gene 
transfer approach allowing expression of proteins of interest in both dividing and non-
dividing cells compared to retrovirus which only allows expression of the transfer 
plasmid in dividing cells. As the hNPC culture had the potential to contain both 
dividing and non-dividing cells, the LV system was the more appropriate choice 
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compared with the retroviral system. Furthermore, LV is thought to be more stable 
when used in vivo compared to retrovirus (Naldini et al., 1996). A third generation LV 
system is considered safer compared to the other two systems (first generation and 
second generation) (Dull et al., 1998) as it requires transfection of four different 
plasmids; two packaging plasmids, one envelope plasmid and one transfer plasmid. In 
this system six out of the nine virulent human immunodeficiency virus genes have 
been removed leaving gag, pol and rev, which are split over two packaging constructs, 
one carrying gag and pol and the other carrying rev (Dull et al., 1998). This system 
also requires the transfer plasmid to contain a customised 5’ long terminal repeat 
(LTR) containing constitutive promoters. Use of third generation LV did not result in 
successful overexpression of the α9-eYFP protein, but did result in overexpression of 
GFP. The transductions were repeated with freshly prepared virus and consistently 
produced no expression of the α9-eYFP protein. After closer inspection of the LV-α9-
eYFP transfer plasmid, it was discovered this construct was designed to be used within 
a second generation system only as it did not contain the chimeric 5’ LTR. It therefore 
required the presence of the tat gene to promote expression. This gene is contained 
within the packaging plasmid of a second generation system. Following this discovery, 
the LV system was changed from third generation to second generation.  
A second generation LV system uses only one packaging and one envelope plasmid 
alongside the transfer plasmid and is considered less safe than the third generation 
system. Within this system gag, pol and rev genes are present alongside tat on one 
packaging plasmid. The addition of the tat gene allows for viral transcriptional 
regulation (Bieniasz et al., 1999). Expression of α9-eYFP and GFP was achieved 
within the PC12 cells (Figures 3.3 and 3.4) and subsequently the hNPCs (Figure 3.7) 
using second generation freshly prepared LV supernatant. A second generation 
transfer plasmid, such as LV-α9-eYFP, can only be packaged using a second 
generation LV system, however a third generation transfer plasmid, such as LV-fGFP, 
can be packaged using either a second or a third generation system. This possibly 
explains why positive GFP expression was observed following use of both second and 
third generation protocols. 
The successful expression of the α9-eYFP protein following a second generation LV 
protocol, compared to third generation, is likely due to the construct constituents used 
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within this system, specifically the addition of the tat gene within the packaging 
plasmid; however, we have considered a number of other possibilities. Firstly, it may 
be due to the size of the LV-α9-eYFP transfer plasmid, which at greater than  
10 kilobases, is quite large and may be reaching the upper limit of the capabilities of a 
third generation system. Research has indicated that viral titre decreases with a larger 
vector size (Kumar et al., 2001) and protocols have been optimised to combat this (al 
Yacoub et al., 2007). Lastly, the production of viral supernatant from a third generation 
system requires successful transfection of four plasmids, whereas second generation 
only requires transfection of three plasmids, therefore increasing the chance of 
successful transfection and viral particle production from a second generation system. 
This however is unlikely as GFP viral supernatant was produced effectively using the 
third generation system, and it is more probable the lack of α9-eYFP expression using 
a third generation system is due to one of the previous explanations.  
The expression of α9-eYFP and GFP was obtained using second generation LV and 2 
µg/mL polybrene. The cationic polymer polybrene is often used to enhance viral 
transduction efficiency by reducing the charge on the target cell membrane to promote 
entry of viral plasmids (Davis et al., 2002; Lizée et al., 2004; Zhao et al., 2014). 
However, polybrene can be toxic to primary cells and it was therefore important to 
optimise the concentration required to minimise cell death, but without compromising 
the α9-eYFP protein expression. Varying polybrene concentrations were trialled in 
PC12 cells using second generation LV, including 2 µg/mL, 4 µg/mL and 6 µg/mL 
and results showed 2 µg/mL was sufficient to achieve α9-eYFP expression and was 
therefore used in subsequent experiments. Furthermore, our results for second 
generation LV indicated one plasmid, noted as ‘1.1.1’ was able to achieve expression 
in PC12s and not the plasmid noted ‘2.2.1’. These two plasmids were prepared from 
glycerol stocks available in the laboratory. Both constructs had previously been 
prepared from colonies following bacterial transformation of DNA from a ligation 
reaction (carried out by Dr Melissa Andrews), however it is possible the ‘2.2.1’ 
plasmid had not been validated for presence of the α9-eYFP coding sequence. 
Confirmation of α9-eYFP expression as well as fGFP control expression was detected 
in PC12 cells using an anti-GFP antibody following WB (Figure 3.4). The results 
showed a double band for both GFP (one at ~30 kDa and one at ~25 kDa) and α9-
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eYFP (one at ~150 kDa and one double band at ~25 kDa). Following WB analysis 
using an α9 integrin antibody, a double band was also detected at the same positions 
in lysates from LV-α9-eYFP PC12s (data not shown) which therefore suggests there 
may be potential cleavage of the eYFP and fGFP proteins. Whether this is the signal 
peptide that is cleaved (the GFP protein is farnesylated, targeting the protein to the cell 
membrane) or is caused by a protease specifically expressed within the PC12 cell line 
or simply degradation is not clear, however this was specific to the PC12 cells as 
double bands were not present when these experiments were repeated with hNPCs.  
To analyse the function of α9 integrin following LV overexpression of α9-eYFP 
protein, the PC12 cells were grown on TN-C as previously published (Andrews et al., 
2009). When the α9β1 integrin heterodimer binds to TN-C, it promotes neurite 
outgrowth (Andrews et al., 2009). Here, we have confirmed these results and have 
observed significant neurite outgrowth of the LV-α9-eYFP PC12 cells compared to 
GFP controls and WT PC12 cells (Figure 3.5). While these results validate the 
previous findings, they do not align with all findings. As previously reported, PC12 
cells do not have an endogenous level of α9 integrin expression, however in our results 
when both GFP-PC12s and WT PC12s are grown on TN-C, neurite outgrowth was 
observed. Andrews and colleagues (Andrews et al., 2009) reported no outgrowth from 
WT PC12 cells under the same culture conditions. Here, the experiment was repeated 
(n=3) with neurite outgrowth consistently observed (see Table 3.2). This suggests that 
perhaps the PC12 cells are able to express another receptor that is able to bind to TN-
C. Research shows other integrin heterodimers, α7β1 and α8β1, are able to bind to TN-
C and promote neurite outgrowth (Mercado et al., 2004) and may therefore have been 
present within the heterogeneous PC12 cell population. To further investigate this, ICC 
or WB could be used to assess α7 or α8 integrin subunit expression. In addition, 
knockdown of these subunits may result in reduced outgrowth from the GFP and WT 
PC12s, leaving α9 integrin function more apparent. Furthermore, in both the Andrews 
et al paper (2009) and the work carried out here, PC12 cells were cultured in the 
presence of NGF in the media which acts to stimulate neurite outgrowth. Removing 
NGF from the media may result in reduced neurite outgrowth from the control groups 
but also potentially the α9-expressing groups. Whether the α9-PC12s would have been 
able to put out axonal projections without NGF has yet to be determined.  
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Compared to the PC12 cell line, the iPSC-derived hNPCs endogenously express both 
α9 and β1 integrin subunits (Figure 3.6 and 3.7). This expression is low, however α9 
integrin expression can be increased following transduction with fresh second 
generation LV supernatant of LV-α9-eYFP. WB and ICC analysis confirmed 
overexpression of both the LV-α9-eYFP plasmid and LV-fGFP plasmid within hNPCs 
(Figure 3.7), although protein expression was only detected by WB after the protein 
concentration loaded per well was increased from 20 µg to 40 µg per well. 
Furthermore, as with the PC12 cells, the functionality of the LV-α9-eYFP was 
analysed using neurite outgrowth assays. Transduced hNPCs were grown on either 
chicken TN-C as previously reported (Andrews et al., 2009) or varying concentrations 
of human TN-C (1 µg/mL, 5 µg/mL, 10 µg/mL, 15 µg/mL, 20 µg/mL, 25 µg/mL or 
30 µg/mL). As the NPCs are human it was hypothesised there may be a difference in 
neurite outgrowth from the cells when grown on human TN-C compared to chicken. 
Specifically, hNPCs may display a higher affinity for human TN-C which may have 
resulted in the increased neurite outgrowth compared to growth on chicken TN-C. 
Following transduction of α9-eYFP into hNPCs there was significant neurite 
outgrowth compared to both GFP and WT controls when grown on 10 µg/mL chicken 
TN-C and 1 µg/mL, 5 µg/mL, 10 µg/mL of human TN-C (Figure 3.10). Each of these 
were repeated a minimum of five times. Interestingly, the results from these initial 
experiments indicated that when cultured specifically on human TN-C, there was a 
gradual increase in outgrowth from the GFP and WT controls as the TN-C 
concentration increased. As a follow up, these experiments were repeated (n=1) using 
higher concentrations of human TN-C: 15 µg/mL, 20 µg/mL, 25 µg/mL or 30 µg/mL 
(Figure 3.10). These experiments, specifically using the 15 and 20 µg/mL human  
TN-C, align with the previous results indicating an increase in outgrowth from the 
GFP and WT hNPC groups as the TN-C concentration increases. At the highest 
concentrations assessed (25 µg/mL or 30 µg/mL) outgrowth appeared to be more 
variable between the groups, however as these experiments were carried out only once 
they would need to be repeated to assess statistical significance.  
Together these results suggest that as the concentration of human TN-C increases, the 
endogenous α9 integrin function is boosted, resulting in a larger impact on neurite 
outgrowth. Investigation into the expression of α7 and α8 integrin subunits has not 
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been carried out in the hNPCs which could potentially have influenced the neurite 
outgrowth in these cases. However, of particular interest is previous research that has 
shown embryonic DRGs can increase integrin subunit expression at the cell surface in 
response to an inhibitory, CSPG-rich environment, promoting integrin-induced 
outgrowth (Condic et al., 1999). It is possible that stem cell-derived NPCs also possess 
this characteristic and as the concentration of TN-C increased, hNPCs adapted thereby 
promoting integrin subunit expression resulting in better neurite outgrowth. These 
results also highlight that hNPC growth fits a sigmoid-shaped curve that can be altered 
by changing either the expression of a growth promoting protein, α9 integrin, or the 
concentration of the ECM ligand, TN-C. Increasing α9 integrin expression produced 
an increase in neurite outgrowth which resulted in a growth plateau at low 
concentrations of TN-C compared to both GFP-expressing and WT hNPCs. However, 
as the concentration of TN-C was increased neurite outgrowth from both GFP-
expressing and WT hNPCs increased while the outgrowth from the α9-expressing 
hNPCs remained consistently high. This further suggests the observed results may be 
specific to the TN-C substrate interacting with the α9 integrin, but could be further 
analysed by examining the outgrowth from these cells when grown on a different ECM 
matrix, such as fibronectin. This also raises an interesting question as to whether 
overexpression of α9 integrin subunit is necessary to increase neurite outgrowth, 
particularly if these cells were used in an injured environment where TN-C expression 
is increased (Zhang et al., 1997). Currently the concentration of TN-C at the injury 
site, or indeed during homeostasis, is not known but further assessment of these cells 
in an injury model would likely add helpful data to this debate. It may be that as the 
concentration of TN-C increases, this stimulates further α9 integrin production, 
transport to the membrane or activation of the integrin. Therefore the adaptation 
potential of stem cell-derived hNPCs needs to be fully investigated in terms of integrin 
expression and neuroregeneration.  
This work so far has focused on increasing α9 integrin expression, however we also 
need to consider how this might impact on endogenous proteins, specifically β1 
integrin expression. As β1 is the binding partner for α9 integrin, the regulation of 
endogenous β1 in terms of production, transport and expression may be altered. This 
has not been assessed in this project but could be monitored using an 
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immunoprecipitation pull-down assay of β1 bound to α9 integrin before and after viral 
transduction. This could also be monitored using WB to analyse lysates from WT cells 
and α9-eYFP-expressing cells and staining the blot for β1 integrin. If a difference in 
β1 integrin band size is apparent it can be measured. There are a number of potential 
outcomes from these experiments. It is possible that more β1 integrin would be 
produced and present within the cell following overexpression of α9-eYFP. It may also 
be possible that there is no increase in β1 expression and perhaps exogenous α9-eYFP 
prevents endogenous β1 from binding other α integrin subunits, modifying 
endogenous integrin function. Whatever the outcome, this is an important question to 
address in order to ascertain how α9 integrin overexpression could impact on the cell’s 
homeostasis and potential activity in vivo.  
The hNPCs used in this project were pre-programmed to become hyCCNs (Axol 
Bioscience). However, during culture the media in which the hNPCs were grown 
promotes spontaneous differentiation. Neural progenitors that are not pre-programmed 
have the ability to differentiate into neuronal or glial cells. From the hNPCs cultured 
during this project, the majority of the cells had a neuronal phenotype and stained 
positively for βIII-tubulin (Tuj1), a recognised neuronal marker, however, the cultures 
were also analysed for presence of other cell types including astrocytes and 
oligodendrocytes (Figure 3.11). Of these further two cell types, only positive staining 
was observed for GFAP, which suggested developing astrocytes or glial precursor cells 
were also present within the hNPC culture. When assessing for oligodendrocytes, cells 
were only in culture for 21 days and it is possible oligodendrocytes had not yet formed. 
Keeping the cells in culture for a longer time period to assess oligodendrocyte presence 
would likely answer this question. Alternatively, staining the cells for a marker of 
immature oligodendrocytes such as NG2 (Polito and Reynolds, 2005), may detect 
OPCs. The use of GFAP as a marker for immature astrocytes has generated 
controversy as research suggests GFAP is only expressed within mature, fully 
differentiated astrocytes (Bignami et al., 1972), but others suggest GFAP is expressed 
within astrocyte progenitors (Baba et al., 1997). Alternatively, vimentin could have 
been used to identify developing astrocytes (Gomes et al., 1999). Here, the presence 
of developing astrocytes was not assessed, however it is likely that glial precursor cells 
were present within the culture. The proportion of astrocytes in the culture was small 
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and for the purposes of transplantation, their presence may be beneficial for the 
survival and differentiation of the NPCs both in vitro and in vivo (Brown, 1999; Park 
et al., 2001; Oh et al., 2010). Astrocytes are known to support neuronal function, 
growth and, via secretion of thrombospondins, can promote synaptogenesis (Ullian et 
al., 2004, 2001; Christopherson et al., 2005) which is important for both synaptic 
plasticity and regeneration after injury. Therefore, transplanting a co-culture of hNPCs 
alongside a small proportion of human astrocytes, may result in a human neuron-glia 
network that can interact and communicate with one another further promoting the 
survival of transplanted hNPCs within the rat cortex. Whether rat astrocytes would be 
able to support the hNPCs in the same way is not fully understood and is out with the 
scope of this project. Results here from ICC showed positive GFAP staining within 
the hNPC culture and indicated astrocytes were present in vitro. There is potential for 
these astrocytes to aid in NPC functioning and synaptogenesis in vitro, as mentioned 
above, which also indicates their presence could have been beneficial to hNPCs 
following transplantation.  
The hNPCs were further characterised by assessing expression of deep-layer cortical 
neuron markers, including Ctip2 and Tbr1, confirming the observations of others (Shi 
et al., 2012b). Expression of specific markers can determine whether axons will project 
to the corpus callosum, to other areas of the cortex or to subcortical targets. Both 
proteins have been identified as markers of layer V/VI cerebral cortex neurons 
(Bulfone et al., 1995; Hevner et al., 2001; Arlotta et al., 2005; Chen et al., 2005). This 
cortical area, consisting mainly of pyramidal cells, is associated with neuronal 
projections to subcortical targets, including the internal capsule, thalamus, brain stem 
and spinal cord. Ctip2 is a zinc finger transcription factor associated with neuronal 
nuclei. It is known to be involved in differentiation of NPCs and is involved in 
regulation and ability of layer V neurons to project to subcortical targets (Arlotta et 
al., 2005; Chen et al., 2008a). Tbr1 is also a DNA-binding protein involved in neuronal 
differentiation (Hevner et al., 2001), migration and axonal targeting of neurons to 
subcortical targets during development (McKenna et al., 2011). Importantly, Ctip2 
expression is required for development of CST axons from cortical layer V (Chen et 
al., 2005) and Tbr1 expression, although mainly associated with layer VI neurons and 
corticothalamic projections (Hevner et al., 2001), it has also been implicated in 
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controlling laminar identity and development of the CST (Bedogni et al., 2010; Han 
et al., 2011). During development, if Tbr1 is not present, this can result in aberant 
projections from layer VI of the cortex (Han et al., 2011). In culture, expression of 
both Ctip2 and Tbr1 were observed in hNPCs following ICC analysis showing hNPCs 
confer deep-layer CCN identity. The results here were significant for progression of 
the project, specifically for transplant of hNPCs into deep layers of the sensorimotor 
cortex, as we hypothesised these cells would project subcortically throughout the CST.  
The hNPCs were also analysed for progenitor cell and growth-promoting 
characteristics using DCX as well as certain neurotrophic factors including BDNF and 
its receptor, TrkB. DCX, a recognised progenitor marker, is highly expressed in 
developing and immature neurons (Magavi et al., 2000; Brown et al., 2003; Couillard-
Despres et al., 2005). The DCX protein is involved in stabilisation of axonal 
microtubules and migration of developing neurons (Francis et al., 1999; Gleeson et 
al., 1999). BDNF is a growth factor associated with neuronal development and growth 
signalling through the transmembrane receptor TrkB. BDNF signalling through TrkB 
results in neuronal outgrowth and elongation, however research suggests endogenous 
expression is not sufficient to promote regeneration after injury (Lu et al., 2001). 
Indeed, overexpression of TrkB within corticospinal neurons can promote 
regeneration after CNS injury (Hollis et al., 2009). Results from experiments in this 
chapter showed expression of these proteins. Finally, neuronal phenotype was 
analysed using antibodies against VGlut1, a recognised marker for excitatory, 
glutamatergic neurons, which make up approximately 80% of the mammalian cortex. 
Results show the hNPCs do have a high expression of VGlut1, confirming previous 
literature (Shi et al., 2012b), suggesting these are glutamatergic cells. Other 
neurotransmitter receptors, such as GABA transporter 1 (GAT1) or choline 
acetyltransferase (ChAT) were not assessed so we cannot be sure there are no 
additional neuronal phenotypes in this culture. Together, the expression of these 
proteins DCX, BDNF, TrkB and VGlut1 within the hNPCs in vitro, heightens the 
potential of these cells to promote neurite outgrowth, elongation and regeneration in 
vivo.  
In summary, here we have successfully generated α9-eYFP-expressing iPSC-derived 
hNPCs. Furthermore, we have demonstrated that once this exogenous protein is 
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expressed, it can promote neurite outgrowth when cultured on TN-C. Equally, these 
cells express endogenous α9 and β1 integrin subunits and are capable of neurite 
outgrowth on TN-C. Moreover, hNPCs express deep-layer cortical neuron markers, 
including Ctip2 and Tbr1, important for axonal projections to reach subcortical targets, 
as well as neurotrophic factors including BDNF and TrkB all of which will be 
beneficial in transplantation experiments. This is because the expression of these 
proteins together may contribute to the promotion of axonal elongation, cell survival 







































Chapter 4: In vivo analysis of  
WT iPSC-derived hNPCs 
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4.1 Introduction and aims 
Following in vitro characterisation of our population of iPSC-derived hNPCs, the next 
step of the project involved transplanting iPSC-derived hNPCs into the neonatal rat 
sensorimotor cortex and characterising them in vivo. Transplantation of stem cell-
derived cells is a rapidly expanding field, particularly in the area of neuroregeneration. 
Stem cells have been used for their ability to promote repair and restoration of function 
in Parkinson’s disease (Bjorklund et al., 2002; Brederlau et al., 2006), stroke (Wang 
et al., 2016), amyotrophic lateral sclerosis (Mazzini et al., 2015), Huntington’s disease 
(McBride et al., 2004) and SCI (Fujimoto et al., 2012; Antonic et al., 2013; Piltti et 
al., 2015). Research has shown transplanted ESC-derived cells are able to project to 
and follow fibre tracts within the brain (Denham et al., 2012), including the CST 
(Ideguchi et al., 2010). The lack of continual, sustainable resources, as well as the 
ethical debate surrounding use of ESCs, has driven researchers to find alternative 
methods. This alternative came from the discovery of iPSCs produced by expressing 
embryonic transcription factors in somatic (including adult-derived) cells resulting in 
cells reverting to a pluripotent state (Takahashi and Yamanaka, 2006; Takahashi et al., 
2007). These pluripotent cells have the same proliferative and expandable properties 
as ESCs and have the capacity to differentiate into any cell type, including NPCs.  
Here we aimed to transplant WT human iPSC-derived hNPCs into the rat sensorimotor 
cortex, specifically layer V, as neurons in this area project axons within the CST. We 
aimed to ascertain whether transplanted cells could project axons long distances and 
follow the CST in vivo. After transplantation, tissue was collected at various time 
points from 2 weeks up to 8 weeks and tissue was analysed using IHC and fluorescent 
microscopy. Human-specific antibodies were used to identify the transplant sites and 
projections within the tissue which allowed cell survival and projection trajectory to 
be mapped over time. In addition, we wanted to build upon the expression profile 
established in Chapter 3 and to assess the in vivo expression of a number of proteins 
over time including, CCN and maturation markers, as well as to assess to what extent 
the grafts had an effect on the surrounding host tissue.  




4.2.1 Neonatal cerebral cortex transplants of WT hNPCs 
All procedures were carried out under the UK Home Office Project Licence number 
60/4472 and Personal Licence number IC71C2B2B, conformed to the UK Animals 
(Scientific Procedures) Act (1986) and approved by the Animal Welfare Ethics 
Committee of the University of St Andrews.  
Human NPCs were removed from the dish after 8-9 days in culture (section 2.5.6). 
Full transplant procedure is detailed in section 2.7.1. Briefly, P0-2 newborn Sprague 
Dawley rat pups were injected under hypothermic anaesthesia, either unilaterally or 
bilaterally into two specific sites (1 µL/injection site) for the predicted neonatal 
sensorimotor cortex (Altman and Bayer, 1995). All pups received 100,000 cells per 
injection site. Following analysis of the initial tissue batches, the coordinates for 
subsequent batches were adjusted to improve accuracy of injection (see Table 2.8 for 
details on injection coordinates). Animals were placed beneath a stereotaxic frame and 
injected using a Hamilton syringe with an attached custom made 30-gauge stainless 
steel needle (ESSLAB UK). Cells were injected manually over the course of 1 minute, 
then the needle was left in place for 2 minutes to prevent backflow from the injection 
site. Following the transplant, animals were transferred to a pre-warmed cage to 
recover. Once the entire litter had undergone surgery and woken up, they were returned 
to the cage with the mother. Pups were monitored closely for 48-72 hours post-surgery 
to assess any signs of rejection by the mother.  
4.2.2 Neural tracing experiments 
See section 2.7.2. 
4.2.3 Tissue perfusion and sectioning 
See section 2.7.4. 
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4.2.4 IHC analysis of hNPC transplants 
Brain tissue was analysed using IHC as described in section 2.8. Briefly, following the 
blocking step tissue sections were incubated with primary antibody diluted in blocking 
solution overnight at 4°C (see Table 4.1, full details in Table 2.5). Specifically, to 
assess graft survival and hNPC projections, human-specific antibodies against HuNu 
and hNCAM were used. The specificity of these antibodies was assessed on control 
rat tissue prior to use (Appendix C). Following primary antibody incubation, tissue 
sections were washed three times for 10 minutes each with 0.02% Tween-20 in PBS. 
Specifically, for the TN-C antibody, pre-treatment with 0.03% hydrogen peroxidase 
was required (section 2.8.1). Tissue was subsequently incubated with fluorescently-
tagged secondary antibodies (1:750) of the corresponding species (see Table 2.6) and 
then DAPI (1:10,000). Sections were washed with PBS, mounted onto gelatin-coated 
slides, dried at RT, and covered with a glass coverslip. Slides were stored at 4°C and 
covered to protect from the light. Slides were imaged using a Leica D5500 
epifluorescent microscope equipped with a DFC550 digital camera (Leica). 
Table 4.1 Primary antibodies and dilutions used for IHC analysis 
Antibody Species IHC dilution 
HuNu Mouse 1:500 
hNCAM Mouse 1:200 
TN-C Rabbit 1:200 
GFAP Rabbit 1:500 
MBP Rabbit 1:50 
Tbr1 Rabbit 1:400 
Ctip2 Rabbit 1:500 
Ctip2 Rat 1:500 
DCX Rabbit 1:500 
PKCγ Rabbit 1:200 
Ki67 Mouse 1:100 
Iba-1 Rabbit 1:500 
WFA -- 1:200 
  




4.3.1 Identification and survival of WT hNPC transplants in vivo 
over time  
Once transplanted into the rat brain, hNPCs were detected in tissue using human-
specific antibodies, HuNu and hNCAM. Specifically, the bolus of hNPCs could be 
detected using the HuNu antibody (Figure 4.1, A-C) and projections from these cells 
could be detected using the hNCAM antibody (Figure 4.1, D-F, white arrows).  
 
 
Figure 4.1 Human NPC graft survival was detected in vivo using human-specific antibodies. 
Following transplantation of hNPCs into neonatal rat brain, tissue was harvested at a number of different 
time points from 2 weeks up until 8 weeks. To detect the transplants, tissue was analysed using IHC 
and human-specific antibodies including HuNu and hNCAM. The anti-HuNu antibody detected the 
nuclei (white arrows in A-C) of the grafted cells showing the bolus sites whilst the projections from 
these cells were detected using an anti-hNCAM antibody (white arrows in D-F). Scale bars A, C, F = 
250 µm, B = 500 µm, D, E = 150 µm. 
 
Transplant survival was observed from 2 weeks up until 8 weeks, however graft 
survival decreased over time. A breakdown of the graft appearance was divided into 
three categories including number of animals showing either graft survival, scarring 
or no graft detected over time from 2 to 8 weeks and is shown in Table 4.2 and Figure 
4.2, A. Scarring was defined as non-specific HuNu or hNCAM staining that 
corresponded with increased GFAP staining (Appendix B).  
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After 2 weeks in vivo, results show there was an 82% (n=14/17) graft survival rate, but 
after 8 weeks this reduced to 38% (n=5/13). Graft survival was expected to be high at 
early time points owing to a lack of full immune response in the neonatal rat potentially 
making graft rejection at this stage very low. Similarly, the number of animals with 
scarring or no grafts increased over time. For example, at 2 weeks post-transplantation, 
only 18% (n=3/17) of cases had no surviving cells detected, but at 8 weeks this was 
increased to just over half the animals 54% (n=7/13). In total, over all time points, no 
graft or scar could be detected in 28% of animals (n=22/78). However, these cases 
cannot be termed as graft rejection, as we cannot confirm cells were transplanted 
because of potential backflow of cells from the injection site or clogging of the needle 
during transplant.  
Table 4.2 Survival of WT hNPC transplants over time 
 
Out of a total of 56 animals with either hNPC grafts surviving or noticeable scarring, 
46% (n=26/56) of those had an on-target hNPC injection within the deep layers of the 
sensorimotor cortex (Figure 4.2, B-C). The remaining 54% (n=30/56) were off target 
and located in regions adjacent to the target site, including the hippocampus, caudate 
and/or putamen of the basal ganglia and lateral ventricles. In an attempt to achieve 
better accuracy with transplant injection and targeting, coordinates were modified over 
time (Table 2.8). The adjustment of coordinates resulted in improved accuracy of 
transplants and in batch 12, the last batch of transplants, 64% (n=9/14) of hNPC grafts 
were on target (Figure 4.2, B). Results also show there was a minimum of 40% of on-
target grafts at each time point (Figure 4.2, C). 
 Number of weeks post-transplantation of WT hNPCs 
Total 









No. of animals with 
transplants surviving 14 (82%) 12 (75%) 8 (47%) 8 (53%) 5 (38%) 
47 
(60%) 
No. of animals with 
scarring 0 (0%) 0 (0%) 2 (12%) 6 (40%) 1 (8%) 
9 
(12%) 
No. of animals with 
no graft detected 3 (18%) 4 (16%) 7 (41%) 1 (7%) 7 (54%) 
22 
(28%) 
Total 17 (22%) 16 (21%) 17 (22%) 15 (19%) 13 (17%) 78 (100%) 




Figure 4.2 Analysis of WT hNPC graft survival and on- and off-target injections. Tissue was 
analysed for transplant survival over different time points (2, 4, 6, 7 and 8 weeks post-transplantation). 
Survival was highest at younger time points of 2 and 4 weeks which declined over time (A). In contrast, 
the number of animals that had a clear scar or no transplant survival increased over time (A). Transplant 
coordinates were optimised with each batch of transplants in a bid to improve transplant accuracy, which 
was relatively low with the first few batches. For example, after the first batch of transplants 30% of 
grafts were on target within the sensorimotor cortex. However, after coordinate optimisation, this 
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number increased to 64% of grafts on target in batch 12 (B). Combined, 46% of total grafts were on 
target. Furthermore, each time point contained 40% or more of grafts on target indicating there were 
on-target injections at each time point (C). 
 
4.3.2 Locations of hNPC transplants and their neuronal projections  
Variation in coordinates and injection sites throughout the different batches resulted 
in a number of different hNPC transplant sites. These injection sites were first 
identified using HuNu and hNCAM antibodies and co-stained using an astrocytic 
marker, GFAP and DAPI, a nuclear stain. Transplant sites included areas of the cortex, 
hippocampus, corpus callosum, caudate and/or putamen of the basal ganglia, and 
striatum (Figures 4.3 and 4.5). These sites varied in size, where the bolus of cells were 
either together in a ball formation (Figure 4.3, E and G) or had spread out over a larger 
area (Figure 4.3, D). Analysis of both coronal and sagittal sections revealed projections 
had started generally within the cortex, corpus callosum, caudate and/or putamen of 
the basal ganglia and ventricles and projected within mainly these same areas, as well 
as to the thalamus, internal capsule, cerebral peduncles and pons. The transplant sites 
and projections for each batch are summarised in brain maps in Figure 4.5. 
 




Figure 4.3 Representative images of hNPC transplant locations detected using human-specific 
antibodies. The tissue was analysed using IHC and injection sites were identified using both HuNu and 
hNCAM antibodies. IHC results revealed some variation in injection sites. These included the dorsal 
striatum and corpus callosum (B and C), areas of the cortex (D, G, H, I, J and K), the lateral ventricles 
(E), as well as the lateral septum (F). Scale bars in B, C, F, G, H, I, J and K = 500 µm; D and E = 250 
µm. 
As a result of the varied injection sites, the projections from the transplanted hNPCs, 
identified using an hNCAM antibody, were located in different neuroanatomical 
regions including the cortex, corpus callosum, lateral septum, dorsal striatum, 
thalamus, hippocampus, internal capsule, cerebral peduncle and pons (Figures 4.4 and 
4.5). These projecting fibres formed bundles and coursed through known axonal 
pathways in the brain, such as the corpus callosum (Figure 4.4, B) and the internal 
capsule (Figure 4.4, C and D). Furthermore, IHC analysis also indicated these 
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projections may be of different thicknesses (indicated by white arrows in Figure 4.4, 
F, I and J) where the fibre thickness appeared to be noticeably larger compared to 
others (white arrows in Figure 4.4, G and H) suggesting fibres may have grown in size 
over time or have bundled together.  
 
 
Figure 4.4 Transplanted WT hNPCs extend hNCAM-positive projections throughout the rat 
brain. The projections from grafted hNPCs could be detected using IHC with an anti-hNCAM antibody 
and were observed in a number of different neuroanatomical regions. These included the corpus 
callosum (B and K), internal capsule (C and D), dorsal striatum (E), lateral septum (F), pons (G), 
thalamus (H), cortex (I) and cerebral peduncles (J). Tissue was also stained with an anti-GFAP antibody 
to identity astrocytes and DAPI to identify all nuclei. Scale bars B, E = 150 µm, C = 200 µm, D, F, K= 
500 µm, G, H, I, J= 250 µm. 
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When transplants were on target, hNCAM-labelled projections were observed within 
the fibre tracts of the CST, including the internal capsule, cerebral peduncles and pons 
as well as the pyramids within the brain stem (Figure 4.6). Out of 47 animals showing 
hNPC survival, 11% (n=5/47) displayed hNCAM-positive projections within the brain 
stem including the ventral brain stem and the dorsal-caudal brain stem. The exact 
location of these hNCAM-positive projections was analysed using IHC, as we were 
interested to ascertain whether these projections were within the CST. Using an  
anti-protein kinase C γ (PKCγ) antibody, the pyramids of the CST within the brain 
stem were detected and highlighted this region of interest (Figure 4.6, E). Furthermore, 
the hNCAM fibres were indeed within this region, suggesting these fibres were 
projecting within the CST (Figure 4.6). In two out of these five animals, projections 
were observed beyond the pyramids, projecting up towards the dorsal brain stem in 
the contralateral cortex, likely beyond the decussation of the pyramids, suggesting 
fibres had crossed over at the pyramidal decussation. The cervical spinal cords of these 
five animals were analysed for further projections, however no hNCAM-positive 
projections were observed within these sections suggesting the hNPCs did not project 
further than the caudal brain stem. These five animals were isolated from batch 12, 
where 64% of transplants were on target within the sensorimotor cortex. 




Figure 4.5 Location of injections and fibre projections from WT hNPCs transplants over time. 
After each batch of transplants, injection sites were analysed for both on- and off-target injections. 
Coordinates were altered for subsequent transplants based on the results from the previous batches. 
Injection sites over the different batches can be seen in the first column and the corresponding projection 
locations are in the second column. The different colours for boxes and dots show the different age 
groups detailed within the key. In batch 12 transplants, 64% of grafts were on target resulting in 
projections following areas of the CST, including the internal capsule, cerebral peduncles and pyramids 
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within the brain stem. Within batch 12 at 4 and at 6 weeks, projections were observed within the dorsal 
part of the caudal brain stem, likely past the pyramidal decussation. 
 
 
Figure 4.6 Projections from hNPCs were detected within the CST within the pyramids 2 weeks 
after transplantation. Following IHC analysis, hNCAM-positive projections were detected within the 
brain stem 2 weeks after transplantation of hNPCs (white and black arrows, A-D). Images B and D have 
been converted to black and white using ImageJ to allow for clearer detection of hNCAM-positive 
projections. Using an anti-PKCγ antibody the pyramidal tract within the brain stem was labelled 
indicated by the white dotted line (as a boundary line) and white arrows in E. Furthermore, hNPC 
projections were located within the pyramidal tract only 2 weeks after hNPC transplantation into the 
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4.3.3  Tracking of hNCAM projections using BDA tracers  
To assess whether the hNPCs could follow projection tracts, such as the CST, or 
whether they may be pre-programmed to project elsewhere, WT hNPCs were injected 
with 50 mg/mL BDA tracer. The rationale for injection of BDA with the hNPCs, rather 
than separate injections at a later time point, was to enable the BDA to be taken up by 
the endogenous cells at the exact site of the transplant. This would have allowed us to 
examine whether the transplanted cells were following fibre tracts originating at the 
injection site, as well as whether the injections were on or off target. Unfortunately, 
preliminary experiments to inject 50 mg/mL BDA together with the hNPCs did not 
result in positive axonal tracing. Instead a red haze was detected at the injection site at 
all time points (data not shown). Unfortunately, time did not allow for optimisation or 
further testing with BDA tracing.  
4.3.4 Did the hNPCs mature in vivo over time?  
Another main question we aimed to address was whether these cells matured in vivo 
over time. In order to assess maturation, we examined the expression of the progenitor 
cell marker DCX. As the hNPCs were in a progenitor cell state when transplanted and 
expressed DCX in vitro (section 3.3.6), DCX expression was analysed over the 
different time points in vivo. Firstly, endogenous DCX expression within the cortex 
was analysed at the different time points. Within the cortex, DCX was detectable 
within a small proportion of progenitor cells at 2 weeks (Figure 4.7, B and C); 
however, over time this expression declined and at 8 weeks very little DCX was 
detected within the cortex (Figure 4.7, J and K). In transplanted animals at 2 weeks, 
hNCAM-labelled hNPC projections were observed expressing the DCX protein 
(Figure 4.8, A-C). Furthermore, and contrary to our hypothesis, at 4 weeks and 8 weeks 
the high expression of DCX remained the same within these cells (Figure 4.8, D-I). In 
fact, our results show that as long as the transplanted cells survived, DCX was 
expressed within the hNPC projections suggesting the cells retained their progenitor 
cell state to some extent. 




Figure 4.7 Endogenous expression of DCX and MBP in contralateral rat sensorimotor cortex over 
time. Using IHC, the endogenous expression of the progenitor cell marker DCX and the 
oligodendrocyte-associated protein MBP, were assessed within the rat sensorimotor cortex over the 
different developmental time points. At 2 weeks there were only a small proportion of cells expressing 
DCX (B-C) and this declined over time (F-G) resulting in very little DCX expression in the cortex at 8 
weeks (J-K). Similarly, at 2 and at 4 weeks of age MBP expression was high within the cortex (D, E, 
H and I). As the brain matured, the number of host myelinated axons increased and resulted in a dense 
MBP-stain of the cortex at the later time points where it was more difficult to pick out single myelinated 
fibres (L-M). Scale bars in B, D, F, H, J and L= 250 µm and C, E, G, I, K and M =150 µm. 
 




Figure 4.8 hNPCs projections express the progenitor cell marker DCX in vivo from 2 weeks up 
until 8 weeks post-transplantation. IHC analysis of the axonal projections from transplanted hNPCs 
indicate DCX expression was retained within neuronal projections extending from the transplanted cells 
from 2 weeks (A-C) up until 8 weeks (G-I) post-transplantation. Tissue was stained using a DCX and 
a hNCAM antibody. DCX-positive staining (A, D and G) co-localised with hNCAM-positive staining 
across all time points (C, F and I). Scale bar A-I = 150 µm.  
 
An additional method used to assess hNPC fibre maturation in vivo was to examine 
myelination of projections from the transplanted hNPCs. An antibody against MBP, a 
protein expressed by myelinating oligodendrocytes, was used to assess this. As with 
DCX expression, endogenous expression of MBP was examined within the rat cortex 
over the different time points which followed a similar pattern to DCX. At 2 and 4 
weeks of age, endogenous expression of MBP was high within the cortex as 
myelination is occurring at this stage of development (Figure 4.7, D, E, H and I). At 8 
weeks, expression of MBP is not clear, likely due to the dense axonal network present 
at this time point (Figure 4.7, L and M). When assessing the hNPC transplants, 
hNCAM-labelled fibres were observed at 2 weeks post-transplant following 
myelinated axonal tracts within the corona radiata (Figure 4.9, A-C), an area of the 
CST where projections are gathered from areas of the cortex and guided towards the 
internal capsule. At 7 weeks, fibre projections were detected within fibre tracts 
coursing caudally within the corpus callosum and hNCAM-labelled fibres were 
observed in close proximity to MBP-positive cells (Figure 4.9, E-G). The MBP 
antibody used in these experiments is able to detect both rat and human variants of the 
MBP protein and it is therefore unclear whether human oligodendrocytes have 
differentiated from transplanted progenitor population or if rat oligodendrocytes may 
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have potentially myelinated the human NCAM-labelled projections. When staining for 
MBP in the hNPC in vitro culture (section 3.3.6), no positive staining was observed 
suggesting there were no myelinating oligodendrocytes within the hNPC population, 
however presence of oligodendrocyte precursors was not assessed. Using a human-
specific antibody for MBP or an antibody for OPCs, such as anti-NG2 (Polito and 
Reynolds, 2005), would help answer this question. Nonetheless, our staining of the 
different age groups indicated that the hNPC projections were able to follow 
myelinated fibre tracts, such as the CST, and were in close proximity to MBP-positive 
cells. Moreover, within the bolus/injection site, MBP-positive staining was observed 
(Figure 4.9, H and I), suggesting either the NCAM-positive fibres from the hNPCs 
were becoming myelinated or potentially, mature myelinated rat axons penetrated the 
bolus of cells to interact with the hNPCs.  
A further marker for maturation assessed was formation of PNNs, which act to stabilise 
synapses of mature neurons. Unfortunately however, using the lectin, WFA, no 
positive WFA staining was observed on or near the transplanted hNPCs (data not 
shown).  




Figure 4.9 Myelination of hNPC projections assessed over time. The hNPC projections were 
analysed for evidence of myelination using IHC and an anti-MBP antibody, which would suggest the 
cells matured in vivo. At 2 weeks post-transplantation, hNPC projections followed myelinated tracts, 
such as those in the corona radiata. Human NCAM-labelled fibres were observed within rat myelinated 
tracts projecting from the top of the corona radiata towards the internal capsule (A-D). At 7 weeks, 
hNPC projections were still detected within myelinated tracts, such as the corpus callosum (E) and 
hNPCs were observed in close proximity to MBP-positive cells (F-G, white arrows) and suggested 
myelination of hNPC projections may have occurred. Furthermore, at 7 weeks, MBP-positive fibres 
were detected within the bolus sites (H-I) suggesting either rat myelinated fibres permeated the human 
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bolus of cells or myelination of hNPCs had occurred. Scale bars A, E = 1 mm, B = 100 µm; C, F = 50 
µm; D, G =20 µm; H, I = 150 µm.  
 
4.3.5 Differences between endogenous rat gene expression and 
hNPCs gene expression at different time points in vivo 
In light of results in Chapter 3 where data showed the expression of deep-layer cortical 
neuron markers, Ctip2 and Tbr1, within the hNPCs in vitro, the expression of these 
two markers was assessed within the hNPCs in vivo. Specifically, we wanted to 
identify whether these cells retained expression of these two markers when 
transplanted in vivo, and also assess if their expression profile would change in 
response to their local environment, for example if cells were transplanted off target. 
Furthermore, we wanted to ascertain whether transplanted hNPCs follow the 
endogenous pattern of expression of these two proteins over time.  
Following IHC staining for Ctip2, results were repeatedly inconsistent and therefore 
not reliable. Two different Ctip2 antibodies were utilised within this project in an 
attempt to identify Ctip2 expression within firstly, the endogenous tissue and secondly, 
within the hNPCs in vivo over time. One antibody was human-specific (Abcam) and 
the other was reported to identify both rat and human Ctip2 (Abcam). The human-
specific Ctip2 antibody unfortunately also detected endogenous Ctip2 within the rat 
tissue, however not consistently. Similarly, this antibody detected Ctip2-expressing 
cells within the HuNu-positive hNPC bolus, but not consistently. The results from this 
human-specific antibody suggested a proportion of the hNPCs expressed Ctip2 
however due to the inconsistency in staining, these results were not reliable. The 
second Ctip2 antibody used unfortunately was also not reliable and often would not 
identify endogenous expression or expression within the hNPC graft across a number 
of trials. These antibodies and analysis of Ctip2 protein expression was therefore not 
pursued (data not shown).  
Results for Tbr1 staining showed that the hNPC population expressed Tbr1 at each 
time point in vivo post-transplantation, from 2 to 8 weeks, regardless of the transplant 
location (Figure 4.10). For example, transplants within the sensorimotor cortex, 
hippocampus or striatum all had a population of Tbr1-positive cells. The endogenous 
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expression of Tbr1 was ascertained using the contralateral cortex, which contained no 
hNPCs. Results indicated Tbr1 was expressed within deep layers of the cortex across 
all time points, but there was a slight reduction in the expression over time (Figure 
4.10, A, E and I). One observation of note was obtained from grafts that were very 
densely packed, which showed no Tbr1-expressing cells within the densely-packed 
centre of the grafts and only cells on the outside of the grafts that were exposed to the 
endogenous ECM expressed Tbr1 (Figure 4.10, J-L). This suggested cells tightly 
packed within a bolus may not have interacted with endogenous signalling proteins to 
further propagate hNPC differentiation. In fact, as our previous results showed, the 
hNPCs had a high expression of both Ctip2 and Tbr1 before transplantation, but these 
in vivo results for Tbr1 suggest the opposite, where the hNPCs may have reverted to a 




Figure 4.10 The endogenous expression of Tbr1 within the contralateral rat sensorimotor cortex 
and expression of Tbr1 within the transplanted hNPCs over time. Staining for endogenous (endo) 
Tbr1 expression in the deep layers of the contralateral rat sensorimotor cortex (that contained no hNPCs) 
highlighted a reduction in Tbr1 expression over time (A, E and I, white arrows). In contrast and 
following on from the in vitro data, hNPCs had a population of Tbr1-expressing cells after 
transplantation in vivo, observed from 2 weeks up until 8 weeks. Furthermore, this expression did not 
appear to decrease over time. At 2 and at 4 weeks, hNPCs stained for anti-HuNu co-localised with Tbr1 
(B-D and F-H, respectively). By 8 weeks, a population of Tbr1-expressing cells was still maintained 
within the hNPCs (J-L). In some grafts it was noticed that densely packed areas of hNPCs did not show 
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expression of Tbr1 (J-L) and instead, Tbr1 expression was localised to hNPCs within less dense regions 
of the graft. Interestingly, the Tbr1 expression in hNPCs was retained in off-target injections, such as 
those located within the lateral ventricles (F-H) suggesting the hNPCs were able to keep their pre-
programmed differentiation cell fate in vivo. Scale bars in A, E, I = 500 µm; B, F, J = 250 µm and C, 
D, G, H, K; L = 150 µm.  
 
4.3.6 hNPCs displayed a progenitor cell phenotype in vivo over time  
The hNPCs were pre-programmed to differentiate into hyCCNs (Axol Bioscience). It 
was hypothesised that these hNPCs should lose their progenitor cell-like phenotype 
over time as they mature. However, progenitor cell features were observed within the 
transplants at all time points, from 2 weeks up to 8 weeks. For example, formation of 
neural rosettes is a common neural stem cell feature and rosette formation was detected 
in densely-packed WT hNPC transplants (Figure 4.11). Furthermore, as the hNPCs 
differentiate over time we would have expected them to lose their proliferative state, 
instead however large, dense formations were observed within 23% of detectable 
transplants (n=13/56) (Figure 4.12) and suggested proliferation of cells in vivo. When 
analysed using IHC for expression of Ki67, a general proliferation marker, hNPCs 
within these large cell formations were Ki67-positive (Figure 4.12, C and D) and 
expression was retained from 2 weeks up to 8 weeks. Furthermore, in a small number 
of animals the size of the ventricles had expanded and in some cases severely distorted, 
suggestive of large tumour formation. However, Ki67 expression was observed across 
all time points within less dense hNPC grafts, suggesting expression was not solely 
within the large bolus formations.  
 




Figure 4.11 WT hNPCs formed neural rosette structures in vivo. Representative images taken at  
4 weeks post-transplantation of hNPCs showed rosette formation, typical of NSCs (A-F, white arrows). 
Rosettes were observed within hNPC grafts from 2 weeks up to 8 weeks in vivo. Tissue was analysed 
using IHC and antibodies against HuNu, GFAP and DAPI. Scale bars A-B = 250 µm; C-D = 500 µm; 
E-F = 150 µm.  
 




Figure 4.12 hNPCs expressed proliferation markers in vivo and displayed large dense cellular 
formations in some cases. In some of the transplants, large grafts were detected, for example within 
the fimbria (A and C) and cortex (B). These grafts displayed neural rosette formations (white arrows in 
A). When stained for Ki67, a marker for proliferation, the cells within the core of these dense formations 
were Ki67-positive (C and D). Scale bars A-C = 1 mm; D = 500 µm. 
 
4.3.7 The effect of hNPC transplants on the ECM and immune 
system  
From the literature we know transplanting human cells into the rat system will 
undoubtedly provoke an immune reaction. We hypothesised that the reason the 
survival of transplanted hNPCs was reduced over time was due to the development 
and maturation of the rat immune system, as our transplants were performed in 
neonatal-aged rats. Using IHC, tissue was analysed for both microglia, the main 
immune cells of the brain using an anti-Iba-1 antibody, and astrocytes, the main glial 
support cell of the brain using an anti-GFAP antibody. These antibodies were used 
alongside either hNCAM or HuNu to detect transplanted hNPCs. Our results show at 
2 and 4 weeks there was only a very little increase in microglial activation in response 
to hNPC transplants (Figure 4.13, K, L, N and O) compared to endogenous control 
Iba-1 IHC (Figure 4.13, J and M) taken from the contralateral cortex that contained no 
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hNPCs. At the same time points, there was a noticeable increase in GFAP staining 
(Figure 4.13, B, C, E and F) compared to endogenous control GFAP expression 
(Figure 4.13, A and D), indicating activation of host astrocytes within the rat brain had 
occurred. However, at 8 weeks post-transplantation, the response from both cell types, 
microglia and astrocytes, was greatly increased (Figure 4.13, H, I, Q and R) compared 
to controls (Figure 4.13, G and P). This result aligned with our hypothesis and showed 
the immune system produced a larger response over time as it matured, likely resulting 
in the observed rejection of the transplanted cells. It is therefore possible, with 
immune-compromised animals, transplant survival could be assessed beyond the 8-
week time point.  
A further observation was made from the GFAP-immunolabelled transplant sites. The 
results showed unusual astrocytic formation where the astrocytes had changed from a 
star-like morphology to an almost neurite-like morphology with elongated processes 
(Figure 4.13, H, I and Figure 4.14, A-C, white arrows). This morphology was detected 
at the later time points (6, 7 and 8 weeks) and was commonly, but not solely, detected 
in grafts where there were large, densely-packed hNPCs. At the earlier time points (2 
and 4 weeks) IHC analysis suggested hNPCs projections may have interacted with 
astrocytes. For example, at 4 weeks hNPC projections were able to reach the caudal 
brain stem, and following IHC analysis, GFAP-positive astrocytes were observed in 
close proximity to hNCAM-labelled projections (Figure 4.14, D-F). This suggests that 
astrocytes may have been interacting with the hNPCs, potentially providing support, a 
function astrocytes would normally provide to host axonal projections (Walz, 2000; 
Magistretti, 2011; Suzuki et al., 2011). This potential glial interaction may have 
enabled elongation of fibres up to a certain peak time point where the axonal hNPC 
projections were at their longest, but before the host immune response was elicited.  
 




Figure 4.13 Transplant of hNPCs provoked the host immune response over time. The hNPC graft 
survival rate was high at 2 and at 4 weeks, which declined over time. Following IHC analysis for 
immune response markers, including microglia (Iba-1) and astrocytes (GFAP), results indicated an 
increase in the immune reaction to the human grafts over time. At 2 weeks there was a mild increase in 
GFAP staining at the injection site (B and C) compared to endogenous control GFAP staining from 
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contralateral cortex (A). This expression increased over time (E, F) and by 8 weeks there was a dramatic 
increase of GFAP staining and a noticeable change in astrocyte morphology (H, I) compared to control 
staining (G). When microglial activity was analysed, using an anti-Iba-1 antibody, there was a relatively 
little immunoreactivity at earlier time points of 2 and 4 weeks (K, L, N and O) compared to control 
staining in the contralateral cortex (J and M), however this response greatly increased by 8 weeks (Q 
and R), and may have resulted in the observed graft rejection. Scale bars in A, C, D, F, G, I, J, L, M, O, 
P, R = 150 µm; B, E, K, and N = 250 µm; H and Q = 500 µm. 
 
Lastly, the expression of the main CNS ECM protein, TN-C was also analysed over 
time. TN-C although highly expressed during development it is also upregulated after 
injury (Zhang et al., 1997; Tang et al., 2003). Results from Chapter 3 indicated the 
hNPCs expressed TN-C in culture and previous research has shown TN-C can be 
secreted by some cells, including PC12 cells, into the ECM (Andrews et al., 2009). 
Following IHC, analysis showed increased TN-C expression at the site of transplant 
from 2 weeks that persisted up to 8 weeks post-hNPC transplantation, with a small 
increase in expression over time (Figure 4.15). The staining in each case was localised 
to the injection site and the bolus of hNPCs. The antibody used in these experiments 
was human-specific and therefore may have only been detecting TN-C either 













Figure 4.14 Transplantation of hNPCs stimulated an astrocytic response. IHC analysis for host 
astrocytic reaction to hNPC grafts revealed an unusual astrocytic response (indicated by GFAP staining) 
showing string-like projections which correlated with a scarred region of HuNu-positive tissue at  
7 weeks post-transplantation (A-C). However, at earlier time points, such as 4 weeks post-
transplantation, in the caudal brain stem hNCAM-positive projections were observed in close proximity 
to GFAP-positive astrocytes suggesting the hNPCs may have been supported by astrocytes in vivo (D-
F). Scale bar A = 500 µm, B and C = 200 µm, D = 50 µm and E and F = 10 µm. 
 
 




Figure 4.15 Increased expression of TN-C in response to hNPC transplantation. Following 
transplantation of hNPCs, IHC analysis revealed an upregulation of TN-C, the main ECM protein of 
the CNS, at the transplant site. This upregulation was apparent at all time points from 2 weeks (A-C) 
up until 8 weeks post-transplantation, however was more apparent at later time points 4 and 8 weeks 
(D-I), suggesting TN-C expression steadily increased over time. Scale bar A-B, D-E, G-H = 500 µm; 
C, F, I = 150 µm.  
 
  




Here we aimed to build upon the in vitro work discussed in Chapter 3 and transplant 
WT iPSC-derived hNPCs, pre-programmed to differentiate into cortical neurons, into 
the neonatal sensorimotor cortex. Specifically, we targeted layer V as this is the area 
that projects axons within the CST with the aim of assessing graft survival and the 
ability of hNPCs to extend long-distance axonal projections over time. Following 
transplantation, tissue was collected at a number of time points, from 2 weeks through 
to 8 weeks, and analysed for graft survival, axonal projections, graft maturation and 
expression of cortical neuron markers. Here we present data highlighting hNPC grafts 
survived up to 8 weeks post-transplant with axonal projections that followed 
endogenous white matter tracts and reached the caudal brain stem after 4 weeks. 
Furthermore, we show hNPCs retained expression of both cortical neuron and 
progenitor cell markers in vivo.  
Once transplanted, hNPCs were detected using human-specific antibodies to highlight 
the graft site as well as the projections. The transplants themselves were carried out 
between P0-2. This age was chosen because the rat immune system is not fully 
developed immediately after birth and is still in the process of maturing (Reviewed in 
Marshall-Clarke et al., 2000; Reviewed in Holsapple et al., 2003). Following birth, 
rodents go through a brief period of immunodeficiency, a window of opportunity, 
before the animals become immunocompetent. Therefore, to give the hNPCs the best 
chance of survival and integration into the rat system, the transplants needed to be 
carried out during this brief window. Transplantation of stem cell-derived cells into 
rodent neonatal brain within this P0-2 window and without immunosuppression has 
been carried out before showing promising graft survival and integration (Ideguchi et 
al., 2010; Denham et al., 2012). Our results show hNPCs can survive in the neonatal 
rat brain up to 8 weeks, however, survival is highest at earlier time points of 2 and 4 
weeks. Beyond this, an immune response is elicited (section 4.3.7) which is likely to 
be the reason for decreased transplant survival at 6, 7 and 8 weeks. Conversely, 
research has shown human ESC-derived neurons can survive up to 10 weeks in the 
Sprague Dawley rat brain following injection at P2 into the striatum without the use 
of immunosuppression (Denham et al., 2012). This difference suggests there may be 
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either regional differences within graft survival or embryonic-derived cells may have 
a better capacity to survive in vivo. As the immune system is immature at the early 
time points, it was expected that there would be 100% survival at 2 and 4 weeks, 
however transplant survival was 82% and 75%, respectively. During some of the 
surgeries, the injection needle did clog and therefore there was a chance some of the 
animals that were designated as not having a detectable transplant, were in fact not 
injected with hNPCs. Furthermore, the injection site was shallow being between -0.4 
and -0.7 mm below the skull and there was a chance the cells could seep back out of 
the injection site once the needle had been removed. Extra care was taken to remove 
the injection needle slowly to minimise any backflow from the injection tract, 
however, it was not always avoidable.  
From analysis of the immune response over time, an increase in both Iba-1- and GFAP-
positive staining was observed at the transplant site over time (section 4.3.7). The 
increased GFAP staining could have been, in part, due to a transplanted population of 
human astrocytes. The antibody used here was able to detect both rat and human 
variants and in combination with data from Chapter 3, a small population of astrocytes 
was present in the hNPC in vitro culture pre-transplant. In uninjured environments, 
astrocytes are known to be involved in providing essential support to neurons, 
including metabolic support (Reviewed in Magistretti, 2011; Suzuki et al., 2011); 
regulation of the ion homeostasis in the surrounding environment (Reviewed in Walz, 
2000); and promotion of synaptogenesis (Ullian et al., 2004, 2001; Christopherson et 
al., 2005). It is therefore possible that astrocytes within the hNPC culture could have 
provided this essential support to the hNPCs once transplanted. Indeed, at younger 
time points, astrocytic cells were observed in close proximity to hNPC projections 
suggesting astrocytes may have interacted with the hNPC projections (Figure 4.14). 
However, over time, the increase in GFAP staining was coupled with an increase in 
microglia activation, highly indicative of an immune reaction (Figure 4.13). This 
suggested astrocytes may have initially provided support, however, following an 
increased immune response, such as microglial activation, they switched to pro-
inflammatory mediators.  
Furthermore, it was observed that in some cases GFAP-expressing cells at the 
transplant site had taken on an unusual morphology compared to WT tissue. Astrocytes 
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positive for GFAP have a star-like morphology, however in some cases GFAP-positive 
cells that had taken on a neuronal-like shape, with a long elongated process, were 
present at the cortical graft site (Figure 4.14). There are two subtypes of astrocytes, 
protoplasmic star-like astrocytes and fibrous astrocytes which have longer processes; 
however, fibrous astrocytes are located within white matter suggesting these cells may 
not be fibrous astrocytes as the transplant sites are located largely in grey matter. Yet, 
these cells did have a similar morphology to another cell type, radial glial cells (RGCs), 
which have an apical elongated process. RGCs develop from neuroepithelial cells 
during embryogenesis and serve as support for neuronal migration during 
development. However, research has indicated they can also function as progenitor 
cells (Reviewed in Hartfuss et al., 2001; Noctor et al., 2002) giving rise to both 
neurons and glia in vivo (Reviewed in Götz et al., 2002; Malatesta et al., 2003). 
Literature suggests this is actually a distinct astroglial cell type, termed GFAP-
expressing radial NSCs, that acts as an intermediate between RGCs and astrocytes (Liu 
et al., 2006). In addition, in vivo, RGCs have been linked to production of adult NSCs 
located within the subventricular zone in mammals (Merkle et al., 2004). It is therefore 
possible there is an RGC/GFAP-expressing radial NSC population within the hNPCs, 
potentially supporting newly forming neurons by aiding migration, but also by 
differentiating into newly formed neuronal and glial cells. In culture, RGCs can be 
derived from embryonic NSCs following epidermal growth factor receptor signalling 
(Gregg and Weiss, 2003), which is known to be a constituent of the hNPC 
reprogramming protocol (Axol Bioscience). If RGC/GFAP-expressing radial NSCs 
are within the hNPC culture, further staining would potentially be able to confirm this. 
Indeed GFAP can detect RGCs (Levitt and Rakic, 1980) and GFAP-expressing radial 
NSCs (Garcia et al., 2004), however, it can also detect astrocytes and therefore use of 
a more specific antibody, such anti-radial glial cell marker 2 (RC2) to detect RGCs 
(Misson et al., 1988), could be used to answer this question. Alternatively, to 
differentiate between GFAP-expressing radial NSCs and fibrous astrocytes, 
expression of LeX/CD15 could be analysed as research suggests these two cell types 
have differential expression of this cell surface protein (Imura et al., 2006). Lastly, use 
of a human-specific GFAP antibody would allow us to ascertain whether these cells 
originated from the hNPC graft or if the graft caused a change in morphology of the 
endogenous cells surrounding the graft site.  
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From tissue analysis of the injection sites, our results showed significant location 
variation. Initially, coordinates were based upon the predicted sensorimotor cortex, 
specifically sensorimotor 1 front limb region (S1FL) layer V, using an atlas of prenatal 
rat brain development (Altman and Bayer, 1995). Specifically, coordinates were used 
for embryonic day 22 (E22), which would correspond to P0, as rat embryo gestation 
is approximately 20-21 days. The first batches of transplants, batch 1 and batch 2, 
resulted in on average 35% of transplants on target within the sensorimotor cortex. 
Off-target injections were mainly located below the corpus callosum within the 
caudate and/or putamen of the basal ganglia. As a result of this and in trying to focus 
on the area of interest, the injection sites were monitored with each batch of transplants 
and the coordinates were adjusted as required. It is likely that operator variability 
affected the transplants. For example, both batch 3 and batch 4 received injections 
using the same coordinates, however in batch 3, 56% of surviving grafts were on 
target, compared with 38% in batch 4. These injections were carried out weeks apart 
and therefore may have introduced operator variability or error. Alternatively, pups in 
these litters may have been of different sizes owing to the large litter sizes, 12 and 14 
respectively, which may have included ‘runts’ therefore altering the location of the 
target site and resulting in an increased number of off-target injections. In batch 6, the 
coordinates were again similar, however, the depth of the transplant was further 
reduced to -0.45 mm and the accuracy of the injection increased marginally from batch 
4, to 40%. The coordinates in batch 12 were altered further to target the sensorimotor 
area more laterally as a number of injection sites resulted in grafts located below the 
corpus callosum, centrally in the brain within the striatum, or within the hippocampal 
region. To correct for this, coordinates were also moved slightly forward and the depth 
of the injection was reduced further. This optimisation resulted in 64% of detectable 
graft sites on target. It is very likely that the combination of altered coordinates and 
user repetition of the technique over time resulted in a large proportion of grafts in 
batch 12 being on target.  
Following IHC analysis, hNCAM-positive fibres were observed emanating from the 
transplanted hNPCs bolus sites. These fibres were located adjacent to the bolus sites, 
however, large hNPC fibre bundles were also observed following white matter tracts 
of the rat brain including the corpus callosum and the internal capsule. Due to the 
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variation in transplant sites, projections reached a number of neuroanatomical regions, 
which included the corona radiata, corpus callosum, olfactory bulb, striatum, pallidum, 
thalamus, internal capsule and areas of the brain stem. In a small proportion of the 
animals, transplants were detected on top of the cortex, which would suggest either 
cells were not transplanted into the cortex or, following transplant, cells had flowed 
out into the subarachnoid space (Figure 4.3, H and Figure 4.12, B). When the injections 
were delivered on target within the deep layers of the sensorimotor cortex, axonal 
projections from the transplanted hNPCs could be observed within the corona radiata, 
internal capsule, cerebral peduncles, pyramids of the brain stem and the dorsal-caudal 
brain stem likely beyond the pyramidal decussation suggesting hNPCs projections are 
able to follow the trajectory of the CST. At 2 weeks, the furthest regions where 
hNCAM positive fibres were observed were the pyramids in the dorsal brain stem 
(Figure 4.5 and Figure 4.6). The HuNu-postive bolus where these hNCAM fibres 
originated was on target within the sensorimotor cortex, however, some HuNu positive 
cells were also observed within the caudate putamen. At 4 and 6 weeks, from on-target 
injections, hNCAM-positive projections reached the caudal brain stem, however, only 
a small number of projections achieved this and in two of the pups, projections were 
observed in the contralateral dorsal-caudal brain stem. A common observation was 
that the further away the hNCAM projections were from the injection site, the fewer 
projections there were, suggesting only a small proportion of fibres were able to project 
these distances. Moreover, these projections appeared very thin, whereas closer to the 
injection sites large fibre bundles could be detected. It is likely that where there were 
dense boluses and therefore more cells, more projections formed and bundled and they 
therefore appeared thicker in diameter. Similarly, as only a few axons projected further 
away from the bolus sites, there were less fibres to bundle together and therefore 
appeared smaller in diameter. Further analysis of the tissue using confocal microscopy 
would provide more information on axon diameter. At later time points where only the 
nuclei of hNPCs could still be detected due to the immune response, projections were 
not observed outside of the bolus site. This had been observed previously under 
different circumstances where projections were not seen outside of boluses within 
specific regions such as the neocortex (Brundin et al., 1988). This further suggests 
there are regional differences within the brain determining cell survival and 
integration.  
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As TN-C is a ligand for our integrin heterodimer of interest, α9β1, its expression was 
analysed over time (Figure 4.15). The antibody used was human-specific. Previously 
our lab has had positive TN-C expression in rat tissue in the absence of human cells 
with this antibody and therefore there is doubt as to whether this antibody is definitely 
human-specific. If this is the case, and the antibody is not specific to human antigens, 
our results here suggest there is an endogenous upregulation of TN-C surrounding the 
transplant site, which has been shown in response to injury (Zhang et al., 1997). 
Alternatively, hNPCs may have expressed and secreted TN-C in vivo which aligns 
with the in vitro results (section 3.3.4). As TN-C is known to be upregulated at CNS 
injury sites (Zhang et al., 1997; Andrews et al., 2009), this result was of interest. An 
upregulation of TN-C at the transplant site, whether from endogenous rat tissue or 
produced by the grafted cells, may promote further neurite outgrowth from α9-eYFP 
expressing cells when transplanted in vivo (see Chapter 5). 
Additionally, one of the main questions we were interested in was whether the 
transplanted cells show any signs of maturation over time. This was assessed by loss 
of DCX expression as well as evidence of myelination using an antibody against MBP, 
a protein expressed by myelinating oligodendrocytes. DCX is a microtubule-
associated protein that acts to stabilise immature, developing neurons. In endogenous 
rat tissue, our data suggested the DCX staining was present in the cortex at 2 weeks of 
age, although at a very low level. This is in line with published literature suggesting 
cell proliferation ends at around P15 (Reviewed in Rice and Barone, 2000). 
Conversely, the hNPCs retained their expression of DCX through until the 8 week time 
point. This suggests the cells retained their immature neuronal state. It may also 
suggest that the cells were not fully reacting to any endogenous environmental signals 
for maturation (such as those from neurotransmitters, growth factors, glial cells and 
adhesion proteins located within the extracellular environment). This was not expected 
and is in contrast to previously published literature (Ballout et al., 2016). 
The myelination of hNPC projections was assessed over time using an antibody against 
MBP. This was able to show the hNPCs can follow myelinated tracts, such as those in 
the corona radiata going into the internal capsule as well as the corpus callosum. At 
later time points, the IHC results show there were MBP-expressing oligodendrocytes 
in close proximity to large fibre bundles from hNPC grafts, however, staining alone is 
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unlikely to confirm myelination, rather electron microscopy and/or confocal 
microscopy would be required for confirmation. Interestingly, there are regional 
differences in myelination of the rodent brain, for example the sensorimotor cortex is 
believed to be fully myelinated by around 2 weeks as research shows no differences in 
myelination were observed within the mouse sensorimotor cortex between P15 and 
P45 (Chahboune et al., 2007). Therefore, if axons from the hNPCs are not myelinated 
at the 2 week time point, this suggests there may be a lag time where the hNPCs take 
longer to myelinate than the endogenous equivalents. Furthermore, research suggests 
myelination is beginning at around P2 (Craig et al., 2003) and therefore this transplant 
window (P0-2) was used to give the hNPCs the best chance of myelination and 
integration. Moreover, it remains to be seen whether rat oligodendrocytes are able to 
myelinate human axonal projections. Research has shown following a C5 lateral spinal 
cord lesion, transplant of human iPSC-derived NSCs can project through the lesion 
site and are seen to be in direct contact with rat oligodendrocytes but myelination of 
human axons was not observed (Lu et al., 2014). However, Lu and colleagues also 
found that projections from the transplanted hNPCs expressed immature neuronal 
markers and suggested myelination may not occur until the hNSCs matured. Similarly, 
previous research has shown human ESC-derived OPCs are able to promote 
remyelination after thoracic contusion injury in adult rats resulting in increased 
functional recovery (Keirstead et al., 2005). Specifically, part of this remyelination of 
injured rodent axons corresponded directly to the transplanted human OPCs. Together, 
this literature suggests myelination of human axons by rat oligodendrocytes may be 
possible, however the maturation status of the transplanted hNPCs may dictate the 
myelination outcome. For this project, if future experiments were able to prolong 
hNPC survival in vivo, the maturation of hNPCs could progress and myelination may 
occur. 
To further assess maturation, tissue was analysed for PNN formation, net-like 
structures composed of extracellular matrix that form around mature neurons, reducing 
synaptic plasticity. No PNN structures were observed in association with the grafts. 
However as many of the cells were closely packed together, it is unclear whether this 
inhibited staining and/or visualisation of PNNs. The retention of an immature cell state 
may be of interest and beneficial when considering axonal elongation and 
Using human iPSC-derived neural progenitor cells to increase integrin expression in the CNS 
160 
 
regeneration, however, over time this may not be advantageous and it begs the question 
as to when will neuronal maturation occur within these cells in vivo. Recently 
published in vitro research has shown following growth on multi-electrode arrays, 
hiPSC-derived cortical neurons (Axol Bioscience) require long-term culture of around 
20-30 weeks to functionally mature and for synapses to form (Odawara et al., 2016). 
It is likely therefore that the hNPCs may need to either be in culture for longer before 
transplantation or survive in vivo for longer to offer the best chances for functional 
integration into the host tissue.  
From analysis of the tissue, it was apparent that some batches of cell populations may 
be more proliferative than others. In 23% of detectable grafts, large dense formations 
were observed suggestive of cell proliferation. When analysed for Ki67 expression, a 
proliferation marker, cells within the centre of these dense boluses were positive for 
Ki67 expression, but those located on the outside of these grafts were not. This 
suggests the in vivo hNPCs transplants may contain two populations of cells: one 
which is more able to differentiate and mature over time, extending long projections; 
and another that remains in a progenitor cell state, resulting in continued proliferation. 
The formation of these two populations may be due to the extent to which the cells are 
exposed to the extracellular environment. For example, some of the transplants have 
formed a tight bolus of cells and the cells on the outside of the bolus may be able to 
interact with host tissue and ECM proteins enabling axonal maturation and growth. On 
the other hand, cells within the centre of this bolus may not be exposed to this 
environment and instead have created a niche that reduces interaction with 
endogenous, and potentially essential, signalling mechanisms to continue the 
development and maturation of these cells. Support for this hypothesis is shown in 
Figure 4.12 where Ki67-positive cells were detected within a dense rosette formation 
within a large bolus of cells. The Ki67-positive cells were retained and localised to the 
neural rosette, but there were very few cells outside of this rosette formation that were 
Ki67-positive suggesting that these cells were no longer proliferating and were instead 
in the process of neuronal maturation. To counter this in future, the number of cells 
injected at one site could be reduced while the number of injections is increased. This 
would potentially result in cells spreading out more evenly over the same size area and 
hopefully reduce the number of tightly packed boluses.  
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There remains a question however as to whether the extracellular environment can 
alter or influence the neuronal phenotype of the transplanted hNPCs pre-programmed 
to differentiate into CCNs. Following collection of in vitro data, the expression of 
deep-layer cortical neuron markers, Ctip2 and Tbr1, were analysed in vivo. 
Unfortunately, the Ctip2 antibody gave inconsistent results over different uses and was 
therefore discarded. As the hNPCs expressed Ctip2 before transplant (section 3.3.6) it 
could be suggested they may have retained their expression in vivo, however this 
cannot be confirmed without further analysis using a different Ctip2 antibody. On the 
other hand, hNPCs retained the expression of Tbr1 in vivo (Figure 4.10) and was 
observed at all time points suggesting the hNPCs have the ability to project to sub-
cortical targets in vivo. Owing to time constraints, expression of other neuronal 
markers, such as hippocampal or thalamic neurons, were not assessed. It would have 
been of particular interest to assess if cells that were transplanted off target into, for 
example, the hippocampus, were influenced by and were able to respond to 
environmental signalling to change their expression of certain phenotypic markers 
associated with different neuroanatomical regions.  
Together these results show the hNPC grafts can survive up to 8 weeks in vivo although 
survival was highest at earlier time points. Once transplanted, these cells are able to 
extend long-distance axonal projections, following white matter tracts, such as the 
CST. When injections were on target, projections from the hNPC grafts travelled from 
the sensorimotor cortex through the CST reaching the caudal brain stem after 4 weeks. 
These results are promising for the progression of the project, providing a viable 






















Chapter 5: In vivo analysis of  
a9 integrin-expressing iPSC-derived hNPCs 
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5.1 Introduction and aims 
Previous research has demonstrated that overexpression of the α9 integrin protein can 
promote neurite outgrowth in the presence of TN-C (Andrews et al., 2009), the ligand 
for the α9β1 integrin heterodimer. This presents a promising target for 
neuroregeneration and in particular, axonal regeneration, in conditions such as SCI 
where long-distance axonal projections may promote repair and restoration of 
function. Recently, reintroducing α9 integrin along with the integrin activator kindlin-
1 into sensory axons of the spinal cord has demonstrated promising results, promoting 
regeneration and recovery of function after injury (Cheah et al., 2016). In addition, 
however, data has also shown that the α9 protein is not transported down CST axons 
following overexpression using viral vectors (Andrews et al., 2016). In light of this, 
here we have outlined one potential opportunity utilising iPSC-derived hNPCs 
expressing α9 integrin as a vehicle to increase α9 expression in the CNS.  
In this chapter we aimed to transplant α9-eYFP-expressing iPSC-derived hNPCs into 
the neonatal rat sensorimotor cortex with the goal of analysing cell survival, exogenous 
integrin expression and long-distance axonal projections over time. This work 
continues on from the results presented in Chapter 3 highlighting the ability to 
overexpress α9-eYFP protein within these cells and combines it with the 
characterisation of WT hNPCs in vivo from Chapter 4. We hypothesised that the cell 
survival and axonal projections from α9-eYFP hNPCs would mirror that observed with 
WT hNPC transplants.  
  




5.2.1 Transplant of α9-eYFP-expressing hNPCs  
All procedures were carried out under UK Home Office Project Licence number 
60/4472 and Personal Licence number IC71C2B2B, conformed to the UK Animals 
(Scientific Procedures) Act (1986) and were approved by the Animal Welfare Ethics 
Committee of the University of St Andrews.  
Following transduction of hNPCs with α9-eYFP second generation LV supernatant 
(section 2.4.12), cells were incubated at 37°C for 4 days before being collected for 
transplantation (section 2.5.6). The procedure for transplantation of  
α9-eYFP-expressing hNPCs was the same as for WT hNPCs, detailed in section 2.7. 
Sprague Dawley pups aged between P0-2 were manually injected either unilaterally or 
bilaterally into two specific sites (1µL/injection site) for the predicted neonatal 
sensorimotor cortex (Altman and Bayer, 1995) (see Table 2.8 for injection 
coordinates). 
5.2.2  Neural tracing experiments using BDA 
See section 2.7.2 
5.2.3 Solutions for perfusion and sectioning 
See section 2.7.4 
5.2.4  IHC analysis of α9-hNPC transplants 
The full IHC protocol is detailed in section 2.8. Primary antibodies used in this analysis 
are detailed in Table 5.1 (full details in Table 2.5). When staining for TN-C, tissue 
required pre-treatment with 0.03% hydrogen peroxidase (section 2.8.1). All tissue was 
mounted onto gelatin-coated slides (section 2.8.2). Tissue was left to air dry before 
coverslips were mounted using FluorSave (Calbiochem).  
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Table 5.1 Primary antibodies and dilutions used for IHC analysis of α9-hNPC transplants 
Antibody Species IHC dilution 
HuNu Mouse 1:500 
hNCAM Mouse 1:200 
GFP Rabbit    1:1,000 
TN-C Rabbit 1:200 
GFAP Rabbit 1:500 
Tbr1 Rabbit 1:400 
DCX Rabbit 1:500 
Iba-1 Rabbit 1:500 




5.3.1  Analysis of α9-hNPC transplant survival in vivo over time 
As with analysis of the WT hNPCs transplants, survival of α9-eYFP hNPC transplants 
was assessed using the human-specific antibodies HuNu and hNCAM. Results 
indicated α9-eYFP hNPC grafts survived up to 8 weeks in vivo (Table 5.2). Out of a 
total of 59 pups that received an α9-eYFP hNPC transplant 63% (n=37/59) had grafts 
that survived. Similar to the WT hNPC transplants, survival was highest at the younger 
time points of 2 and 4 weeks and decreased over time (Table 5.2 and Figure 5.1, A).  
Table 5.2 Survival of α9-hNPC transplants over time 
 
After 4 weeks in vivo, 92% (n=11/12) of α9-hNPCs grafts survived, which was 
expected in light of results obtained in Chapter 4 from survival of WT transplants. 
After this, at 6 weeks, survival fell to below 50% and by 8 weeks only 36% (n=4/11) 
of grafts survived. Furthermore, over time as survival of grafts decreased, the number 
of pups where scarring was detected increased. Specifically, at 2 and 4 weeks no scars 
were detected, but at 7 weeks just over half (55%, n=6/11) of the pups had scars and 
at 8 weeks this increased to 64% (n=7/11). Overall 32% (n=19/59) of pups showed 
noticeable scarring indicating potential rejection of the cells over time. Out of a total 
of 59 pups, only 5% (n=3/59) showed no signs of α9-eYFP hNPC survival or scarring. 
Interestingly, these pups were at the younger time points of 2, 4 and 6 weeks (Table 
5.2 and Figure 5.1, A). These three cases cannot be termed as graft rejection, as we 
 Number of weeks post-transplantation of α9-eYFP hNPCs Total 










No. of animals 
with transplants 
surviving  
12 (92%) 11 (92%) 5 (42%) 5 (46%) 4 (36%) 37 (63%) 
No. of animals 
with scarring 0 (0%) 0 (0%) 6 (50%) 6 (55%) 7 (64%) 19 (32%) 
No. of animals 
with no graft 
detected  
1 (8%) 1 (8%) 1 (8%) 0 (0%) 0 (0%) 3 (5%) 
Total 13 (22%) 12 (20%) 12 (20%) 11 (19%) 11 (19%) 59 (100%) 
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cannot confirm cells were transplanted, because of potential backflow of cells from 
the injection site or clogging of the needle during transplant. 
Of the 56 pups that had detectable graft sites, 34% (n=19/56) were on target within the 
deep layers of the sensorimotor cortex (Figure 5.1, B-C). The remaining 66% 
(n=37/56) were off target and located in regions such as the striatum, hippocampus, 
caudate and/or putamen of the basal ganglia and other areas of the cortex away from 
the sensorimotor cortex. Batch 11 had the highest percentage of on-target grafts (60%, 
n=6/10), most likely due to optimisation of transplant coordinates. Following 
transplantation of WT hNPCs and the injection targeting information gained from 
those grafts, α9-eYFP transplants were carried out after the WT hNPC grafts and 
optimisation of transplant coordinates was continued within these grafts. When on- 
and off-target injections were analysed over the various time points, results show only 
a small proportion of pups had on-target injections at each time point, with 4 weeks 
comprising the lowest (18%, n=2/11) and 6 and 8 weeks comprising the highest (46%, 
n=5/11 in both) (Figure 5.1, C). 




Figure 5.1 Analysis of α9-eYFP hNPC surival and on- and off-target injections. The α9-eYFP 
hNPC grafts were analysed for survival over the different time points (2, 4, 6, 7 and 8 weeks). Results 
indicated survival was highest at the younger time points of 2 and 4 weeks, but decreased with age (A). 
Similarly, the number of animals with clear scarring increased over time (A). The α9-eYFP hNPC grafts 
were assessed as to whether they were localised on target within the deep layers of the sensorimotor 
cortex. The optimisation of coordinates resulted in variation of on-target injections across the different 
batches (B). Transplants within batch 11 resulted in the highest number of on-target injections with 60% 
of grafts within the sensorimotor cortex (B). Over all the α9-eYFP hNPC grafts, 34% of detectable 
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grafts were on target (B) When the on- and off-target analysis was split into the different age groups, 
there was a small percentage of on-target injections at all time points (C). At 4 weeks, specifically there 
was the lowest amount of on-target injections at 18% (n = 2/11) and 6 and 8 weeks comprised the 
highest, 46% (n = 5/11) for both (C).  
 
5.3.2 Locations of α9-hNPC transplants and their neuronal 
projections 
The target for injections was the sensorimotor cortex, however only 34% of α9-eYFP 
transplants were localised within this region. Injection sites were identified using IHC 
and antibodies against HuNu or hNCAM alongside GFP, which identified the 
exogenous expression of α9-eYFP. Across all time points, GFP-positive staining was 
observed in the surviving cell bolus and their hNCAM-positive projections shown in 
Figures 5.2 and 5.3, respectively. Off-target injections were located in a number of 
regions including the striatum, lateral ventricles, hippocampus and caudate and/or 
putamen of the basal ganglia (Figures 5.2 and 5.4). Progressing through each batch of 
transplants, as with WT hNPCs, coordinates were altered in an attempt to further 
improve the accuracy of injections. The transplant sites and projections for each batch 
are summarised in brain maps in Figure 5.4.  
As a result of the varied injection sites, projections from α9-eYFP transplants were 
localised in a number of sites including the corpus callosum, internal capsule, 
thalamus, hippocampus, corona radiata and areas of the cortex (Figure 5.3 and Figure 
5.4). Projections were identified with a hNCAM antibody, and the α9-eYFP protein 
was identified using a GFP antibody. The hNCAM projections co-immunolabelled 
with GFP expression across all time points (Figure 5.3 and 5.5).  
 
 




Figure 5.2 Representative images of α9-hNPC transplant locations. As with the WT hNPC grafts, 
the α9-eYFP injection sites were identified using human-specific antibodies for HuNu and hNCAM. 
Additionally, the α9-eYFP grafts were stained for GFP to detect α9-eYFP protein expression. Injection 
sites varied and included sites within the sensorimotor cortex (F and J), but also off-target sites 
including the lateral ventricles (E), the caudate and/or putamen of the basal ganglia (B, C, D and I), the 









Figure 5.3 Projections from transplanted α9-hNPCs over time. The fibres projecting from the 
transplanted α9-eYFP hNPCs were detected using antibodies against hNCAM as well as GFP. NCAM-
positive projections were observed at all time points, however, at the older time points of 7 and 8 weeks, 
projections were not observed in many pups and often did not project far from the bolus site. Projections 
were observed within white matter tracts of the brain including the corpus callosum (C, I and F), corona 
radiata (D) as well as the internal capsule (G). Fibres were also detected in the striatum (B and H), 
cortex (E and K) and thalamus (J). Scale bar in B = 25 µm; C, I and K = 150 µm; D = 50 µm; E = 100 
µm; F and H = 250 µm; G and J = 500 µm.  
 




Figure 5.4 α9-hNPC injection sites and their projections over time. Injection sites from α9-eYFP 
hNPCs were monitored over time and coordinates were altered accordingly. The injection sites from 
each batch of α9-eYFP hNPC grafts were mapped across the different time points (first column) and 
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the corresponding projections can be observed in the second column. The different colours, for boxes 
and dots show the different age groups, detailed within the key. The majority of pups at 7 and 8 weeks 
displayed few or no hNCAM-positive projections, which is reflected in the brain maps above. Batch 11 
resulted in the most on-target injections with 60% of pups (n=6/10) showing grafts within the 
sensorimotor cortex and projecting to areas of the CST including the internal capsule, cerebral peduncles 
and brain stem. At 2 weeks, projections were observed within the pyramids of the brain stem in this 
batch. 
 
5.3.3 α9-eYFP-expressing hNPCs retained their exogenous integrin 
expression up to 8 weeks post-transplantation 
One of the main questions addressed within this chapter was whether transplanted 
hNPCs retained exogenous α9-eYFP expression in vivo over time. Results showed 
expression of α9-eYFP was retained within hNPC projections as long as the cells 
survived. At 2 weeks, GFP-positive staining indicated α9-eYFP was localised within 
the axonal compartment of hNCAM-stained hNPC projections, which appeared 
vesicular and punctate (Figure 5.5, A-C). At 4 and 6 weeks, positive GFP staining was 
observed along the entire length of the hNCAM-labelled projections (Figure 5.5, D-I). 
From results shown in section 5.3.1, at 7 weeks, survival was reduced and a number 
of pups showed scarring at the injection site. As a result, fewer axonal projections were 
observed at 7 weeks; however, where hNCAM-positive fibres were present, these 
fibres consistently co-labelled with GFP expression (Figure 5.3, H-I). In a number of 
pups, however, even though projections were not observed, a bolus of cells remained 
with NCAM-positive cells co-labelled with GFP (Figure 5.5, J and K). Similarly, at 8 
weeks, a small number of pups had hNCAM-positive fibres which co-labelled with 
GFP (Figure 5.3, J-K); however, it was more common for there to be a scar at this time 
point (64%). Where a scar was present, GFP-positive staining was often, but not 
always, observed in the centre of the scar, most likely labelling the remnants of 
degenerating α9-eYFP grafts (Figure 5.5, L and M). Where no hNPCs survival or 
scarring was evident, there was also no detectable GFP expression (data not shown). 
As a control, tissue containing WT hNPCs was also stained for GFP which showed no 
positive GFP staining as expected (Appendix D).  




Figure 5.5 Exogenous α9-eYFP expression in transplanted hNPCs over time. Using an anti-GFP 
antibody, the expression of the exogenous α9-eYFP protein could be detected. Results show that integrin 
expression was maintained as long as the cells survived. At 2 weeks (A-C), α9-eYFP was co-expressed 
in hNCAM-positive projections with a vesicular, punctate appearance (A-C, white arrows). At 4 (D-F) 
and 6 weeks (G-I), the α9-eYFP expression was observed along the length of the hNCAM-positive 
fibres. At 7 weeks, few pups showed hNCAM-positive projections, however, where a bolus was still 
present, α9-eYFP protein was detected within surviving cells (J and K, white arrows). Similarly, at 8 
weeks, GFP-positive staining was detected within a scarred area suggesting hNPCs can maintain 
exogenous α9-eYFP expression, but expression diminishes as cells die off (L and M, white arrows). 
Scale bar in A-B = 5 µm; C = 2.5 µm; D, E, H and I = 25 µm; F and J = 10 µm and K-N = 250 µm.  
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5.3.4 α9-eYFP hNPC gene expression over time 
Expression of the deep-layer cortical neuron marker, Tbr1, was examined in α9-eYFP 
expressing hNPC grafts. Results indicated that a small proportion of α9-hNPCs 
expressed Tbr1 at each time point (Figure 5.6). Tbr1-positive cells were mostly located 
on the outside of the hNPC-packed boluses with the centre of the bolus remaining 
largely devoid of Tbr1 expression (Figure 5.6). Expression of Ctip2 in both 
endogenous rat tissue and transplanted hNPCs was also analysed using two different 
antibodies, one human-specific and one rat-specific. Results from using these 
antibodies were unfortunately not consistent across several trials (described in section 
4.3.5) and therefore no results could be generated (data not shown).  
 
Figure 5.6 Expression of deep-layer cortical neuron maker, Tbr1, in transplanted hNPCs over 
time. The expression of deep-layer cortical neuron marker, Tbr1, was analysed in the α9-hNPC grafts. 
Results show at 2 weeks, α9-hNPCs expressed Tbr1, however the expression was not in every cell 
(white arrows in A-C). Similarly, at 4 (D-F) and 8 (G-I) weeks, a number of cells were expressing Tbr1, 
but the expression was largely confined to surviving α9-hNPCs located on the outside of the bolus. 
Scale bar in A, D and G = 250 µm; B, C, E, F, H and I = 150 µm. 
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5.3.5 The effect of α9-hNPC transplants on the extracellular matrix 
and the immune system 
As observed in data presented in Chapter 4, transplantation of WT hNPCs induced an 
immune response at the later time points analysed. The immune response was also 
assessed in α9-eYFP hNPC transplants, examining both the astrocytic response, using 
an anti-GFAP antibody, and microglia activation, using an anti-Iba-1 antibody. After 
2 weeks in vivo, there was a small increase in GFAP staining around the α9-eYFP 
hNPC graft sites suggesting activation of astrocytes (Figure 5.7, A and B). At the same 
time point, there was no noticeable increase in Iba-1 staining at the injection sites 
(Figure 5.7, C and D) compared to control tissue (control images are included in Figure 
4.13) and this expression is comparable to WT hNPC grafts. At 4 weeks post-
transplantation however, a microglial response was detected around the α9-eYFP 
hNPC graft denoted by a marked increase in Iba-1 immunoreactivity. At 8 weeks, the 
response from both astrocytes and microglia around the α9-eYFP hNPC injection sites 
was found to be substantially increased (Figure 5.8, I-L) compared to controls (Figure 
4.13). Furthermore, expression of TN-C at the transplant sites of α9-hNPCs was 
monitored over time. The expression of TN-C was found to be greater at the injection 
sites soon after transplantation which increased slightly over the different time points 
(Figure 5.8).  
 




Figure 5.7 The immune response after transplantation of α9-hNPCs. Following analysis of α9-
eYFP hNPC grafts over time, transplant survival diminished with time as observed with WT hNPC 
grafts. Following IHC analysis for immune response markers including activated microglia (Iba-1) and 
astrocytes (GFAP), results indicate an increase in the immune reaction to the grafts over time. At 2 
weeks, the astrocytic reaction (A and B) and the microglial response (C and D) was not noticeably 
increased from control levels (Figure 4.13). At 4 weeks there was a small astrocytic response (E and F), 
however there was a large increase in Iba-1 staining (G and H), suggesting a marked increase in 
microglial activity, in contrast to the immune response results observed with WT grafts (Figure 4.13). 
At 8 weeks, both GFAP and Iba-1 staining had greatly increased (K and L) compared to control tissue, 
suggesting an immune response had been activated, likely resulting in the observed graft rejection. Scale 
bar A, C, E and G = 250 µm; I and K = 500 µm; B, D, E, H, J and L = 150 µm.  
 




Figure 5.8 Expression of TN-C following transplant of α9-hNPCs. The expression of TN-C was 
observed following transplant of α9-eYFP-hNPCs and results were comparable to expression levels 
found with WT hNPC grafts (Figure 4.15). At all time points (A-I) (6 and 7 week data not shown) there 
was an increased expression of TN-C at the injection site (co-labelled with DCX staining in A, D and 
G). Scale bar A, B, C, E, G and H = 500 µm; C, F and I = 150 µm. 
 
 
5.3.6 Tracking of α9-eYFP hNPCs projections using BDA tracers 
As with WT hNPCs preliminary experiments to inject 50 mg/mL BDA together with 
the α9-eYFP hNPCs did not result in positive axonal tracing (data not shown). 
Unfortunately, time did not allow for optimisation or further testing with BDA tracing.  
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5.4 Discussion  
In this chapter, the transplantation of α9-eYFP-expressing hNPCs into the rat 
sensorimotor cortex has been characterised, taking into account the data collected in 
Chapters 3 and 4. The main aims of this part of the project were to ascertain whether 
α9-eYFP-expressing hNPCs could survive in vivo, extend long-distance projections 
from the transplant site and retain the exogenous α9-eYFP expression in vivo. It was 
hypothesised that the overexpression of the α9-eYFP protein may have resulted in 
longer projections from the hNPCs compared to WT hNPCs due to the growth-
promoting properties of α9 integrin. Results showed the α9-eYFP hNPCs followed a 
similar pattern of graft survival to the WT hNPC transplants where survival was 
highest at earlier time points. Similarly, surviving grafts produced projections that 
followed white matter tracts within the brain, including areas of the CST. Furthermore, 
results showed hNPCs were able to retain expression of α9-eYFP protein in vivo over 
time and this expression was localised to hNCAM-positive projections suggesting it 
was trafficked within the axonal projections of these cells.  
Following IHC using human-specific antibodies, survival of α9-eYFP hNPCs grafts 
was analysed. Results from α9-eYFP hNPCs emulated the survival findings obtained 
from transplantation of WT hNPCs. At 2 and 4 weeks, survival was highest with more 
than 90% of pups showing graft survival (Table 5.2). Beyond these time points, graft 
survival was observed, but steadily decreased and by 8 weeks only 36% of pups had 
surviving grafts. Furthermore, at the older age groups, particularly 7 and 8 weeks, 
although a proportion of transplanted cells survived, only a few pups showed 
projections outside of the bolus sites. These sites were also surrounded by scar tissue 
which suggested the cells were in the process of degenerating and the immune 
response may have inhibited the cells from extending axonal projections through the 
brain parenchyma. 
As for the WT hNPCs, optimisation of coordinates was continued with the α9-eYFP 
transplants and batch 11 (the last α9-eYFP batch transplanted) coordinates resulted in 
the most on-target injections with 60% of pups showing grafts located within the 
sensorimotor cortex. This was probably due to the depth of the grafts being reduced 
from -0.5 mm to -0.4 mm (Table 2.8). It is also important to note that across the time 
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points assessed where no graft was detected, it cannot be concluded as transplant death 
as we cannot determine whether the cells were transplanted.  
The furthest projections from α9-eYFP hNPCs were observed in batch 11 at 2 weeks, 
where hNCAM-positive fibres were present within the pyramids of the brain stem, 
however, this occurred in only one animal. In general, this was noticeably different 
from WT hNPC projections, where we observed a number of pups showing hNCAM-
positive fibres projecting to the caudal brain stem. From analysis of the α9-eYFP 
hNPC grafted tissue, it became apparent that projections from α9-eYFP hNPCs were 
not projecting as far, although projections were not measured and so this cannot be 
confirmed. This may have been due to a potential reduction in cell numbers after 
transplant. From the in vitro data in Chapter 3, it was noted that following viral 
transduction approximately 40% of cells detached from the cell culture dish which 
may have been due to the toxic effects of the polybrene reagent. A number of 
transduction optimisation experiments were trialled with polybrene to minimise cell 
death whilst still obtaining α9-eYFP expression (see Chapter 3). Taken together, these 
two observations lead us to question whether cell death of α9-eYFP hNPCs continued 
when transplanted in vivo and therefore resulted in reduced cell survival and 
projections compared to WT hNPCs, however individual cell numbers were not 
counted post-transplantation. It is important to remember, above all, that this was a 
xenogenic transplant where human cells were transplanted into a rat host.  
In accordance with this, the immune reaction occurring in α9-eYFP hNPC transplanted 
tissue may also shed light on why projections may have been reduced from these cells. 
IHC data for the immune response indicated there was an increase in activation of 
microglia at 4 weeks (Figure 5.7). This immune response was observed earlier 
compared to that of the WT hNPCs (section 4.3.7), suggesting that the immune 
reaction was greater or accelerated in response to α9-eYFP hNPC grafts. For example, 
at 6 weeks in WT hNPC grafts, 12% of pups had scarring whereas in α9-eYFP hNPCs 
50% of pups showed scarring. This suggested that potentially a lack of immune 
reaction to the WT hNPCs may have accounted for their increased survival in vivo 
compared to the α9-eYFP hNPCs. By 7 weeks, scarring in both groups was similar 
whereby 47% of pups showed scarring after WT hNPC transplants and 55% of pups 
showed scarring after α9-eYFP hNPC transplants. This comparison suggests an 
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increased immune response to α9-eYFP hNPCs may have occurred earlier indicating 
a longer time window in which the WT hNPCs survived, allowing for extension of 
longer axonal projections in a greater number of animals. The main question remains, 
however, as to why there was a lag time and a difference in immune reaction between 
the two cell populations. The answer to this may also be linked to the previous 
discussion point that α9-eYFP hNPCs may have been compromised by the viral 
transduction using polybrene and this process may have destabilised the grafted cells 
and their ability to interact or fight off any challenges posed by the host environment. 
This may have caused the cells to continue to die following transplantation as they did 
in culture. If a proportion of transplanted cells were undergoing cell death or were in 
the process of degenerating this may have resulted in secretion of pro-inflammatory 
and apoptotic factors, which could have stimulated microglial activity, which in turn 
secrete further cytokines, such as tumour necrosis factor-α (TNF-α) (Reviewed in 
Hanisch, 2002). Indeed, research has shown that the survival and growth of NSPCs 
can be hindered by apoptotic factors in the local environment, including interferon-
gamma and TNF-α (Ben-Hur et al., 2003; Guadagno et al., 2013). However, this 
theory contradicts the large body of research suggesting NSPC transplants are anti-
inflammatory (Pluchino et al., 2005; Einstein et al., 2007; Lee et al., 2008; Cusimano 
et al., 2012).  
That said it will be important for future work to ascertain whether or not it is the 
process of viral transduction or the expression of the α9-eYFP protein that is causing 
this reaction. This was not examined in this project, however as reported in Chapter 3, 
approximately 40% of cells detached in the days following viral transduction, which 
was hypothesised to be due to the toxic effects of polybrene. As this result was the 
same for both viral transduction of α9-eYFP and viral transduction of fGFP, this 
suggests it was an effect of the viral transduction and not of the α9-eYFP expression. 
If GFP-expressing hNPCs could be transplanted with survival and projections from 
these cells assessed, we would expect the results to be similar to the α9-eYFP grafts. 
Here, 2 µg/mL of polybrene was used as results indicated this to be the most effective 
concentration to obtain expression whilst maintaining sufficient cell survival. 
Alternative methods for stable protein overexpression or the use of 
immunocompromised hosts should be investigated. Stem cells exposed to higher 
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concentrations of polybrene before transplantation have been studied, for example 
Song and colleagues transduced MSCs with integrin using LV and 8 µg/mL of 
polybrene before transplantation into the myocardium of immunosuppressed mice 
(Song et al., 2009). Importantly, with this study, animals were immunocompromised 
and transplanted cells were analysed only after one week in vivo. This means any 
immune reaction elicited in response to grafted cells dying off due to exposure to 
polybrene after one week in vivo may possibly not have been detected.  
In general, the literature shows that many animal models receiving genetically 
modified transplants are immunosuppressed and therefore survival of grafts would be 
prolonged due to the lack of or delay in immune rejection. However, as mentioned 
earlier, the process of viral transduction may have additionally resulted in cell survival 
being compromised. If the hNPC grafts were transplanted into immunosuppressed 
hosts, this would likely prevent cell death as a result of the immune rejection, however 
the cells may still be compromised. Previous literature would suggest that genetic 
modification of transplanted cells using LV prior to engraftment does not affect cell 
viability, providing the immune system is compromised using either 
immunosuppression or immunocompromised animal models (Behrstock et al., 2008; 
Fujimoto et al., 2012). Research has also shown some types of stem cells, such as bone 
marrow-derived MSCs, do not elicit such an increased immune response (Chopp and 
Li, 2002). Modifying mouse bone marrow-derived MSC grafts to express specific 
immune-supressing factors such as interleukin-13, can prolong graft survival within 
the rodent brain, although this is marginal with the difference in survival being only 1 
or 2 days (Hoornaert et al., 2016). Modification of the cells in this way would mean 
the host would not be left vulnerable to infection, but would mean further genetic 
manipulation of the grafted cells would be required. Following mouse NSC 
engraftment into the immunocompetent adult mouse brain, research suggests 
approximately 80% of cells die off and undergo apoptotic cell death within the first 24 
hours after transplantation, with only 1% of cells surviving 14 days after transplant. In 
the days following transplant, the number of cells expressing the hypoxic cell marker, 
Hypoxyprobe-1, within the graft site increased (Reekmans et al., 2012). This suggests 
a lack of nutrients, such as oxygen, but also no blood supply, could be contributing 
factors in transplant cell death.  
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Transplanted α9-eYFP hNPCs were analysed for the expression of the deep-layer 
cortical neuron marker, Tbr1, over time. Results showed that some of the α9-eYFP 
hNPCs retained expression over time in vivo, however not every cell expressed Tbr1. 
In particular, the expression was limited to cells located on the outside of the bolus 
where they could possibly have interacted with the ECM. Furthermore, it was noted 
that there may have been a smaller proportion of α9-eYFP hNPCs expressing Tbr1 
compared to WT hNPCs. One relevant point to make is the potential of the hostile 
immune environment to alter the phenotype and differentiation status of the 
transplanted cells, thus changing their protein expression profile. Research has 
suggested that following injury, activated astrocytes and microglia can secrete factors, 
including interleukin-6 and leukaemia inhibitory factor, both of which promote NPC 
grafts to differentiate into astrocytes (Faijerson et al., 2006; Nakanishi et al., 2007). 
Furthermore, neonatal astrocytes have been examined for their GFAP expression in 
relation to adult astrocytes and results indicate that neonatal astrocytes are more 
reactive than adult astrocytes (Reviewed in Wu and Schwartz, 1998). Whether this 
would alter the phenotype of the human NPCs used in this project remains to be 
determined; however, we would hypothesise this was not the case as these cells have 
been pre-programmed in vitro to become CCNs and were therefore already on a 
specified differentiation path.  
As described in Chapter 4, transplants of WT hNPCs results in a localised upregulation 
of TN-C at the injection site. From analysis of α9-eYFP hNPCs, there was a similar 
expression over time. As mentioned previously, the TN-C antibody was human-
specific but has previously been used in the laboratory in rodent tissue with positive 
results. As TN-C is present at the injection site of α9-eYFP hNPCs, we would have 
expected this to potentiate the effect of the overexpressed α9-eYFP protein and 
potentially to have promoted axonal elongation due to its ligand being present, 
however this was not clearly observed. It is possible that because there was a high 
concentration of TN-C at the injection site, this would encourage the α9-eYFP hNPCs 
to remain localised to the graft site rather than extend long distances beyond the 
injection site. To confirm this, a rat-specific TN-C antibody could be used to assess 
whether the observed upregulation of TN-C at the graft site is due to endogenous rat 
expression or is originating from the hNPCs. Indeed, the in vitro results discussed in 
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section 3.3.4, indicated the hNPCs expressed TN-C in culture. Secondly, the ability of 
α9-hNPCs to project towards a TN-C rich environment could be assessed, initially in 
vitro, but also in vivo, using a cortical stab injury model. In this model, α9-eYFP 
hNPCs would be transplanted into one region of the cortex with a cortical stab wound 
in a separate distinct region, which should promote an upregulation of TN-C at the 
lesion site. The projections from α9-eYFP hNPCs would be analysed for their ability 
to preferentially project to a TN-C-rich environment.  
Furthermore, data from Chapter 3 highlighted that the α9 expression within hNPCs 
was functional prior to transplantation. Research has shown proteins associated with 
CNS injury, such as CSPGs and Nogo-A, can inactivate integrins (Hu and Strittmatter, 
2008; Tan et al., 2011), but this inactivation can be overcome with the modulation of 
integrins into their active state using activators, including kindlin-1 (Cheah et al., 
2016). As mentioned in Chapter 1, kindlin-1 is not expressed within the CNS 
(Reviewed in Ussar et al., 2006) and therefore would need to be administered 
alongside the α9-eYFP hNPCs to induce integrin activation. However, another option 
is activation of integrins using human-specific antibodies, such as TS2/16 (Hu and 
Strittmatter, 2008; Tan et al., 2011), which may be the subject of future 
experimentation. The expression of inhibitory proteins, such as aggrecan, was not 
assessed within the hNPC-grafted tissue, but there is scope for the expression of such 
proteins to be upregulated, as an injury-like environment may have been created 
following injection of the cells.  
Together these results show the expression of α9-eYFP protein is maintained within 
hNPCs following transplantation into the rat brain. Cells are able to maintain this 
expression throughout the duration of their survival in vivo. Furthermore, α9-eYFP 
expression co-labelled within hNCAM-positive axonal projections, suggesting the 
exogenous integrin protein was localised and may have been actively transported 
within the axonal compartment of the hNPCs. Additionally, a proportion of the cells 
maintained an expression of the deep-layer cortical neuron marker, Tbr1, and as with 
the WT hNPCs there was a localised upregulation of the main ECM component of the 
CNS, TN-C, at the transplant site. After obtaining data from transplanted WT hNPCs, 
where on-target grafts were able to project to the caudal brain stem, likely beyond the 
pyramidal decussation (see Chapter 4), we hypothesised that α9-eYFP hNPCs may 
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have the potential to match, if not exceed, the projections observed in WT hNPCs due 
to the characteristic growth-promoting properties of α9 integrin. However, projections 
from the α9-eYFP hNPCs only reached the medullary pyramids. There are a number 
of possibilities that may have led to this outcome, such as a lack of available TN-C 
ligand outside the transplant site, integrin inactivation at the injection site, lack of cell 
numbers over time, and/or reduced ability of the cells to extend projections due to viral 
transduction or increased immune response.  
It is possible that any or all of these options occurred following α9-eYFP hNPC 
transplant. The first line of inquiry in any future study should focus on the viral 
transduction protocol to examine the mechanisms behind the increased cell death after 
transplantation and whether their viability had been compromised owing to exposure 
of the cells to polybrene in vitro. To test this, it would be beneficial to transplant GFP-
expressing cells to inform further discussion and rule out α9-eYFP expression as a 
contributing factor to graft rejection. Furthermore, injecting α9-eYFP hNPCs into 
immune-compromised animals would likely result in further graft survival (of both 
transplant groups), allowing increased analysis of the α9-eYFP protein capabilities in 
vivo.  
  









Chapter 6: Final discussion  
and future perspectives 
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6.1 Summary of key findings 
Research surrounding stem cells has expanded since the discovery of iPSCs, 
transforming the field of neurodegenerative diseases and conditions, such as SCI, 
where cell replacement may significantly promote CNS repair. With a regenerative 
approach in mind, this thesis has focused on the use of iPSC-derived human NPCs, 
assessing their suitability and ability to survive and express growth-promoting 
integrins after transplantation into the rat neonatal cerebral cortex. This body of work 
has provided an extensive characterisation of the iPSC-derived hNPCs, both in vitro 
and in vivo, showing that these cells endogenously express a number of neuronal and 
growth-promoting proteins and can survive in the naive neonatal rat brain up to  
8 weeks after transplantation. Explicitly, this project addressed whether these cells 
could be utilised to increase the expression of the growth-promoting integrin subunit, 
α9, within the CNS. The data presented here has shown exogenous expression of  
α9-eYFP within hNPCs was achieved following LV transduction. Once expressed 
within the hNPCs, this protein was functional when grown on TN-C in vitro and 
indeed, once transplanted, α9-eYFP hNPCs retained the expression of α9 integrin for 
as long as the cells survived in vivo.  
 
6.2 Survival of transplanted hNPCs 
Survival of WT and α9-eYFP hNPCs in vivo was highest at younger time points 
(Tables 4.2 and 5.2) and gradually declined over time as cells underwent immune-
mediated rejection. This was expected as human cells were transplanted into a rat and 
no immunosuppression was performed. However, previous research has shown 
transplants of ESC-derived neurons between P0-P2 in the rat striatum can result in 
substantial survival 10 weeks after grafting without the use of immunosuppression 
(Denham et al., 2012). These two projects are similar in many ways, including the 
animal model used, age of animal at time of transplant, the number of cells transplanted 
and use of stem cell-derived cells. However, there are distinct differences in 
experimental procedure that may explain the changes in graft survival. These include 
transplant into the striatum compared to the cortex, the use of ESC-derived cells 
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compared to iPSC-derived cells, as well as the differentiation status of the cells at the 
time of transplant, i.e. neurons compared to progenitor cells.  
In our study and in Denham et al (2012), 100,000 cells were transplanted per site, 
which may have acted as a protective barrier. For example, cells in the centre of a large 
bolus of cells may be protected from the immune response due to lack of interaction 
with the immune system as it is the cells on the outside of the bolus that are 
compromised first. This theory has previously been investigated with research 
showing that the greater the number of hNPCs transplanted, the larger the immune 
response, thus more cells does not necessarily equate to better survival (Ostenfeld et 
al., 2000). Specifically, results following transplant of 200,000, one million or two 
million hNPCs into the striatum of a Parkinson’s disease rat model showed projections 
were more common from smaller grafts and an increased immune response was noted 
in those animals that received a larger cell graft (Ostenfeld et al., 2000). The 
differences in graft survival discussed here suggest it is therefore either the transplant 
target site or the animal model that affected graft survival. For example, research has 
shown regional differences can impact graft survival and maturation following 
transplantation of hNSCs into the cortex and striatum of uninjured adult 
immunodeficient mice (Tennstaedt et al., 2015a, 2015b). Importantly this work found 
the environment of the cortex can promote survival and maturation of hNSCs 
compared to the striatum and has suggested this could be due to differential 
neurotrophic protein expression within these regions. Although not directly 
comparable, one study has suggested the immune response to grafted cells may be 
different in grey and white matter tissues and has shown the striatum (grey matter) can 
actually support survival of grafted mouse glial precursors, compared to the forceps 
minor (white matter) after transplant into immunocompetent mice (Janowski et al., 
2014). As both the striatum and cortex are mainly grey matter, this may not explain 
the differences in graft survival in the cortex compared to the striatum observed by 
Tennstaedt and colleagues (2015a; 2015b). In our project, differences in cell survival 
within distinct brain regions were not analysed, however it would be interesting to 
assess whether on-target injections within the cortex survive longer than off-target 
injections. To do this, cells would need to be stereologically counted in vivo to directly 
measure cell survival versus cell death. 
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Research further suggests that the animal model used can greatly influence graft 
survival. The Denham study (2012) and our study both utilised a neonatal rat model 
which resulted in survival beyond one month. This is in contrast to recent research by 
Mattis and colleagues with human NPCs, derived from iPSCs and injected between 
P0-P4 into the striatum of immune competent mice. In their experiment, cells were 
rejected within 4 weeks post-transplantation and no grafted cells could be detected 
beyond this time point (Mattis et al., 2014). Furthermore, 50,000 cells were injected 
per hemisphere, and they report a dramatic decline in cell survival in the days 
following transplantation. For example, at 10 days post-transplant, only around 3% of 
grafted cells survived. They hypothesised iPSC-derived cells could have created a cell-
specific immune response, however, when this theory was tested similar rejection was 
observed after fetal-derived hNPCs were transplanted into the same mouse model 
(Mattis et al., 2014). Similarly, when P2 immunodeficient mice received hNPC 
transplants into the cortex, only 1.21% of the graft remained after 8 weeks in vivo 
(Zhou et al., 2015). Therefore, the literature strongly suggests the animal model used 
in transplantation experiments determines the time scale for immune rejection, with 
mouse models in general rejecting grafts more quickly compared to rat models 
(Englund et al., 2002; Reviewed in Roberton et al., 2013; Mattis et al., 2014). The 
reasons for this are not yet known, but the increased microglial response in mice is one 
currently recognised theory (Reviewed in Roberton et al., 2013).  
It is of utmost importance to consider not only whether the hNPCs are surviving in 
vivo, but also whether they are maturing, extending projections and interacting with 
host tissue. Moreover, in an injury model, are grafts able to promote any functional 
outcome? The lack of graft survival after xenotransplantation experiments can often 
prevent full examination of the graft integration in vivo, therefore prolonging cell 
survival is of high importance. It is possible to extend graft survival using 
immunodeficient animal models, such as non-obese diabetic/severe combined 
immunodeficiency (NOD/SCID) mice, however, alternative methods could also be 
pursued in rats including autologous transplantation, or neonatal desensitisation (Kelly 
et al., 2009), although there is controversy over whether the latter technique actually 
prevents immune-mediated rejection (Janowski et al., 2012; Mattis et al., 2014). 
Alternatively, recent results from a clinical trial in stroke patients revealed the 
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neuroprotective effects of a bone marrow-derived MSC transplant outlasted the 
survival of the cells (Steinberg et al., 2016), likely due to secretion of neurotrophic 
factors, therefore bringing into question the requirement for long-term transplant 
survival. When considering SCI however, where transplants would be used to replace 
damaged cells, particularly neurons as in our case, the transplanted cells would likely 
need to survive in order to maintain reconstructed neuronal connections which have 
extended through an injury site.  
In this project, the low survival of α9-hNPCs specifically has raised some interesting 
questions regarding use of LV and polybrene to increase expression of proteins in cells 
destined for transplant. Use of this methodology may compromise the cell survival in 
vivo. However earlier studies have demonstrated that cells which have undergone LV 
modification without polybrene prior to transplantation are not compromised in vivo ( 
Englund et al., 2002; Behrstock et al., 2008). Yet those that have been exposed to 
polybrene prior to transplant have resulted in poor survival rates (Zhou et al., 2015) 
including in our study. However, Zhou and colleagues hypothesised that the observed 
poor survival of GFP-expressing hNPCs grafted within the immunodeficient mouse 
cortex was due to differentiation status of the cells, the animal model used or 
neuroanatomical location of transplant. The transduction protocol using LV and  
8 µg/mL of polybrene was not reported to be a contributing factor. 
 
6.3 Targeting of hNPC transplants to the sensorimotor cortex 
The cells transplanted during this project were targeted to the sensorimotor cortex, 
specifically layer V, which contains pyramidal cells that project to the spinal cord. 
Initially, coordinates were chosen using an E22 rat brain atlas as reference (Altman 
and Bayer, 1995). Following the first round of transplants, grafts were monitored and 
the subsequent coordinates were altered to better target the region of interest. For each 
batch of transplants, coordinates were optimised in this way, basing the next set of 
coordinates on the graft location from the previous batches. In general, the depth of 
the transplants was reduced over time from -0.7 mm to -0.4 mm. Grafts were also 
moved more laterally from 1/-1 mm to 1.5/-1.5 mm and finally grafts were moved 
further forward from -1/-0.5 mm to bregma/1 mm. This optimisation resulted in 
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improvement of on-target injections for WT hNPCs increasing from 30% in batch 1 to 
64% in batch 12. For α9-hNPCs, the coordinates were based on results from WT hNPC 
grafts in batch 1-6 (excluding batch 5, as this litter was cannibalised by the mother 
after surgery). Transplants conducted in batches 11 and 12 were based on coordinates 
from all litters (1-10, excluding 5), and this is likely why these batches resulted in the 
highest percentage of on-target injections, 60% and 64% respectively.  
Batches 3 and 9 had the next most on-target injections with 56% and 57% respectively. 
Batch 9 coordinates were similar to those used in batch 11 and 12, but the depth of 
grafts in batch 9 was -0.5 mm compared to -0.4 mm in batch 11 and 12. However, the 
coordinates in batch 3 were very different compared to batches 9, 11 and 12. After 
analysis of batch 3 transplants, batch 4 and 6 were transplanted using the same 
coordinates, however both of these batches resulted in a much lower percentage of on-
target injections, 38% and 40%, respectively. This indicated a high degree of variation 
between the graft location that was not due to coordinates alone. The neonatal skull is 
very thin and can be pierced easily using a 26-gauge needle, however the injection 
needle (attached to the Hamilton syringe containing the cells) is not strong enough to 
go through the skull. Therefore, by hand, a 26-gauge needle was utilised to pierce a 
hole through the skull to target the injection sites, using a stereotaxic frame to first 
mark the coordinates with a pen onto the skin, and then to stabilise the needle for 
injection. Because piercing the skull was done by hand, it was challenging to pierce 
only the skull and not penetrate into the brain parenchyma. Furthermore, the injection 
needle containing the hNPCs then had to be lowered (using the stereotaxic frame) so 
that it was below the skull, but on top of the brain (Figure 6.1, A). From there, the 
stereotaxic frame was used to lower the syringe and needle containing the hNPCs to 
the designated coordinates. However, it was not always clear when the tip of the 
injection needle was on the surface of the brain compared to when it was within the 
brain tissue (Figure 6.1, B). This therefore resulted in the potential addition of depth 
to the coordinates and, instead of transplants injected at the desired -0.4 mm, they were 
injected deeper than this, for example at -0.6 mm. This process of making sure the 
needle was at the top of the brain rather than within the brain was very delicate and 
was not obvious and would often have to be gauged using the resistance felt within the 
needle.  
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The injection protocol likely added variation to the transplant locations, but may not 
have been the only source of error resulting in off-target injections. Neonatal rats 
cannot readily be stabilised during surgery by conventional methods, such as ear bars, 
because at this age their ears have not fully developed. Therefore, alternative methods 
need to be used, including potentially cheek bars. Initially, rats were stabilised using 
Blu Tack (reusable putty-like pressure-sensitive adhesive produced by Bostik), which 
is easily mouldable to secure the animals in position, however this did not provide 
consistent stabilisation of the animal for injection. Instead, the head of each animal 
was measured and a small frame was designed which was kindly 3-D printed by Dr 
Robert Hammond (School of Medicine, St Andrews University) and used in batches 
3-12. This frame was designed to improve stabilisation of the pup’s head during the 
transplantation procedure. 
 
Figure 6.1 Potential variation in injection sites due to transplant protocol. Injection of hNPCs in 
the layer V of the sensorimotor cortex was carried out using a stereotaxic frame and a Hamilton syringe. 
However, the needle attached to the Hamilton syringe was not strong enough to pierce through the rat’s 
skull and therefore a 26-guage needle was first used to pierce a hole in the skull by hand (A). Using the 
stereotaxic frame, the injection needle attached to the Hamilton syringe could then be manoeuvred to 
the designated coordinates (A). However, it was not always clear when the tip of the injection needle 
was on the surface of the brain compared to when it was in the brain tissue resulting in the potential 
addition of depth to the coordinates (B). 
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Despite the difficulties associated with targeting of injections, results indicate 60% or 
more of grafts were on target within the last two batches (11 and12) and overall, out 
of a total of 112 animals with detectable graft sites used across this study 40% 
(n=45/112) had grafts on target. Future work with these cells should focus on further 
improving transplant accuracy. For example, some studies in transplant of ESC-
derived NPCs into neonatal cerebral cortex of mice have drilled into the skull, to 
expose the brain surface before injection (Ideguchi et al., 2010), which may increase 
the accuracy of the depth of the transplant. 
 
6.4 Protein expression and maturation of hNPCs 
For transplanted cells to project from the cortex to the spinal cord, it is important to be 
aware of the expression profile of the cells (Finger et al., 2002; Arlotta et al., 2005; 
Sano et al., 2017). The hNPCs used within this project expressed the deep-layer 
cortical neuron marker Tbr1 both in vitro and in vivo as well as the glutamatergic 
marker VGlut1 in vitro. It would be interesting to further characterise the expression 
profile in vivo examining markers known to be required for projection of neurons 
within the CST, such as Ctip2 and neuropilin-1 (Arlotta et al., 2005; Sano et al., 2017). 
Furthermore, as misexpression of these proteins, for example Tbr1, could be 
preventing CST projections (Han et al., 2011), further research would be beneficial to 
identify the regulation of these genes within the hNPCs before and after transplant. 
Our results suggest the hNPC population used here may be more heterogeneous than 
originally thought, with expression of both astrocytes and GFAP-expressing radial 
stem cells potentially present within the culture. Further analysis of these and other 
cells types would need to be carried out before transplantation into an injury model.  
One of the recurrent questions throughout this project was whether these cells were 
mature enough to allow for integration into host tissue. Neural development in a rat is 
much shorter than development in a human. Recent research has shown maturation of 
human iPSC-derived NPCs in vitro occurs over the course of 20-30 weeks (Odawara 
et al., 2016) suggesting the hNPCs may need further differentiation in vitro before 
transplantation to promote better tissue integration in vivo. However, it may be that a 
balance is needed between immature and mature features, as these cells still need to 
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retain the ability to put out long-distance projections through white matter tracts. One 
of the advantages of using NPCs is their ability to promote secretion of neurotrophins, 
likely contributing to a growth-promoting environment. It is unclear whether a more 
differentiated cell type would retain this ability. The hNPCs here were pre-
programmed to become CCNs, although this was not confirmed fully within the 
project. Yet previous research has shown hNPCs can mature over time in vitro, 
including formation of synapses and generation of spontaneous firing (Odawara et al., 
2016). This question may be answered by prolonging graft survival in vivo. Even 
though these hNPCs have been derived from iPSCs and are progressing towards 
differentiation into CCNs, they still retain a number of stem cell traits, raising 
questions about the developmental stage of these cells. Markers associated with stem 
cells, such as Oct4, are present within a high proportion of the hNPCs in culture. 
Furthermore, both in vitro and in vivo hNPCs express Ki67, a proliferation marker 
associated with oncogenic cells. It is perhaps more accurate to refer to these transplants 
as stem cells rather than neuronal progenitor grafts. Future work may address this, 
including in-depth analysis of stem cell markers, loss of stem cell traits over time in 
vitro and allowing the cells to differentiate further to CCN stage before transplantation.  
Furthermore, it would be interesting to investigate whether maturation of these cells 
affects their ability to integrate into the host brain. Transplanted stem cells and neurons 
can integrate into the rodent cerebral cortex, indicated by grafts forming synapses and 
producing functional action potentials in vivo (Espuny-Camacho et al., 2013; Tornero 
et al., 2013). Therefore, there is hope that these iPSC-derived hNPCs could also 
integrate, providing they have the correct expression profile and are at the correct 
developmental stage at the time of transplant. As mentioned earlier, these are human 
cells injected into a rat system, so there is likely to be a lag time. Recent research has 
indeed demonstrated human NSCs injected into the adult lesioned immunodeficient 
rat spinal cord only show signs of maturation 3 months post-transplant with 
oligodendrocytes not detected until 1 year after transplant (Lu et al., 2017). This work 
highlights the challenges of using human NSPCs within a rat system where maturation 
of human cells does not match that of the rat host. Longer-term survival of grafted 
human cells would therefore be required to enable full physiological and functional 
Using human iPSC-derived neural progenitor cells to increase integrin expression in the CNS 
196 
 
characterisation. Yet whether a more differentiated equivalent would result in better 
integration remains to be seen. 
 
6.5 Is the overexpression of α9 required? 
The observed reduction in projections from transplanted α9-eYFP hNPCs compared 
to WT hNPCs was not expected. As discussed in Chapter 5, this was likely due to the 
viral transduction and use of polybrene to overexpress the α9-eYFP protein, potentially 
compromising cell survival following transplantation. Alternative methods of 
constitutive protein expression could be trialled, however, this body of work has also 
questioned the requirement for overexpression of α9, as these cells express an 
endogenous level of the protein which our preliminary results suggest is functional 
when grown on TN-C. Combining the results from Chapter 3 with the literature, there 
is evidence to suggest hNPCs could adapt to the environment as shown previously 
with embryonic DRGs (Condic et al., 1999). When grown on increasing 
concentrations of human TN-C, WT hNPCs and GFP-hNPCs increasingly put out 
longer neurites (section 3.3.5), suggesting hNPCs could actively increase expression 
of TN-C-binding integrins, such as α9β1, α7β1 or α8β1 (Mercado et al., 2004) in 
response to an inhibitory environment. Previously, embryonic DRGs in culture were 
able to overcome an inhibitory CSPG-rich environment by endogenously increasing 
the expression of integrin on the cell surface (Condic et al., 1999; Condic, 2001). This 
trait is not continued beyond development into adulthood, but increasing exogenous 
integrin expression in adult DRGs can promote outgrowth (Condic, 2001). If this is 
the case, and hNPCs are able to adapt in response to glial scar components, it questions 
whether overexpression of α9 is truly necessary to achieve long-distance axonal 
outgrowth from hNPCs. As TN-C is upregulated at CNS injury sites, this increase in 
expression (the concentration of which is currently unknown) may be enough for 
hNPCs to increase their integrin, including α9, expression. Whether rat TN-C would 
be able to promote the same adaptation response in hNPCs as human TN-C remains to 
be seen, and could be tested in vitro, however this would likely lead to further 
experiments for analysing both α9 hNPCs and WT hNPCs in a rat injury model.  
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6.6 New potential techniques for imaging cell transplants in vivo 
Graft survival and integration is only part of the challenge when it comes to cell 
replacement studies. The other aspect that must be considered is monitoring of 
transplanted grafts over time and their spatial distribution in relation to whole brain 
tissue and neuronal circuitry. Imaging techniques, such as magnetic resonance imaging 
(MRI), can provide fundamental information regarding the anatomical location of 
grafted cells. They cannot however provide information regarding graft-host 
interaction or cell viability, both of which are important when considering 
xenotransplantation. The majority of studies, including this one, have utilised 2-
dimensional (2-D) IHC protocols to analyse transplanted cells in PFA-fixed, sectioned 
tissue. Immuno-stained tissue is imaged using light microscopy, such as epifluorescent 
or confocal, both of which have restricted tissue penetration and therefore tissue must 
be sectioned thinly. The thickness of tissue sections can present limitations when 
analysing or tracking cell migration or growth, as numerous serial sections must be 
analysed to be able to fully map grafts in vivo, a process that is very time consuming, 
for example if an entire rodent brain is to be imaged. Within the last decade, a number 
of new methods have been developed, such as serial two-photon microscopy (Ragan 
et al., 2012); optical projection tomography (Gleave et al., 2013); wide-field large-
volume tomography (Gong et al., 2016); and light sheet fluorescence microscopy 
(LSFM) (Ahrens et al., 2013). All of these are recognised for their ability to analyse 
thicker tissue sections which enable the creation of 3-dimensional (3-D) views of 
neural circuitry. Follow-on work from this project has taken tissue from WT hNPC 
grafts and imaged this using LSFM in preliminary collaborative experiments with 
Professor Kishan Dholakia’s group (School of Physics and Astronomy, St Andrews 
University). This work has set out to image transplanted hNCAM-positive projections 
from hNPCs alongside host astrocytes with the aim of analysing 3-D human grafts 
within the rat brain (Figure 6.2). It would be interesting to examine deeper sections of 
grafted cells within the host rat brain using additional methods of analysis in 
conjunction with LSFM, such as optical tissue clearance to further characterise our 
cell transplants. 
 




Figure 6.2 Projections from WT hNPCs detected using LSFM. Analysis was carried out on the 
hNPC grafts in vivo using LSFM where a 3-D image of the transplanted cells and axonal projection can 
be observed. Tissue was stained using the standard IHC protocol (section 2.8.1) to detect hNCAM-
positive NPC projections 6 weeks post-transplantation (A). Following LSFM analysis, a dense region 
of projections was identified where it is difficult to single out lone projection fibres (B). However, in a 
less dense region, single fibres can clearly be identified in 3-D view (C). Furthermore, two cell types, 
such as hNPCs (indicated by hNCAM staining) and astrocytes (indicated by GFAP staining), can be 
imaged together (D) with the aim of acquiring larger scale images to analyse the graft in 3-D view in 
vivo interacting with surrounding tissue. Scale bar in A = 50 µm. Tissue was stained using anti-hNCAM 
and anti-GFAP primary antibodies and AlexaFluors goat-anti mouse 568 and goat-anti rabbit 488 (see 
Tables 2.5 and 2.6 for full antibody details). LSFM was carried out by Dr Kaley McCluskey and Dr 
Jonathan Nylk in Professor Kishan Dholakia’s group within the School of Physics and Astronomy at 
the University of St Andrews. 
 
To analyse thicker sections of tissue using optical brain imaging, such as LSFM, light 
scattering and refraction can be reduced using tissue clearing. Optical tissue clearing 
involves infiltrating the brain tissue with clearing agents and methods, such as 
CLARITY and iDISCO, to remove lipids from the brain effectively making the tissue 
transparent, letting light travel through it and thus allowing analysis of brain tissue, 
including the intact rodent brain (Ertürk et al., 2011; Hama et al., 2011; Chung et al., 
2013; Ke et al., 2013; Tomer et al., 2014; Costantini et al., 2015; Renier et al., 2016). 
With respect to cell transplantation, it is of high importance that an imaging technique 
can primarily decipher grafted cells from host cells, but also provide information on 
transplanted cell engraftment, tracking cell migration and identifying graft-host 
interactions. Recent work has shown human eGFP-expressing ESC-derived 
neuroepithelial stem cell transplants can be imaged in vivo following transplant into 
the mouse striatum or hippocampus, using a combination of tissue clearing, LSFM, 
3D MRI and rabies virus-based retrograde tracing which enabled projections of grafted 
cells to be tracked throughout the host brain. Furthermore, this work has highlighted 
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the ability of this combination of techniques to identify innervation of human grafted 
boluses by host rat cells, suggesting potential graft-host interaction (Doerr et al., 2017).  
Some methods of optical clearing can result in loss of tissue structure and reduction of 
fluorescent fluorophores, but newer protocols are being developed to prolong 
fluorescent signals (Schwarz et al., 2015). Furthermore some imaging techniques, such 
as block-face serial tomography (FAST), do not require any clearing (Seiriki et al., 
2017). Although this new technique requires histological sectioning, it allows imaging 
of large sections of tissue with high resolution, including an entire mouse brain, large 
sections of primate tissue, including a nuclear-stained adult marmoset hemisphere, and 
a nuclear-stained, 1,000 mm3 region of the primary visual cortex in human post-
mortem tissue. Furthermore, FAST can image tissue at the same speed as current 
LSFM techniques, yet it does not require tissue clearing thereby preventing any 
interference with the fluorescence signal (Seiriki et al., 2017). Thus, new optical brain 
imaging techniques are providing exciting opportunities for imaging whole brain 
tissue at the cellular and subcellular level in both animal and human post-mortem 
tissue.  
One further optical imaging technique that has proven useful for analysis of cell grafts 
in vivo is bioluminescence imaging (BLI) (Sher et al., 2009; Takahashi et al., 2011; 
Bernau et al., 2014; Hwang et al., 2014; Tennstaedt et al., 2015a). This technique relies 
on transplanted cells exogenously expressing luciferase, which can emit light when in 
contact with its substrate luciferin, which is injected into the animal after cell 
transplantation and before imaging. The advantages of using BLI are that it is a non-
invasive approach that allows analysis of grafted cells without compromising the host. 
Furthermore, and contrary to previous opinions within the field, recent research has 
confirmed that grafted cells deep within the tissue, for example the striatum, can be 
detected long term using this technique (Bernau et al., 2014). Following transplant of 
luciferase-expressing hNPCs into the adult rat cortex and striatum, BLI was used to 
track the survival and migration of cells up to 12 weeks after transplant (Bernau et al., 
2014). Furthermore, luciferase expression can be designed to be under the control of 
cell-specific promoters, for example DCX or synapsin-I, allowing the differentiation 
and maturation of transplanted cells to be monitored in vivo (Tennstaedt et al., 2015a). 
Although BLI may not provide as much information, such as graft integration, as the 
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previous imaging techniques discussed, it allows the survival of grafted cells to be 
analysed over time without the need to compromise the animal and the experiment. 
This technique may prove useful for the progression of this project when thinking 
about SCI injury models and assessing cell migration and projections towards an injury 
site. Indeed, luciferase-expressing NSPCs have been injected into the mouse spinal 
cord following laminectomy at L3 and tracked using BLI (Takahashi et al., 2011). 
Therefore, it is possible to detect these cells within the rodent spinal cord, however 
there is a limit on detection of grafts less than 1,000 cells without opening up the 
animal. This method may therefore allow analysis of migration of hNPCs in vivo, but 
it also presents challenges, such as tracking of long-distance projections, especially 
single fibres, from luciferase-expressing hNPCs which would likely not be detected.  
 
6.7 Concluding remarks 
In terms of stem cell transplantation, and specifically iPSC-derived hNPC grafts, this 
work has confirmed previous research showing grafts can survive in immune 
competent neonatal rats, including longer than what has been documented in mice 
(Denham et al., 2012; Mattis et al., 2014). After a month in vivo, these cells can project 
to the caudal brain stem from the cerebral cortex. Unfortunately, these cells have not 
projected as far as in other comparable studies and this is likely due to targeting of the 
injections and gene expression, both of which would need further optimisation and 
analysis. In terms of integrin expression in vivo, this project has sparked a number of 
interesting questions around α9 integrin expression in hNPCs. Firstly, does 
overexpression of α9 using LV and polybrene hinder cell survival in vivo? Secondly, 
can hNPCs adapt to an inhibitory environment and upregulate expression of growth-
promoting integrins, a trait shown previously in embryonic DRGs (Condic et al., 
1999)? 
Although these cells were not characterised within a SCI model, there is substantial 
evidence from both the literature and data derived within this project that these cells, 
both WT and α9-expressing, should be transplanted into a rat injury model to assess 
their regenerative capacity, whether that be through cell replacement to reconstruct 
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damaged axonal connections or to provide trophic support by secretion of growth-
promoting factors. Further support for transplantation of both α9-hNPCs and WT 
hNPCs into a rat injury model stems from research showing a lesioned environment 
can actually enhance both hNPC survival and migration compared to intact control 
animals (Behrstock et al., 2008). This work specifically focused on hNPC grafts into 
the lesioned striatum of a Huntington’s disease rat model under immunosuppression. 
In this case, before transplantation, the hNPCs were modified using LV (with no 
reported use of polybrene) to secrete GDNF. Furthermore, even though this project 
has focused largely on potential repair of SCI, there is scope for the transplantation of 
these genetically manipulated cells to be applied to a number of other neurological 
diseases and conditions where cells are lost, such as Parkinson’s disease and 
Alzheimer’s disease.  
Here, this body of work has positively presented one potential avenue to target 
neuronal replacement in SCI and beyond, using genetically manipulated cells to 
overcome components of the inhibitory milieu created after CNS injury. However, due 
to the multitude of inhibitory proteins associated with CNS axonal injury, it is 
anticipated that cell transplantation alone would not be able to promote long-term 
functional recovery. Rather further interventions to influence the SCI 
pathophysiology, perhaps relating to the environment, alongside cell grafts would be 
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Appendix A: Neurite outgrowth assays from hNPCs  





alpha9 GFP WT alpha9 GFP WT alpha9 GFP WT alpha9 GFP WT alpha9 GFP WT alpha9 GFP WT
284.20 47.10 40.14 481.84 57.86 90.21 443.26 54.71 34.96 195.66 48.28 42.97 103.81 59.03 106.93 274.13 135.02 41.27
130.73 65.19 22.74 354.35 35.80 69.17 165.12 22.34 65.40 261.55 71.74 61.57 239.04 104.62 79.71 455.68 59.28 65.37
178.94 39.73 21.69 295.62 121.29 52.94 176.11 41.05 26.78 229.64 76.63 79.63 106.29 88.29 40.42 202.97 55.36 75.11
149.12 62.04 24.32 155.29 36.63 60.32 336.06 28.79 48.36 132.55 38.60 58.28 194.01 37.61 84.43 151.32 35.85 39.43
170.85 67.51 21.66 331.85 75.91 53.59 161.72 56.66 44.73 94.04 46.77 88.53 111.68 39.35 47.92 120.43 64.15 27.84
114.36 56.89 18.47 230.95 52.90 81.20 207.52 48.18 38.45 113.41 79.94 97.83 169.42 112.10 82.51 115.09 59.88 62.62
137.68 76.16 25.62 134.90 40.14 35.86 168.64 38.04 39.59 260.24 48.68 37.05 107.54 86.13 72.70 128.96 61.01 66.28
163.63 56.41 30.59 111.88 37.10 46.23 179.06 29.66 32.04 227.77 75.30 55.02 109.11 48.97 62.32 154.57 37.71 54.18
186.79 58.76 21.52 212.46 55.94 26.95 267.47 54.01 63.03 177.16 79.43 53.24 118.89 54.80 34.03 384.47 89.31 51.25
144.90 41.28 18.84 92.30 46.46 45.99 308.53 45.95 50.15 148.00 49.50 54.93 70.81 112.77 89.50 376.18 50.56 47.79
174.22 45.81 38.87 253.60 33.70 29.52 248.24 39.17 25.01 158.06 43.66 78.37 151.52 28.16 81.53 147.15 42.07 72.59
251.63 42.09 59.71 149.55 39.47 74.73 149.02 39.26 26.00 123.46 46.48 54.56 161.79 44.01 84.64 115.20 53.51 44.37
234.57 72.09 13.17 145.85 41.60 48.13 275.75 56.14 60.35 103.59 42.10 26.76 149.84 51.80 72.89 331.31 53.10 47.17
156.00 63.11 28.49 1017.26 37.93 50.21 198.78 32.62 47.78 138.94 55.67 42.78 175.56 47.78 51.86 147.33 65.02 59.58
137.89 68.78 36.37 427.24 35.30 50.44 226.49 36.54 27.47 182.48 75.01 44.69 183.34 40.35 65.61 159.06 64.26 47.88
135.16 59.91 103.44 414.07 53.38 46.71 158.99 34.53 19.88 116.01 23.58 76.64 203.82 54.81 54.13 163.04 77.50 83.77
139.53 51.66 49.24 405.14 38.90 47.61 167.08 28.52 31.21 160.91 37.57 41.50 120.71 100.68 61.71 244.73 87.49 49.66
202.34 28.11 105.54 554.94 43.64 33.13 172.84 42.86 53.58 80.53 69.88 57.79 140.09 49.15 53.45 201.20 104.04 33.60
156.79 100.22 56.70 202.37 41.72 32.18 179.60 47.67 22.39 182.82 38.93 106.42 172.61 37.16 54.22 170.89 75.94 77.57
96.10 71.96 23.72 238.62 45.60 63.13 128.46 69.32 39.42 174.66 30.69 66.33 138.72 44.95 38.58 136.66 53.85 77.00
257.57 65.64 44.86 183.33 40.84 53.90 208.71 29.83 77.92 99.65 97.22 63.34 208.90 143.97 65.74 142.80 44.45 38.92
117.84 42.53 44.20 175.41 47.38 39.34 623.62 34.59 42.59 195.40 48.25 94.42 162.44 95.38 57.89 113.67 76.23 56.70
118.18 59.79 48.30 178.86 27.59 33.39 273.90 32.38 34.29 125.71 73.88 54.15 183.10 57.95 75.50 149.93 72.42 55.71
228.65 32.40 56.87 234.94 40.61 44.60 203.75 28.32 20.53 138.27 57.26 71.27 140.46 33.18 40.19 166.88 49.78 63.36
89.85 37.61 25.21 306.72 46.70 44.32 137.00 54.84 30.86 137.03 89.64 59.92 152.65 39.81 60.84 262.30 68.97 39.72
128.06 97.36 47.60 222.53 55.61 41.78 184.80 39.66 57.84 169.71 38.58 70.48 184.04 32.24 73.16 337.47 45.42 59.02
150.00 55.55 15.78 145.19 48.48 44.74 176.10 24.40 19.93 193.77 27.86 55.33 134.73 33.31 47.00 240.14 66.31 71.20
79.20 33.89 58.39 108.83 24.98 67.22 228.09 93.96 27.35 149.72 37.97 99.99 132.69 83.15 96.93 184.59 57.07 62.30
182.83 29.53 35.61 258.41 72.51 37.13 281.75 41.53 31.42 121.27 80.84 75.83 140.33 88.10 64.24 478.72 58.94 58.53
108.79 42.06 27.68 357.30 52.97 34.66 142.10 84.07 52.34 215.04 55.88 66.31 125.43 44.97 80.28 121.12 88.65 31.06
n=4 n=5 n=6n=1 n=2 n=3
alpha9 GFP WT alpha9 GFP WT alpha9 GFP WT alpha9 GFP WT alpha9 GFP WT alpha9 GFP WT
284.20 47.10 40.14 481.84 57.86 90.21 443.26 54.71 34.96 195.66 48.28 42.97 103.81 59.03 106.93 274.13 135.02 41.27
130.73 65.19 22.74 354.35 35.80 69.17 165.12 22.34 65.40 261.55 71.74 61.57 239.04 104.62 79.71 455.68 59.28 65.37
178.94 39.73 21.69 295.62 121.29 52.94 176.11 41.05 26.78 229.64 76.63 79.63 106.29 88.29 40.42 202.97 55.36 75.11
149.12 62.04 24.32 155.29 36.63 60.32 336.06 28.79 48.36 132.55 38.60 58.28 194.01 37.61 84.43 151.32 35.85 39.43
170.85 67.51 21.66 331.85 75.91 53.59 161.72 56.66 44.73 94.04 46.77 88.53 111.68 39.35 47.92 120.43 64.15 27.84
114.36 56.89 18.47 230.95 52.90 81.20 207.52 48.18 38.45 113.41 79.94 97.83 169.42 112.10 82.51 115.09 59.88 62.62
137.68 76.16 25.62 134.90 40.14 35.86 168.64 38.04 39.59 260.24 48.68 37.05 107.54 86.13 72.70 128.96 61.01 66.28
163.63 56.41 30.59 111.88 37.10 46.23 179.06 29.66 32.04 227.77 75.30 55.02 109.11 48.97 62.32 154.57 37.71 54.18
186.79 58.76 21.52 212.46 55.94 26.95 267.47 54.01 63.03 177.16 79.43 53.24 118.89 54.80 34.03 384.47 89.31 51.25
144.90 41.28 18.84 92.30 46.46 45.99 308.53 45.95 50.15 148.00 49.50 54.93 70.81 112.77 89.50 376.18 50.56 47.79
174.22 45.81 38.87 253.60 33.70 29.52 248.24 39.17 25.01 158.06 43.66 78.37 151.52 28.16 81.53 147.15 42.07 72.59
251.63 42.09 59.71 149.55 39.47 74.73 149.02 39.26 26.00 123.46 46.48 54.56 161.79 44.01 84.64 115.20 53.51 44.37
234.57 72.09 13.17 145.85 41.60 48.13 275.75 56.14 60.35 103.59 42.10 26.76 149.84 51.80 72.89 331.31 53.10 47.17
156.00 63.11 28.49 1017.26 37.93 50.21 198.78 32.62 47.78 138.94 55.67 42.78 175.56 47.78 51.86 147.33 65.02 59.58
137.89 68.78 36.37 427.24 35.30 50.44 226.49 36.54 27.47 182.48 75.01 44.69 183.34 40.35 65.61 159.06 64.26 47.88
135.16 59.91 103.44 414.07 53.38 46.71 158.99 34.53 19.88 116.01 23.58 76.64 203.82 54.81 54.13 163.04 77.50 83.77
139.53 51.66 49.24 405.14 38.90 47.61 167.08 28.52 31.21 160.91 37.57 41.50 120.71 100.68 61.71 244.73 87.49 49.66
202.34 28.11 105.54 554.94 43.64 33.13 172.84 42.86 53.58 80.53 69.88 57.79 140.09 49.15 53.45 201.20 104.04 33.60
156.79 100.22 56.70 202.37 41.72 32.18 179.60 47.67 22.39 182.82 38.93 106.42 172.61 37.16 54.22 170.89 75.94 77.57
96.10 71.96 23.72 238.62 45.60 63.13 128.46 69.32 39.42 174.66 30.69 66.33 138.72 44.95 38.58 136.66 53.85 77.00
257.57 65.64 44.86 183.33 40.84 53.90 208.71 29.83 77.92 99.65 97.22 63.34 208.90 143.97 65.74 142.80 44.45 38.92
117.84 42.53 44.20 175.41 47.38 39.34 623.62 34.59 42.59 195.40 48.25 94.42 162.44 95.38 57.89 113.67 76.23 56.70
118.18 59.79 48.30 178.86 27.59 33.39 273.90 32.38 34.29 125.71 73.88 54.15 183.10 57.95 75.50 149.93 72.42 55.71
228.65 32.40 56.87 234.94 40.61 44.60 203.75 28.32 20.53 138.27 57.26 71.27 140.46 33.18 40.19 166.88 49.78 63.36
89.85 37.61 25.21 306.72 46.70 44.32 137.00 54.84 30.86 137.03 89.64 59.92 152.65 39.81 60.84 262.30 68.97 39.72
128.06 97.36 47.60 222.53 55.61 41.78 184.80 39.66 57.84 169.71 38.58 70.48 184.04 32.24 73.16 337.47 45.42 59.02
150.00 55.55 15.78 145.19 48.48 44.74 176.10 24.40 19.93 193.77 27.86 55.33 134.73 33.31 47.00 240.14 66.31 71.20
79.20 33.89 58.39 108.83 24.98 67.22 228.09 93.96 27.35 149.72 37.97 99.99 132.69 83.15 96.93 184.59 57.07 62.30
182.83 29.53 35.61 258.41 72.51 37.13 281.75 41.53 31.42 121.27 80.84 75.83 140.33 88.10 64.24 478.72 58.94 58.53
108.79 42.06 27.68 357.30 52.97 34.66 142.10 84.07 52.34 215.04 55.88 66.31 125.43 44.97 80.28 121.12 88.65 31.06
n=4 n=5 n=6n=1 n=2 n=3
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alpha9 GFP WT alpha9 GFP WT alpha9 GFP WT alpha9 GFP WT alpha9 GFP WT
227.69 104.10 39.02 513.86 37.02 31.68 124.62 71.68 122.89 83.41 103.46 98.95 244.50 78.63 91.63
115.73 41.67 61.19 230.76 43.47 52.38 121.80 88.78 84.39 81.83 107.76 69.61 262.24 33.24 36.59
351.66 26.59 55.58 232.64 33.82 59.38 164.55 108.87 83.57 119.42 79.00 136.42 166.56 109.80 32.23
230.61 60.73 81.18 197.65 37.19 55.77 88.00 110.15 64.13 172.14 59.35 131.30 158.10 39.52 30.07
223.84 34.50 32.68 432.86 21.40 39.00 114.07 42.28 77.58 94.15 115.21 98.15 138.38 29.68 80.53
197.12 37.48 36.48 368.90 24.18 31.93 110.68 53.22 66.87 125.76 136.54 83.75 181.24 39.02 80.33
295.26 39.93 49.31 441.04 43.03 31.16 100.98 61.43 94.98 191.50 138.47 70.43 206.56 47.69 25.91
234.03 33.66 41.16 220.42 43.32 54.35 218.33 107.69 103.80 138.34 107.08 126.18 250.28 47.75 71.08
535.38 59.65 31.34 337.01 56.78 39.00 161.06 70.82 86.88 123.43 132.06 74.32 155.13 43.47 124.12
565.81 38.83 67.77 151.28 226.98 46.62 91.65 52.94 73.63 101.67 117.84 45.84 158.19 33.80 69.18
223.06 45.92 50.63 168.19 30.20 45.26 118.90 64.33 69.92 132.52 109.08 76.27 186.11 41.50 45.45
215.09 46.04 34.80 153.40 28.21 33.93 88.43 90.93 60.76 98.63 164.29 119.86 322.12 38.33 61.94
277.07 36.37 46.21 175.51 28.29 52.67 84.70 82.36 97.75 103.41 104.37 70.36 165.22 42.73 55.14
290.11 90.72 47.59 220.10 25.66 34.56 119.02 80.88 58.20 86.13 54.48 98.43 231.25 37.18 51.69
138.90 52.42 59.08 250.26 47.60 22.41 128.22 85.14 49.62 159.24 88.38 63.75 177.82 28.10 28.22
165.03 30.56 37.73 223.26 23.41 27.32 119.21 84.47 49.43 135.68 83.62 89.51 186.91 44.16 48.75
128.57 29.78 41.22 165.85 27.05 27.79 162.66 104.95 73.41 86.35 104.41 113.88 249.98 54.18 49.69
177.14 26.64 65.74 289.65 27.32 22.06 76.56 61.34 70.94 90.13 46.37 83.71 201.11 38.95 36.16
205.28 33.05 41.68 155.35 58.86 16.56 167.62 101.89 53.12 50.30 73.40 126.59 266.41 48.29 34.00
235.76 32.35 57.36 293.04 62.25 25.83 152.28 82.05 89.35 74.61 134.58 70.83 207.12 33.46 56.81
109.27 64.77 55.53 167.26 47.91 42.72 161.03 91.18 120.79 141.40 83.28 85.04 150.05 32.52 34.05
105.52 71.04 36.98 148.03 66.88 29.25 125.92 77.29 76.98 67.26 94.18 57.01 130.20 42.35 68.64
123.11 81.73 85.81 286.89 47.91 44.05 133.98 57.55 53.18 130.01 79.38 98.80 144.53 66.89 60.62
128.81 40.64 100.40 300.30 78.93 40.85 179.88 58.97 45.64 139.61 77.02 209.44 141.34 49.31 34.26
425.17 44.92 37.54 200.81 39.65 36.07 147.61 67.87 96.94 164.38 148.49 60.90 159.32 59.10 65.70
279.89 58.87 36.45 216.51 52.88 67.55 96.69 50.66 48.17 151.15 32.68 86.17 174.61 122.54 31.49
174.41 39.29 52.62 190.17 52.39 43.12 92.87 31.76 85.99 140.84 68.23 63.81 173.06 69.38 53.39
202.46 51.35 89.36 353.11 31.16 47.04 185.90 67.58 68.17 200.17 73.92 141.15 239.05 41.53 65.33
218.37 89.33 58.93 243.37 26.39 50.55 125.17 86.37 91.84 86.51 87.52 69.49 176.25 56.10 59.38
242.42 40.15 37.76 181.78 31.34 74.79 161.19 56.10 57.13 159.28 70.44 146.08 181.11 61.22 38.47
n=5n=1 n=2 n=3 n=4
alpha9 GFP WT alpha9 GFP WT alpha9 GFP WT alpha9 GFP WT alpha9 GFP WT
227.69 104.10 39.02 513.86 37.02 31.68 124.62 71.68 122.89 83.41 103.46 98.95 244.50 78.63 91.63
115.73 41.67 61.19 230.76 43.47 52.38 121.80 88.78 84.39 81.83 107.76 69.61 262.24 33.24 36.59
351.66 26.59 55.58 232.64 33.82 59.38 164.55 108.87 83.57 119.42 79.00 136.42 166.56 109.80 32.23
230.61 60.73 81.18 197.65 37.19 55.77 88.00 110.15 64.13 172.14 59.35 131.30 158.10 39.52 30.07
223.84 34.50 32.68 432.86 21.40 39.00 114.07 42.28 77.58 94.15 115.21 98.15 138.38 29.68 80.53
197.12 37.48 36.48 368.90 24.18 31.93 110.68 53.22 66.87 125.76 136.54 83.75 181.24 39.02 80.33
295.26 39.93 49.31 441.04 43.03 31.16 100.98 61.43 94.98 191.50 138.47 70.43 206.56 47.69 25.91
234.03 33.66 41.16 220.42 43.32 54.35 218.33 107.69 103.80 138.34 107.08 126.18 250.28 47.75 71.08
535.38 59.65 31.34 337.01 56.78 39.00 161.06 70.82 86.88 123.43 132.06 74.32 155.13 43.47 124.12
565.81 38.83 67.77 151.28 226.98 46.62 91.65 52.94 73.63 101.67 117.84 45.84 158.19 33.80 69.18
223.06 45.92 50.63 168.19 30.20 45.26 118.90 64.33 69.92 132.52 109.08 76.27 186.11 41.50 45.45
215.09 46.04 34.80 153.40 28.21 33.93 88.43 90.93 60.76 98.63 164.29 119.86 322.12 38.33 61.94
277.07 36.37 46.21 175.51 28.29 52.67 84.70 82.36 97.75 103.41 104.37 70.36 165.22 42.73 55.14
290.11 90.72 47.59 220.10 25.66 34.56 119.02 80.88 58.20 86.13 54.48 98.43 231.25 37.18 51.69
138.90 52.42 59.08 250.26 47.60 22.41 128.22 85.14 49.62 159.24 88.38 63.75 177.82 28.10 28.22
165.03 30.56 37.73 223.26 23.41 27.32 119.21 84.47 49.43 135.68 83.62 89.51 186.91 44.16 48.75
128.57 29.78 41.22 165.85 27.05 27.79 162.66 104.95 73.41 86.35 104.41 113.88 249.98 54.18 49.69
177.14 26.64 65.74 289.65 27.32 22.06 76.56 61.34 70.94 90.13 46.37 83.71 201.11 38.95 36.16
205.28 33.05 41.68 155.35 58.86 16.56 167.62 101.89 53.12 50.30 73.40 126.59 266.41 48.29 34.00
235.76 32.35 57.36 293.04 62.25 25.83 152.28 82.05 89.35 74.61 134.58 70.83 207.12 33.46 56.81
109.27 64.77 55.53 167.26 47.91 42.72 161.03 91.18 120.79 141.40 83.28 85.04 150.05 32.52 34.05
105.52 71.04 36.98 148.03 66.88 29.25 125.92 77.29 76.98 67.26 94.18 57.01 130.20 42.35 68.64
123.11 81.73 85.81 286.89 47.91 44.05 133.98 57.55 53.18 130.01 79.38 98.80 144.53 66.89 60.62
128.81 40.64 100.40 300.30 78.93 40.85 179.88 58.97 45.64 139.61 77.02 209.44 141.34 49.31 34.26
425.17 44.92 37.54 200.81 39.65 36.07 147.61 67.87 96.94 164.38 148.49 60.90 159.32 59.10 65.70
279.89 58.87 36.45 216.51 52.88 67.55 96.69 50.66 48.17 151.15 32.68 86.17 174.61 122.54 31.49
174.41 39.29 52.62 190.17 52.39 43.12 92.87 31.76 85.99 140.84 68.23 63.81 173.06 69.38 53.39
202.46 51.35 89.36 353.11 31.16 47.04 185.90 67.58 68.17 200.17 73.92 141.15 239.05 41.53 65.33
218.37 89.33 58.93 243.37 26.39 50.55 125.17 86.37 91.84 86.51 87.52 69.49 176.25 56.10 59.38
242.42 40.15 37.76 181.78 31.34 74.79 161.19 56.10 57.13 159.28 70.44 146.08 181.11 61.22 38.47
n=5n=1 n=2 n=3 n=4
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alpha9 GFP WT alpha9 GFP WT alpha9 GFP WT alpha9 GFP WT alpha9 GFP WT
181.34 72.85 46.44 232.01 88.19 52.27 129.38 113.28 144.20 84.30 59.14 118.19 143.80 62.46 92.23
176.00 70.93 72.81 268.70 97.70 87.43 137.77 83.06 63.71 138.42 56.20 138.77 127.00 46.14 121.30
377.43 86.17 53.67 180.24 50.81 55.19 194.67 227.25 121.85 109.30 76.69 91.66 157.40 80.78 164.65
180.14 42.56 30.68 319.83 49.96 53.07 151.60 88.52 68.91 85.35 73.67 115.48 141.19 55.16 175.35
189.80 78.61 63.62 406.75 31.24 44.29 119.40 163.31 74.49 96.96 70.03 26.32 134.81 79.52 98.91
134.35 56.93 79.80 250.79 28.38 39.92 78.48 104.89 75.93 230.15 52.20 64.29 267.66 199.48 70.27
431.92 55.18 77.06 188.93 43.79 53.12 178.75 49.18 134.04 138.17 59.00 107.35 145.99 93.46 101.03
228.23 40.21 159.86 134.72 46.00 31.44 102.82 50.63 66.35 141.08 83.72 96.87 290.70 78.61 159.60
137.62 44.40 49.15 255.48 48.43 44.09 74.71 50.30 121.76 91.85 34.49 76.39 215.23 178.42 119.43
117.83 51.94 68.64 165.48 36.41 38.86 116.46 149.29 62.93 172.66 67.03 66.51 165.34 83.37 155.23
156.75 84.18 106.85 172.59 61.73 66.47 79.43 114.96 81.49 133.44 54.58 36.44 179.38 146.26 123.11
163.63 31.16 108.18 171.55 64.92 49.49 151.76 48.29 60.44 107.21 98.18 98.83 158.37 91.99 139.31
116.95 37.97 81.05 151.65 144.05 80.46 240.16 72.29 75.97 149.29 76.96 84.25 314.42 85.95 125.53
113.26 41.51 46.16 159.46 87.68 77.63 125.24 81.70 87.90 91.99 103.09 48.41 275.20 80.68 123.46
99.17 49.14 58.77 241.76 50.97 70.13 75.78 119.29 31.49 118.81 132.13 91.99 87.09 227.79 132.56
143.61 20.87 50.50 98.00 38.21 109.60 122.40 41.62 96.12 77.67 96.25 110.44 265.30 95.16 139.31
133.47 26.88 86.53 148.13 39.90 48.37 74.48 60.88 54.11 87.15 97.87 136.86 164.00 60.35 165.76
237.88 32.54 90.53 151.76 71.68 72.33 178.80 65.83 24.23 194.16 154.80 49.66 371.13 56.32 111.59
210.98 72.60 54.02 163.31 36.79 19.49 132.96 75.05 43.56 120.68 110.83 129.81 287.97 169.11 126.16
388.91 90.98 48.70 185.61 25.74 70.80 137.87 127.05 41.12 92.03 130.69 116.12 126.52 154.41 124.72
196.07 78.41 42.24 467.63 42.90 41.82 177.75 69.30 56.37 108.41 97.20 94.04 192.00 81.62 155.75
195.57 99.63 54.61 220.44 46.85 33.51 82.79 93.17 56.59 140.34 100.97 62.57 132.38 147.93 90.82
287.75 85.43 73.30 194.83 28.02 45.36 91.05 35.28 86.03 87.26 62.97 62.59 130.02 196.89 132.34
257.38 49.63 65.59 271.70 45.46 49.22 82.65 57.67 78.77 138.28 77.26 28.59 88.65 188.90 123.25
172.51 121.33 103.19 326.41 34.66 30.64 91.89 42.64 90.75 145.37 110.05 44.26 78.68 218.95 69.61
255.83 40.11 80.97 186.28 46.56 48.28 120.54 126.73 54.23 101.65 85.99 42.30 64.30 218.95 128.74
249.70 42.11 86.89 172.67 55.81 54.01 176.74 129.21 78.78 97.30 85.50 61.56 258.15 208.71 123.21
211.66 46.24 97.77 337.64 44.89 56.90 176.17 84.79 86.25 150.85 135.91 134.33 352.53 191.44 119.62
158.38 79.67 74.56 944.33 44.45 41.09 82.25 88.00 61.84 207.39 142.75 123.16 128.64 195.96 118.38
194.54 46.09 77.67 536.50 58.17 47.33 96.74 95.23 62.52 96.07 100.56 51.49 370.10 214.59 112.35
n=5n=1 n=2 n=3 n=4
alpha9 GFP WT alpha9 GFP WT alpha9 GFP WT alpha9 GFP WT alpha9 GFP WT
181.34 72.85 46.44 232.01 88.19 52.27 129.38 113.28 144.20 84.30 59.14 118.19 143.80 62.46 92.23
176.00 70.93 72.81 268.70 97.70 87.43 137.77 83.06 63.71 138.42 56.20 138.77 127.00 46.14 121.30
377.43 86.17 53.67 180.24 50.81 55.19 194.67 227.25 121.85 109.30 76.69 91.66 157.40 80.78 164.65
180.14 42.56 30.68 319.83 49.96 53.07 151.60 88.52 68.91 85.35 73.67 115.48 141.19 55.16 175.35
189.80 78.61 63.62 406.75 31.24 44.29 119.40 163.31 74.49 96.96 70.03 26.32 134.81 79.52 98.91
134.35 56.93 79.80 250.79 28.38 39.92 78.48 104.89 75.93 230.15 52.20 64.29 267.66 199.48 70.27
431.92 55.18 77.06 188.93 43.79 53.12 178.75 49.18 134.04 138.17 59.00 107.35 145.99 93.46 101.03
228.23 40.21 159.86 134.72 46.00 31.44 102.82 50.63 66.35 141.08 83.72 96.87 290.70 78.61 159.60
137.62 44.40 49.15 255.48 48.43 44.09 74.71 50.30 121.76 91.85 34.49 76.39 215.23 178.42 119.43
117.83 51.94 68.64 165.48 36.41 38.86 116.46 149.29 62.93 172.66 67.03 66.51 165.34 83.37 155.23
156.75 84.18 106.85 172.59 61.73 66.47 79.43 114.96 81.49 133.44 54.58 36.44 179.38 146.26 123.11
163.63 31.16 108.18 171.55 64.92 49.49 151.76 48.29 60.44 107.21 98.18 98.83 158.37 91.99 139.31
116.95 37.97 81.05 151.65 144.05 80.46 240.16 72.29 75.97 149.29 76.96 84.25 314.42 85.95 125.53
113.26 41.51 46.16 159.46 87.68 77.63 125.24 81.70 87.90 91.99 103.09 48.41 275.20 80.68 123.46
99.17 49.14 58.77 241.76 50.97 70.13 75.78 119.29 31.49 118.81 132.13 91.99 87.09 227.79 132.56
143.61 20.87 50.50 98.00 38.21 109.60 122.40 41.62 96.12 77.67 96.25 110.44 265.30 95.16 139.31
133.47 26.88 86.53 148.13 39.90 48.37 74.48 60.88 54.11 87.15 97.87 136.86 164.00 60.35 165.76
237.88 32.54 90.53 151.76 71.68 72.33 178.80 65.83 24.23 194.16 154.80 49.66 371.13 56.32 111.59
210.98 72.60 54.02 163.31 36.79 19.49 132.96 75.05 43.56 120.68 110.83 129.81 287.97 169.11 126.16
388.91 90.98 48.70 185.61 25.74 70.80 137.87 127.05 41.12 92.03 130.69 116.12 126.52 154.41 124.72
196.07 78.41 42.24 467.63 42.90 41.82 177.75 69.30 56.37 108.41 97.20 94.04 192.00 81.62 155.75
195.57 99.63 54.61 220.44 46.85 33.51 82.79 93.17 56.59 140.34 100.97 62.57 132.38 147.93 90.82
287.75 85.43 73.30 194.83 28.02 45.36 91.05 35.28 86.03 87.26 62.97 62.59 130.02 196.89 132.34
257.38 49.63 65.59 271.70 45.46 49.22 82.65 57.67 78.77 138.28 77.26 28.59 88.65 188.90 123.25
172.51 121.33 103.19 326.41 34.66 30.64 91.89 42.64 90.75 145.37 110.05 44.26 78.68 218.95 69.61
255.83 40.11 80.97 186.28 46.56 48.28 120.54 126.73 54.23 101.65 85.99 42.30 64.30 218.95 128.74
249.70 42.11 86.89 172.67 55.81 54.01 176.74 129.21 78.78 97.30 85.50 61.56 258.15 208.71 123.21
211.66 46.24 97.77 337.64 44.89 56.90 176.17 84.79 86.25 150.85 135.91 134.33 352.53 191.44 119.62
158.38 79.67 74.56 944.33 44.45 41.09 82.25 88.00 61.84 207.39 142.75 123.16 128.64 195.96 118.38
194.54 46.09 77.67 536.50 58.17 47.33 96.74 95.23 62.52 96.07 100.56 51.49 370.10 214.59 112.35
n=5n=1 n=2 n=3 n=4
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alpha9 GFP WT alpha9 GFP WT alpha9 GFP WT alpha9 GFP WT alpha9 GFP WT alpha9 GFP WT
242.84 123.10 75.34 257.27 85.71 46.95 123.98 89.14 241.35 282.46 125.05 108.67 296.01 394.88 135.21 266.59 277.11 209.86
126.19 82.77 71.44 471.54 68.55 79.56 100.21 149.18 112.79 183.50 98.55 181.58 260.54 125.88 155.55 189.69 225.63 179.14
116.88 63.67 67.91 413.44 65.37 67.04 107.76 61.34 141.07 185.24 141.12 68.55 302.16 104.64 82.10 298.45 128.83 321.75
330.71 58.05 89.85 541.13 104.59 103.60 98.91 93.76 126.41 195.31 106.61 137.55 230.24 116.90 112.95 225.21 136.78 241.54
117.63 67.81 73.58 308.18 43.50 90.89 183.87 144.87 77.43 151.18 141.61 153.24 221.60 283.59 94.22 112.54 209.29 242.30
189.27 71.13 108.94 139.90 51.97 52.18 92.25 145.14 87.05 366.53 75.33 86.16 248.59 247.86 148.31 120.29 139.97 179.10
116.57 139.23 98.58 138.15 103.80 36.75 114.08 77.91 131.00 220.10 79.31 190.92 117.39 110.34 54.80 259.08 203.01 196.24
175.92 84.56 58.35 314.08 54.48 40.55 76.99 175.90 57.02 137.87 230.37 186.84 131.68 84.50 104.12 122.29 82.22 301.27
109.25 95.03 44.61 268.26 44.95 38.02 184.01 76.66 97.73 168.90 176.18 141.94 131.63 188.63 206.17 201.98 178.97 115.38
207.54 45.02 66.60 322.32 36.39 115.32 235.58 122.81 48.46 179.82 115.66 89.25 102.96 125.46 84.63 156.78 131.61 100.68
93.80 55.93 82.13 213.34 45.77 158.02 200.69 76.00 53.70 79.19 86.05 127.04 150.20 118.39 155.04 310.99 68.16 98.36
123.75 43.08 89.96 280.76 38.27 45.76 132.45 142.26 80.45 113.88 130.40 79.53 98.59 117.21 117.26 250.00 209.65 121.30
254.62 57.72 67.98 228.94 138.61 40.32 102.69 118.66 156.92 116.67 134.09 93.05 203.62 82.99 96.64 156.04 175.40 123.85
181.96 182.11 64.32 226.76 59.17 53.55 62.38 72.12 81.24 107.43 114.91 146.15 334.53 114.41 110.34 208.20 109.92 131.00
120.95 153.35 64.72 159.92 140.95 74.47 109.62 93.35 66.19 154.91 126.47 199.93 142.76 154.37 96.28 278.70 158.08 120.83
135.53 143.33 144.83 214.25 76.55 93.29 142.30 75.55 34.97 157.56 97.81 197.46 213.69 185.11 217.85 223.67 126.99 143.08
136.02 189.75 149.15 321.65 69.72 66.54 90.69 126.74 152.24 166.05 193.51 222.52 183.39 220.76 44.25 129.13 160.73 108.65
204.96 104.16 67.58 507.09 55.74 57.36 166.94 93.07 199.99 125.91 125.97 68.83 160.93 76.81 108.19 126.32 145.95 73.47
270.91 82.70 74.61 264.04 159.78 120.33 138.54 106.87 111.95 157.91 67.38 115.41 205.99 145.24 124.11 147.70 120.12 181.09
123.84 55.07 87.86 302.75 85.51 86.67 130.22 84.20 117.93 114.71 63.67 65.49 132.46 166.79 165.15 132.27 113.58 165.08
167.36 132.92 63.94 247.03 95.31 59.88 190.65 141.09 104.67 201.91 172.91 85.08 135.90 184.50 124.60 139.12 135.99 130.36
300.80 86.12 78.58 238.47 85.25 49.65 243.83 182.71 136.73 96.38 110.78 53.91 192.01 77.91 178.20 220.64 96.92 104.45
154.60 43.58 79.25 149.25 92.25 30.72 98.94 120.20 47.84 175.94 142.82 106.83 233.92 134.81 171.31 123.01 92.77 64.25
71.13 48.07 61.88 366.84 54.41 47.40 129.17 94.89 94.64 121.40 113.67 175.62 148.29 251.10 151.00 224.51 92.38 101.73
382.37 34.43 54.95 298.07 63.57 38.68 250.86 72.05 94.51 135.37 115.06 85.62 146.62 225.59 113.95 214.78 157.05 89.86
458.04 44.21 54.44 383.91 56.34 71.66 170.02 60.85 119.28 238.95 100.73 198.74 225.48 140.88 194.86 215.33 198.43 256.38
242.56 111.31 61.67 309.34 109.21 191.45 97.88 128.35 89.04 20.61 202.49 87.04 169.72 265.02 96.45 203.32 172.86 100.07
102.11 91.53 55.63 192.70 44.69 99.50 141.28 74.70 63.62 97.90 146.52 72.62 175.50 139.53 77.06 196.60 146.36 173.23
150.87 119.76 84.21 218.74 193.52 106.87 99.25 49.64 68.09 173.04 70.82 151.09 120.97 158.18 102.03 133.38 207.37 143.50
147.15 93.55 113.75 206.21 120.62 110.35 159.97 107.32 129.45 141.84 116.54 196.35 115.15 231.84 115.60 188.69 182.40 123.21
n=5 n=6n=1 n=2 n=3 n=4
alpha9 GFP WT alpha9 GFP WT alpha9 GFP WT alpha9 GFP WT alpha9 GFP WT alpha9 GFP WT
242.84 123.10 75.34 257.27 85.71 46.95 123.98 89.14 241.35 282.46 125.05 108.67 296.01 394.88 135.21 266.59 277.11 209.86
126.19 82.77 71.44 471.54 68.55 79.56 100.21 149.18 112.79 183.50 98.55 181.58 260.54 125.88 155.55 189.69 225.63 179.14
116.88 63.67 67.91 413.44 65.37 67.04 107.76 61.34 141.07 185.24 141.12 68.55 302.16 104.64 82.10 298.45 128.83 321.75
330.71 58.05 89.85 541.13 104.59 103.60 98.91 93.76 126.41 195.31 106.61 137.55 230.24 116.90 112.95 225.21 136.78 241.54
117.63 67.81 73.58 308.18 43.50 90.89 183.87 144.87 77.43 151.18 141.61 153.24 221.60 283.59 94.22 112.54 209.29 242.30
189.27 71.13 108.94 139.90 51.97 52.18 92.25 145.14 87.05 366.53 75.33 86.16 248.59 247.86 148.31 120.29 139.97 179.10
116.57 139.23 98.58 138.15 103.80 36.75 114.08 77.91 131.00 220.10 79.31 190.92 117.39 110.34 54.80 259.08 203.01 196.24
175.92 84.56 58.35 314.08 54.48 40.55 76.99 175.90 57.02 137.87 230.37 186.84 131.68 84.50 104.12 122.29 82.22 301.27
109.25 95.03 44.61 268.26 44.95 38.02 184.01 76.66 97.73 168.90 176.18 141.94 131.63 188.63 206.17 201.98 178.97 115.38
207.54 45.02 66.60 322.32 36.39 115.32 235.58 122.81 48.46 179.82 115.66 89.25 102.96 125.46 84.63 156.78 131.61 100.68
93.80 55.93 82.13 213.34 45.77 158.02 200.69 76.00 53.70 79.19 86.05 127.04 150.20 118.39 155.04 310.99 68.16 98.36
123.75 43.08 89.96 280.76 38.27 45.76 132.45 142.26 80.45 113.88 130.40 79.53 98.59 117.21 117.26 250.00 209.65 121.30
254.62 57.72 67.98 228.94 138.61 40.32 102.69 118.66 156.92 116.67 134.09 93.05 203.62 82.99 96.64 156.04 175.40 123.85
181.96 182.11 64.32 226.76 59.17 53.55 62.38 72.12 81.24 107.43 114.91 146.15 334.53 114.41 110.34 208.20 109.92 131.00
120.95 153.35 64.72 159.92 140.95 74.47 109.62 93.35 66.19 154.91 126.47 199.93 142.76 154.37 96.28 278.70 158.08 120.83
135.53 143.33 144.83 214.25 76.55 93.29 142.30 75.55 34.97 157.56 97.81 197.46 213.69 185.11 217.85 223.67 126.99 143.08
136.02 189.75 149.15 321.65 69.72 66.54 90.69 126.74 152.24 166.05 193.51 222.52 183.39 220.76 44.25 129.13 160.73 108.65
204.96 104.16 67.58 507.09 55.74 57.36 166.94 93.07 199.99 125.91 125.97 68.83 160.93 76.81 108.19 126.32 145.95 73.47
270.91 82.70 74.61 264.04 159.78 120.33 138.54 106.87 111.95 157.91 67.38 115.41 205.99 145.24 124.11 147.70 120.12 181.09
123.84 55.07 87.86 302.75 85.51 86.67 130.22 84.20 117.93 114.71 63.67 65.49 132.46 166.79 165.15 132.27 113.58 165.08
167.36 132.92 63.94 247.03 95.31 59.88 190.65 141.09 104.67 201.91 172.91 85.08 135.90 184.50 124.60 139.12 135.99 130.36
300.80 86.12 78.58 238.47 85.25 49.65 243.83 182.71 136.73 96.38 110.78 53.91 192.01 77.91 178.20 220.64 96.92 104.45
154.60 43.58 79.25 149.25 92.25 30.72 98.94 120.20 47.84 175.94 142.82 106.83 233.92 134.81 171.31 123.01 92.77 64.25
71.13 48.07 61.88 366.84 54.41 47.40 129.17 94.89 94.64 121.40 113.67 175.62 148.29 251.10 151.00 224.51 92.38 101.73
382.37 34.43 54.95 298.07 63.57 38.68 250.86 72.05 94.51 135.37 115.06 85.62 146.62 225.59 113.95 214.78 157.05 89.86
458.04 44.21 54.44 383.91 56.34 71.66 170.02 60.85 119.28 238.95 100.73 198.74 225.48 140.88 194.86 215.33 198.43 256.38
242.56 111.31 61.67 309.34 109.21 191.45 97.88 128.35 89.04 20.61 202.49 87.04 169.72 265.02 96.45 203.32 172.86 100.07
102.11 91.53 55.63 192.70 44.69 99.50 141.28 74.70 63.62 97.90 146.52 72.62 175.50 139.53 77.06 196.60 146.36 173.23
150.87 119.76 84.21 218.74 193.52 106.87 99.25 49.64 68.09 173.04 70.82 151.09 120.97 158.18 102.03 133.38 207.37 143.50
147.15 93.55 113.75 206.21 120.62 110.35 159.97 107.32 129.45 141.84 116.54 196.35 115.15 231.84 115.60 188.69 182.40 123.21
n=5 n=6n=1 n=2 n=3 n=4
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alpha9 GFP WT alpha9 GFP WT alpha9 GFP WT alpha9 GFP WT
216.52 173.26 186.92 236.26 206.23 188.45 310.81 237.15 179.74 132.26 258.04 179.22
296.05 185.17 141.70 164.99 362.92 132.41 264.29 210.07 232.67 227.30 304.32 262.23
122.75 316.90 146.09 132.56 326.60 199.60 225.47 278.35 282.10 169.43 251.07 197.11
226.97 206.95 172.91 374.94 239.33 220.49 134.77 156.38 202.75 149.74 284.02 159.36
118.85 135.21 147.06 184.59 223.83 242.21 118.02 414.30 279.57 176.53 215.92 147.14
145.34 225.06 185.59 312.17 161.01 198.81 136.00 182.70 146.55 179.67 193.50 216.81
303.38 208.20 135.26 105.96 196.97 131.60 168.91 133.49 166.44 238.86 200.02 184.59
231.25 118.08 220.03 80.98 125.74 198.62 237.83 231.87 187.04 118.82 176.88 176.93
116.97 149.77 104.79 98.95 143.49 193.15 162.04 75.95 234.27 125.27 181.10 166.16
122.48 202.76 201.57 750.08 194.05 128.88 433.29 99.90 191.04 165.13 190.38 201.74
97.34 147.20 143.95 323.08 92.96 119.82 134.68 107.12 274.20 157.64 332.27 187.46
87.74 217.12 105.95 157.95 175.54 183.47 170.90 110.16 239.65 177.96 128.78 241.36
99.36 174.45 145.19 119.40 143.10 136.81 103.01 155.91 166.23 122.19 358.42 153.87
96.99 124.25 137.85 134.89 93.25 171.89 124.95 152.31 268.63 172.58 232.99 146.66
100.55 103.50 144.24 187.82 150.69 179.81 162.56 164.12 253.17 183.13 240.17 169.23
384.27 101.60 128.85 107.09 151.05 199.68 299.19 88.70 245.43 172.65 224.16 92.83
182.97 95.77 159.84 282.29 121.90 128.31 184.30 222.73 164.92 261.49 198.46 124.37
228.92 151.69 90.82 149.21 142.42 166.25 324.33 149.25 320.78 126.98 210.62 207.52
104.60 113.70 120.47 106.58 141.63 96.53 140.58 85.96 213.94 251.95 194.24 213.31
127.11 138.25 144.05 120.72 222.51 203.35 232.66 87.31 205.87 169.55 286.28 141.56
119.97 113.11 93.39 91.96 240.88 157.29 391.02 85.13 130.28 144.78 249.58 149.79
289.97 154.29 141.07 110.13 239.40 254.46 159.17 86.11 368.95 181.37 192.97 395.84
161.24 103.58 120.18 194.63 134.71 126.67 123.67 98.46 369.75 633.00 174.63 127.34
182.05 192.09 127.91 228.97 164.33 200.90 122.92 93.23 242.97 331.90 150.35 201.05
185.79 95.53 160.42 124.52 153.65 137.59 177.84 132.70 237.45 190.53 228.77 195.19
142.49 104.80 132.26 124.91 167.61 135.57 145.61 179.14 192.61 138.13 175.48 129.36
234.18 91.52 121.05 121.39 236.14 199.71 146.48 81.43 296.36 155.42 171.22 126.73
272.53 226.38 115.57 171.70 183.61 164.86 146.08 155.16 213.89 127.61 225.13 143.82
196.24 301.08 163.77 173.40 166.10 209.39 145.45 188.99 423.77 160.56 303.88 244.02









alpha9 GFP WT alpha9 GFP WT alpha9 GFP WT alpha9 GFP WT
216.52 173.26 186.92 236.26 206.23 188.45 310.81 237.15 179.74 132.26 258.04 179.22
296.05 185.17 141.70 164.99 362.92 132.41 264.29 210.07 232.67 227.30 304.32 262.23
122.75 316.90 146.09 132.56 326.60 199.60 225.47 278.35 282.10 169.43 251.07 197.11
226.97 206.95 172.91 374.94 239.33 220.49 134.77 156.38 202.75 149.74 284.02 159.36
118.85 135.21 147.06 184.59 223.83 242.21 118.02 414.30 279.57 176.53 215.92 147.14
145.34 225.06 185.59 312.17 161.01 198.81 136.00 182.70 146.55 179.67 193.50 216.81
303.38 208.20 135.26 105.96 196.97 131.60 168.91 133.49 166.44 238.86 200.02 184.59
231.25 118.08 220.03 80.98 125.74 198.62 237.83 231.87 187.04 118.82 176.88 176.93
116.97 149.77 104.79 98.95 143.49 193.15 162.04 75.95 234.27 125.27 181.10 166.16
122.48 202.76 201.57 750.08 194.05 128.88 433.29 99.90 191.04 165.13 190.38 201.74
97.34 147.20 143.95 323.08 92.96 119.82 134.68 107.12 274.20 157.64 332.27 187.46
87.74 217.12 105.95 157.95 175.54 183.47 170.90 110.16 239.65 177.96 128.78 241.36
99.36 174.45 145.19 119.40 143.10 136.81 103.01 155.91 166.23 122.19 358.42 153.87
96.99 124.25 137.85 134.89 93.25 171.89 124.95 152.31 268.63 172.58 232.99 146.66
100.55 103.50 144.24 187.82 150.69 179.81 162.56 164.12 253.17 183.13 240.17 169.23
384.27 101.60 128.85 107.09 151.05 199.68 299.19 88.70 245.43 172.65 224.16 92.83
182.97 95.77 159.84 282.29 121.90 128.31 184.30 222.73 164.92 261.49 198.46 124.37
228.92 151.69 90.82 149.21 142.42 166.25 324.33 149.25 320.78 126.98 210.62 207.52
104.60 113.70 120.47 106.58 141.63 96.53 140.58 85.96 213.94 251.95 194.24 213.31
127.11 138.25 144.05 120.72 222.51 203.35 232.66 87.31 205.87 169.55 286.28 141.56
119.97 113.11 93.39 91.96 240.88 157.29 391.02 85.13 130.28 144.78 249.58 149.79
289.97 154.29 141.07 110.13 239.40 254.46 159.17 86.11 368.95 181.37 192.97 395.84
161.24 103.58 120.18 194.63 134.71 126.67 123.67 98.46 369.75 633.00 174.63 127.34
182.05 192.09 127.91 228.97 164.33 200.90 122.92 93.23 242.97 331.90 150.35 201.05
185.79 95.53 160.42 124.52 153.65 137.59 177.84 132.70 237.45 190.53 228.77 195.19
142.49 104.80 132.26 124.91 167.61 135.57 145.61 179.14 192.61 138.13 175.48 129.36
234.18 91.52 121.05 121.39 236.14 199.71 146.48 81.43 296.36 155.42 171.22 126.73
272.53 226.38 115.57 171.70 183.61 164.86 146.08 155.16 213.89 127.61 225.13 143.82
196.24 301.08 163.77 173.40 166.10 209.39 145.45 188.99 423.77 160.56 303.88 244.02
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Appendix B: Presence of scar after hNPC transplantation 
 
Figure 1 Representative images showing scarring at 7 weeks post-transplantation of WT hNPCs. 
Scarring was defined as non-specific HuNu (A-D) or hNCAM staining that corresponded with 
increased GFAP staining (B-E). Scale bar A-C = 250 µm; D-F = 500 µm. 
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Appendix C: HuNu and hNCAM antibodies are human-specific 
 
Figure 2 Both HuNu and hNCAM antibodies are human-specific. The HuNu and hNCAM 
antibodies were assessed for their human-specificity using the contralateral cortex which contained no 
hNPCs. Both HuNu (A-B) and hNCAM (C-D) did not stain the endogenous rat tissue indicating both 
antibodies were indeed specific to only the human cells. Scale bar in A and C = 150 µm; B and D = 50 
µm. 
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Appendix D: WT hNPC grafts and projections are not positive for 
GFP 
 
Figure 3 WT hNPC grafts and projections are not GFP-positive. The WT hNPC grafts were 
assessed using IHC and an anti-GFP antibody so assess whether they stain positive for GFP. Results 
show no GFP-positive staining was observed within the grafts (A) or the projections (B) from WT 
hNPCs suggesting the GFP expression within the α9-eYFP hNPCs and fGFP-hNPCs is indeed due to 
the exogenous protein expression. Scale bar in A = 250 µm and B = 150 µm.  
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